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Abstract 
Neurotrophins and their cognate receptors are part of an important signalling system 
in the vertebrate nervous system. This includes the control of cell survival during the 
development of the peripheral nervous system. Whilst the neurotrophins and their 
respective tyrosine kinase receptors are closely related in structure, unexpected 
differences have begun to appear with regard to their function. In particular, the 
tropomyosin receptor kinase A (TrkA) has been reported to cause the death of neurons 
in the absence of its neurotrophin ligand, nerve growth factor (NGF). By contrast, 
there have been no indications as of yet that the expression of the closely related brain-
derived neurotrophic factor (BDNF) and neurotrophin-4 (NT4) receptor TrkB induces 
the death of neurons during development. A better understanding of the function of 
these receptors has important implications as unlike TrkA in the peripheral nervous 
system, TrkB is widely expressed in the central nervous system where BDNF does not 
seem to play a significant role as a survival factor. To further explore the role of these 
receptors, novel in vitro and in vivo models were generated that allowed the 
conditional overexpression of TrkA and TrkB. It was found that the ubiquitous 
overexpression of TrkA from the earliest stages of mouse gestation led to a perinatal 
death phenotype, whilst mice overexpressing TrkB were viable and fertile. Detailed 
histological examination indicated that the overexpression of TrkA led to the loss of 
neurons known to depend on NGF for their survival during development. Indeed 
TrkA-overexpressing mice phenocopy mutants lacking both Ngf alleles. By contrast, 
the postnatal survival of TrkB-overexpressing mice was unimpaired, despite a loss of 
cranial sensory neurons approaching what has been reported for mice lacking the 
genes encoding BDNF and NT4. Potential explanations for these surprising 
observations are discussed. 
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1. Introduction 
 
Neurons are the core unit of the nervous system and as a result, their number impacts 
the output of the brain, spinal cord and peripheral nerves. For this reason, the number 
of neurons needs to be tightly controlled to maintain appropriate functionality of the 
nervous system (Dekkers et al., 2013). In vertebrates, the number of neurons is, in 
part, regulated by the availability of growth factors that prevent cell death. The best 
characterised family of such growth factors comprises the neurotrophins, a small 
family of four related genes (Dekkers et al., 2013). Whilst it has long been established 
that neurotrophins exert their pro-survival effects by interactions with tropomyosin 
receptor kinases (Trk), it was only recently that the Trk receptors had been found to 
have an additional role in determining the fate of neurons by actively inducing cell 
death in the absence of their neurotrophic ligands (Nikoletopoulou et al., 2010). As 
very little is known about the biological functions of the Trk receptors in the absence 
of their ligands, the main objective of this thesis was to test possible functions of these 
receptors in development by expressing them from the earliest stages of 
embryogenesis (before significant ligand expression), at times and in tissues where the 
receptor is not normally expressed.  
 
1.1. Cell death  
 
1.1.1. Cell death in development 
 
During development, entire organisms are generated from a single fertilised oocyte. 
To achieve this, there is a rapid proliferation of cells, leading to growth and expansion 
of the organism. However strict regulation of the number of cells is essential for proper 
development and thus proliferation is balanced with developmental cell death (Vaux 
and Korsmeyer, 1999). The first recording of developmental cell death is attributed to 
Carl Vogt in 1842 when he noted the “destruction of embryonic cells” during 
development of the notochord in toads (Zakeri and Lockshin, 2008). Cell death was 
later characterised as being a highly conserved process present in all Metazoans 
(Bender et al., 2012; Cikala et al., 1999). In 1964 Lockshin and Williams noted that 
the death of muscles in American silk moths followed a biological plan which they 
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termed programmed cell death (PCD; also referred to as apoptosis) (Lockshin and 
Williams, 1964). These apoptotic cells resembled each other in that they demonstrated 
DNA fragmentation, shrinkage of the cell, chromatin condensation and zeiosis (rapid 
bleb formation that gives the cell an appearance of boiling) (Kerr et al., 1972). In 
contrast, cells that had encountered stress or injury, such as mechanical stress or heat, 
had different death characteristics; the plasma membranes ruptured and led to 
inflammation of surrounding tissues (Sun and Wang, 2014). Indeed, it is now 
established that these observed differences are due to the fact that there are three 
different types of cell death in the developing embryo; necrosis as a response to injury, 
apoptosis as a developmental programme, and autophagocytosis, a catabolic process 
that results in removal of cell organelles (Doherty and Baehrecke, 2018). However, 
what has been lacking for a long time was a mechanistic understanding of PCD until 
the results of studies with the nematode worm, Caenorhabditis elegans (C. elegans), 
revolutionised the field of cell death. 
 
1.1.2. C. elegans as a model of apoptosis 
 
C. elegans was introduced as a model organism by Nobel prize winner Sydney 
Brenner to allow study of a simple nervous system, and used to great effect by co-
laureates John Sulston and Robert Horvitz to advance the understanding of the 
mechanisms of apoptosis (Nobel Media Ab, 2018a). The C. elegans, comprised of 
only 1090 cells, has a short generation time (3.5 days) that makes it ideally suited for 
genetic studies. Furthermore its transparency made it possible to directly observe cell 
division utilising differential interference contrast (DIC) microscopy (Sulston et al., 
1983). Utilising this method, Sulston was able to map the cell lineage of the C. elegans 
from fertilisation up to the adult organism, and noted that the cells followed a 
remarkably predictable programme of division and differentiation (Sulston et al., 
1983), with 113 cells always being eliminated during development, and the same 18 
cells being eliminated post-embryonically (Sulston et al., 1983). The fact that cell fate 
could be mapped so precisely indicated that the process of apoptosis was intrinsically 
determined, i.e. cell autonomous (Sulston and White, 1980). The C. elegans could also 
be genetically modified to test fundamental questions about development that were 
more time consuming, expensive and complex in larger organisms (Brenner, 1974). 
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In a continuation of the work initiated by Brenner (Brenner, 1974), Horvitz began to 
define several of the key apoptotic genes in C. elegans that were later found to have 
homologs in mammals (Conradt and Horvitz, 1998; Hengartner and Horvitz, 1994; 
Trent et al., 1983; Yuan et al., 1993). The key observation, that the identified genes 
were active within the dying cells themselves, led to the notion that cell death is part 
of a “cell-suicide” mechanism. In other words, that cells activate an intrinsic cell death 
programme which leads to their elimination (Yuan and Horvitz, 1990).  
 
1.1.3. Genetic regulators of apoptosis 
 
The key genes involved in apoptosis in C. elegans, identified by Robert Horvitz, were 
identified as: egg-laying defective-1 (egl-1), cell-death abnormal-9 (ced-9), ced-4 and 
ced-3 (Hengartner and Horvitz, 1994; Trent et al., 1983; Yuan et al., 1993). It was 
revealed that these genes encode proteins that interact with each other to regulate 
apoptosis (Figure 1.1), and have homologs in mammals that interact in a similar 
manner.  
The Ced-9 mammalian homolog is B cell lymphoma 2 (Bcl-2) (Hengartner and 
Horvitz, 1994), an intracellular protein that was originally discovered due to its role 
as a proto-oncogene in human follicular lymphoma (Bakhshi et al., 1985; Tsujimoto 
et al., 1985). Mutations to ced-9 led to embryonic lethality of the C. elegans larvae, 
and it was discovered that CED-9 protein, or BCL-2 in mammals, actually act in an 
anti-apoptotic manner, protecting cells from cell death (Hengartner et al., 1992; Vaux 
et al., 1988). Due to sequence similarities in BCL-2 homology (BH) domains (BH1-
4), fourteen other BCL-2 family members have been identified in mammals, all of 
which are located in the outer membrane of the mitochondria (Adams and Cory, 2001). 
The BCL-2 family can be subdivided based on whether they are anti- or pro-apoptotic. 
Anti-apoptotic BCL-2 family members such as BCL-2, and BCL-XL, which contain 
BH domains 1-4, act to prevent cell death (Adams and Cory, 2001). BCL-2 pro-
apoptotic family members are further divided depending on presence or absence of 
particular BH domains. For example, BAX and BAK contain BH1-3, while BH3-only 
pro-apoptotic proteins include BIK, BID and BAD (Chittenden et al., 1995; 
Korsmeyer, 1999). Similarly, Egl-1 in C. elegans was found to be pro-apoptotic, and 
have homology with the mammalian BH3 domain, indicating that it may act in  a 
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similar way to BIK and BAD (Conradt and Horvitz, 1998; Del Peso et al., 1998). 
Interactions of the pro- and anti-apoptotic BCL-2 family members (such as BCL-2 and 
BAX) determines the sensitivity of a cell to apoptosis by modulating mitochondrial 
outer membrane permeabilisation (MOMP), resulting in the release of a normally 
sequestered protein called cytochrome c from the mitochondrial membrane (Kluck et 
al., 1997; Narita et al., 1998; Yang et al., 1997) (Figure 1.1). 
Finally the mammalian ced-4 homolog was identified as apoptotic protease activating 
factor-1 (Apaf-1) (Liu et al., 1996; Zou et al., 1997), and ced-3 as homologous to 
cysteine-aspartic protease (caspase)-3 (Xue et al., 1996; Yuan et al., 1993). The 
caspases are a family of fourteen cysteine proteases that cleave at specific aspartic acid 
residues (Cohen, 1997; Howard et al., 1991). They are ubiquitously expressed 
zymogens, inactive enzymes that first require cleavage themselves to be active, and 
upon activation they initiate a protease cascade that amplifies the apoptotic signal 
which leads to rapid cell death (Hengartner, 2000). The caspase family is separated 
into three groups of enzymes; 1) initiator caspases (caspase-2, -8, -9 and -10) that bind 
to adaptor molecules that promote further caspase-activation, 2) executioner caspases 
(caspase-3, -6 and -7) that activate various proteases and nucleases that leads to the 
breakdown of the cell, and 3) the inflammatory caspases (caspase-1, -4, -5, -11, and -
12) that inhibit pyroptosis during infection and stress (McIlwain et al., 2013). In C. 
elegans, CED-4 activates CED-3 processing to induce apoptosis (Seshagiri and Miller, 
1997), however in mammals, the situation is a little more complex. In mammals, the 
CED-4 homolog APAF-1 binds released cytochrome c (Figure 1.1), and undergoes a 
conformational change to recruit caspase-9, forming a multimeric complex called the 
apoptosome. Upon recruitment to the apoptosome caspase-9 is autocatalytically 
cleaved to its active form (Li et al., 1997; Saleh et al., 1999; Zou et al., 1999). This in 
turn leads to activation by cleavage of the zymogen executioner caspases that 
ultimately result in apoptosis, such as caspase-3 or caspase-7. Caspase-3 and -7 are 
thought to initiate apoptosis by cleaving cellular substrates that lead to apoptosis. For 
example, active caspase-3 and -7 induces DNA fragmentation through proteolytic 
inactivation of DNA fragmentation factor-45/inhibitor of caspase-activated 
deoxyribonuclease (DFF45/ICAD) which normally inhibits the endonuclease DNA 
fragmentation factor-40/caspase-activated DNase (DFF40/CAD). Upon unbinding of 
DFF45/ICAD and DFF40/CAD, the endonuclease can cleave DNA, leading to 
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fragmentation (Enari et al., 1998; Liu et al., 1998; Liu, Zou, et al., 1997; Sakahira et 
al., 1998; Wolf et al., 1999). Similarly, caspase-3 can cleave gelsolin, an actin binding 
protein, which results in membrane blebbing and nuclear fragmentation (Kothakota et 
al., 1997). 
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Figure 1.1 Comparison of apoptotic pathways in C. elegans and mammals.   
A) In the C. elegans, EGL-1 (green) is pro-apoptotic, and inhibits anti-apoptotic 
CED-9 (orange) which results in CED-4 (blue) activating CED-3 (yellow). CED-3 
is then able to induce apoptosis. B) In mammals the CED-9 homolog BCL-2 (orange) 
modulates the mitochondrial outer membrane permeability by interacting with 
related proteins. Under normal conditions BCL-2 is anti-apoptotic, but upon pro-
apoptotic stimuli BCL-2 is inhibited and cytochrome c can be released from the 
mitochondria (black). Cytochrome c binds to the CED-4 homolog APAF-1 (blue), 
resulting in conformational changes that lead to recruitment and activation of the 
CED-3 homolog caspase-9 (yellow) in the apoptosome.  In turn the apoptosome 
activates the executioner caspases, caspase-3 (red) and caspase-7 (purple) to induce 
apoptosis. 
A                                         B 
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1.1.4. The role of apoptosis in the mammalian nervous system 
 
The fact that 80% of apoptotic cells in the C. elegans were neurons quantitatively 
illustrates the significance of cell death in regulating the development of the nervous 
system. Remarkably however, inhibiting apoptosis in the C. elegans did not cause any 
overt phenotype in terms of lifespan or behaviour (Ellis, 1986). By contrast, in larger 
organisms including the Drosophila melanogaster (D. melanogaster) (White et al., 
1994) and the mouse (Kuida et al., 1996), ablation of apoptosis turned out to be lethal 
embryonically. This suggests that the dependence of an organism on apoptosis 
increases with the size, and complexity of the nervous system. This was supported by 
the observation that, in addition to the intrinsic apoptotic pathway outlined in section 
1.1.3 , mammals have evolved an additional, extrinsic pathway of apoptosis that is not 
found in the C. elegans (Aravind et al. 2001, see review (Flusberg and Sorger, 2015)). 
The observation that around half of newly generated neurons are eliminated during 
mammalian development, led to the hypothesis that there is an initial overabundance 
of neurons as a mechanism to ensure that distal target tissues are appropriately 
innervated (Oppenheim, 1991). Indeed, this was not a really novel thought, as it had 
already been suggested in the early 1900s that the number of peripheral nervous 
system (PNS) neurons was regulated by the size of peripheral tissues (Shorey, 1909). 
However the question remained as to how the superfluous neurons were triggered to 
undergo apoptosis.   
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1.2. Neurotrophins 
 
1.2.1. Discovery of the neurotrophins 
 
The discovery of never growth factor (NGF) by Rita Levi-Montalcini and Stanley 
Cohen led to the first mechanistic explanation as to how neuronal number could be 
regulated by the size of the target to be innervated. Their work, which in 1986 led to 
them being awarded the Nobel Prize in Physiology and Medicine (Nobel Media Ab, 
2018b), began with delicate manipulations of chick embryos. The transplantation of 
mouse sarcoma 180 into the body wall of chick embryos by Elmer Bueker led to the 
unexpected observation of substantial innervation by sensory and sympathetic nerves 
into the transplanted tumour (Bueker, 1948), more so than could be observed by 
transplantation of homologous tissues from the chick (Levi‐Montalcini and 
Hamburger, 1951). On the other hand, removal of developing chick limb buds resulted 
in a reduction of the number of motor and sensory neurons in the spinal cord and dorsal 
root ganglia, respectively (Hamburger, 1934; Hamburger and Levi-Montalcini, 1949). 
The observation that the hyper-innervated transplants were, in some cases, remotely 
located from the innervating neurons led to the hypothesis that the sarcoma cells may 
secrete a diffusible agent. This was confirmed through the use of an in vitro culture of 
chick sensory and sympathetic ganglia supplemented with mouse sarcoma 180, or 
mouse sarcoma 37 extracts, which showed a significant increase in axonal outgrowth 
(Cohen et al., 1954; Levi-Montalcini et al., 1954). Ultimately the factor, named NGF, 
was isolated (Cohen, 1960; Cohen et al., 1954; Levi-Montalcini and Cohen, 1956), 
and an antiserum was developed against the protein. Daily injections of this antiserum 
into newborn mice led to massive loss of sympathetic neurons such as those in the 
superior cervical ganglia (SCG) (Cohen, 1960; Levi-Montalcini et al., 1969; Levi‐
Montalcini and Cohen, 1960). The discovery of NGF supported the idea that excess 
neurons are generated during development to ensure adequate innervation of the target 
tissue, and that the presence of a limited amount of the diffusible factor is a mechanism 
by which to control the number of surviving neurons; cells that would not come into 
contact with NGF would undergo intrinsically programmed apoptosis (Raff, 1992).  
NGFs effects on survival of PNS sensory neurons sparked a concentrated effort to find 
a comparable growth factor in the central nervous system (CNS) that would support 
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the growth and survival of developing neurons. This led to the discovery of brain-
derived neurotrophic factor (BDNF) in 1982, initially isolated from pig brains (Barde 
et al., 1982). Analysis of the sequence similarities between NGF and BDNF revealed 
substantial comparative sequences (Leibrock et al., 1989), that led to the thought that 
NGF and BDNF were part of a larger gene family, now called the neurotrophins. By 
generating polymerase chain reaction (PCR) primers against the homologous 
sequences, two additional neurotrophins, neurotrophin-3 (NT3) (Hohn et al., 1990; 
Jones and Reichardt, 1990; Maisonpierre, Belluscio, Squinto, et al., 1990; Rosenthal 
et al., 1990) and neurotrophin-4 (NT4) (Berkemeier et al., 1991; Hallbook et al., 1991; 
Ip et al., 1992) were subsequently identified in various mammals.  There are no 
neurotrophin-related genes in C. elegans (Zlotkowski et al., 2013), suggesting that 
evolution of this gene family accompanied that of more complex nervous systems. 
 
1.2.2. Biosynthesis of the neurotrophins  
 
The four neurotrophins are synthesised as pre-proneurotrophins which consist of a pre-
prodomain on the N-terminus, and the mature neurotrophin domain on the C-terminus 
(Berkemeier et al., 1991; Ernfors et al., 1990; Leibrock et al., 1989; Scott et al., 1983; 
Suter et al., 1991). The N-terminus pre-protein directs nascent polypeptide synthesis 
to the rough endoplasmic reticulum, following which the pre-sequence is cleaved, to 
produce the proneurotrophin (Seidah et al., 1996). The proneurotrophins form non-
covalent homodimers, in which disulphide bridges form a “cystine knot”, a feature 
also found in other secreted growth factors (Bradshaw et al., 1993). The function of 
the prodomain is to ensure effective folding. Indeed, studies have shown that 
disrupting the proneurotrophin sequence prevents the formation of biologically active 
mature neurotrophins (Suter et al., 1991). The proneurotrophins are then trafficked 
through the Golgi apparatus to the Golgi network vesicles, where post-translational 
modifications such as N-glycosylation and possibly cleavage of proneurotrophins 
occur (Mowla et al., 2001). In neurons the resulting mature neurotrophins, together 
with the cleaved prodomain, are stored in large, dense-core vesicles in pre-synaptic 
terminals.  
Much less is known about the biosynthesis of neurotrophins in non-neuronal tissues, 
although it is thought that unprocessed proneurotrophins can also be trafficked, via 
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interactions with sortilin, to vesicles for secretion (Chen, 2005; Evans et al., 2011; 
Matsumoto et al., 2008; Skaper et al., 2001). Upon release, proneurotrophins can either 
undergo extracellular cleavage by matrix metalloproteases, or plasmin to produce a 
mature neurotrophin (Bradshaw et al., 1993; Bruno and Cuello, 2006; Lee et al., 2001), 
or may function without any further processing (Teng et al., 2010). The release of 
proneurotrophins from healthy neurons has historically been a point of controversy. 
Some studies have indicated that proneurotrophins can be released from neurons, but 
the majority of this work has utilised in vitro neuronal models (Hasan et al., 2003), 
either using antimitotic agents that may have compromised the health of the neurons, 
or overexpression paradigms. The use of overexpression paradigms for testing this 
hypothesis is questionable due to the fact that neurons seem to have a limited capacity 
to process pro-neurotrophins, as following injury proneurotrophins appear to escape 
neuronal processing and can be secreted (Dicou, 2008). 
 
1.2.3. Localisation of the neurotrophins 
 
NGF is found both in neuronal and non-neuronal cells, but most notably in the 
peripheral target tissues of sensory and sympathetic neurons, including the dermal 
layers (Wheeler and Bothwell, 1992), the whisker pad (Ernfors et al., 1992; Leon et 
al., 1994; Selby et al., 1987), salivary gland (Levi‐Montalcini and Cohen, 1960), heart 
(Selby et al., 1987), retina and iris (Ernfors et al., 1992; Selby et al., 1987). The areas 
of the CNS where NGF is secreted at the highest quantities are the hippocampus 
(Pascual et al., 1998; Rocamora et al., 1996), and cortex (Selby et al., 1987).  
As a point of comparison, the levels of BDNF mRNA in the hippocampus are around 
50-fold higher than those of NGF mRNA. In the CNS Bdnf is primarily expressed by 
neurons with the highest levels in the hippocampus, neocortex (Hofer et al., 1990; 
Timmusk, Palm, et al., 1993), cerebellum, and pituitary gland (Timmusk, Belluardo, 
et al., 1993). BDNF mRNA and protein has also been localised in the cochlea, 
vestibule macula (Ernfors et al., 1992; Pirvola et al., 1992), heart (Ibáñez et al., 1993), 
lung (Timmusk, Belluardo, et al., 1993), and kidney (Timmusk, Belluardo, et al., 
1993).  
Ntf4 (the gene encoding NT4 in mice), like Bdnf, is expressed in the hippocampus, 
cortex, cerebellum, and striatum. NT4 can also be detected in non-neuronal tissues 
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such as the heart, lung, and kidney. However in contrast to BDNF, NT4 can also be 
found in the testis, skeletal muscle, and thymus (Timmusk, Belluardo, et al., 1993).  
Ntf3, the gene for NT3 in mice, has a more restricted expression pattern in the adult 
CNS than other neurotrophins; and is located in the hippocampus, and cerebellum 
(Ernfors et al., 1992; Maisonpierre, Belluscio, Friedman, et al., 1990). During 
development Ntf3 is the most highly expressed neurotrophin, and expression decreases 
as cells undergo mitosis. One such example of this is the cortex. NT3 can also be 
detected in non-neuronal tissues such as the whisker pad, muscle spindles, epithelium, 
iris, cochlea and heart (Maisonpierre, Belluscio, Friedman, et al., 1990; Pirvola et al., 
1992). 
 
1.2.4. The neurotrophin receptors  
 
The neurotrophins interact with two different classes of receptors; tropomyosin 
receptor kinase (Trk) receptors and the p75 neurotrophin receptor (p75NTR) (Figure 
1.2). p75NTR shares a similar affinity for all four mature neurotrophins (Kd = 10
-9 M) 
(Esposito et al., 2001; Hempstead et al., 1991; Rodriguez-Tebar et al., 1990), but binds 
proneurotrophins with higher affinity (Kd = 10
-11 M) (Lee et al., 2001). The three Trk 
receptors, designated TrkA, TrkB and TrkC, bind mature neurotrophins with a similar 
affinity to that of p75NTR (Kd = 10
-9 M) (Esposito et al., 2001; Hempstead et al., 1991), 
but with significantly more selectivity; while NGF preferentially binds TrkA (Kaplan 
et al., 1991; Klein, Jing, et al., 1991), BDNF and NT4 bind TrkB (Klein et al., 1992; 
Klein, Nanduri, et al., 1991; Soppet et al., 1991; Squinto et al., 1991), and NT3 to 
TrkC (Lamballe et al., 1991) (Figure 1.2). However NT3 has been found to also bind 
to both TrkA and TrkB in vitro (Cordon-Cardo et al., 1991; Klein, Nanduri, et al., 
1991; Soppet et al., 1991; Squinto et al., 1991). Interaction of p75NTR and the Trk 
receptors leads to high affinity binding sites for the neurotrophins (Kd = 10
-11 M) 
(Esposito et al., 2001). 
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Figure 1.2 Binding of the neurotrophins to the Trk and p75NTR receptors.  The 
mature neurotrophins selectively bind to one of three Trk receptors, although NT3 can 
bind to TrkA or TrkB in vitro (dotted arrows). p75NTR can be bound by all four 
neurotrophins in both mature and proneurotrophin form. The Trk receptors share a 
similar structure, with an extracellular domain consisting of two cysteine-rich clusters 
(C1, C2; red), three leucine-rich repeats (LRR1-3; blue), and two immunoglobulin-
like domains (Ig1, Ig2; green). Each Trk has a single transmembrane domain, and a 
single cytoplasmic tyrosine kinase domain (TK; purple). p75NTR has four cysteine-rich 
domains (CR1-4; yellow) that are responsible for ligand binding, a single 
transmembrane domain, and an intracellular death domain (green).  
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1.2.4.1. p75NTR 
 
p75NTR was the first identified neurotrophin receptor, and first identified member of 
the tumour necrosis factor (TNF) superfamily (Chao et al., 1986; Johnson et al., 1986; 
Radeke et al., 1987). The gene encoding p75NTR, named Ngfr, is located on 
chromosome 11 in mice (17q12-17q22 in humans  (Huebner et al., 1986; Sehgal et al., 
1988)). The p75NTR receptor is a 75 kDa transmembrane glycoprotein with an 
extracellular domain (consisting of four cysteine-rich (CR) domains responsible for 
interactions with the neurotrophins (Baldwin et al., 1992; He and Garcia, 2004; Yan 
and Chao, 1991)), a transmembrane domain, and an intracellular domain. The 
intracellular domain contains a palmitoylation site which is involved in subcellular 
trafficking of the receptor (Barker et al., 1994), two potential sites of binding for TNF 
receptor-associated factor (TRAF) that modulate intracellular signalling (Zotti et al., 
2017), and a type II death domain that regulates downstream apoptotic signalling via 
p75NTR (Lin et al., 2015). p75NTR can bind both mature and pro-neurotrophins, and 
other ligands, such as prion protein fragment PrP (106-206) (Della-Bianca et al., 
2001), and the amyloid precursor protein (APP) Aβ-peptide (Yaar et al., 1997). 
Alternative splicing of exon III produces an isoform of p75NTR that lacks the cysteine 
rich domains 2-4 (referred to as s-p75NTR) and consequently, is unable to bind 
neurotrophins (Figure 1.3). The function of this isoform is still unknown, although it 
has been found to be expressed in mice, rats and humans (Von Schack et al., 2001).   
Several studies have implicated the expression of p75NTR in many CNS and PNS 
neuronal types across different species (Ernfors et al., 1988; Schatteman et al., 1988; 
Shelton and Reichardt, 1986; Yan et al., 1988), however recent comparison of p75NTR 
mRNA levels between chick and murine samples have shown that some regions with 
high p75NTR expression in the chick, do not show any expression in the mouse, and 
vice versa, indicating that cell-specific comparisons regarding p75NTR expression 
levels cannot be drawn between these species (S. Wyatt and A. Davies, by 
communication). Within the mouse, p75NTR is expressed in several CNS populations 
such as the hippocampus during development, and decreases postnatally (Bernabeu 
and Longo, 2010).  
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1.2.4.2. TrkA, TrkB and TrkC 
 
The Trk receptors are members of a family of fifty eight enzyme-linked 
transmembrane glycoproteins called the receptor tyrosine kinases (RTKs). The RTKs 
share a common structure; with an extracellular ligand binding domain, 
transmembrane domain, and intracellular tyrosine kinase domain (Hubbard and 
Miller, 2007). There are three Trk receptors; TrkA, TrkB and TrkC, that share  
~40-45% pairwise sequence homology (Ultsch et al., 1999).  
All three Trk receptors have an extracellular domain which is comprised of two 
cysteine-rich clusters (C1, C2), three leucine-rich repeats (LRR1-3), and two 
immunoglobulin-like domains (Ig1, Ig2) (Schneider and Schweiger, 1991; Windisch 
et al., 1995). The immunoglobulin-like (Ig) domains are the main site of neurotrophin 
binding (Holden et al., 1997; Ultsch et al., 1999; Urfer et al., 1995), and the leucine-
rich domains seem to also play a role in binding (Windisch et al., 1995). Indeed, TrkC 
chimeras where the immunoglobulin domains had been replaced by TrkB or TrkA Ig 
sequences allowed binding of BDNF and NGF (Urfer et al., 1995).  The extracellular 
domain of the Trk receptors are also subject to post-translational glycosylation of the 
N-terminus which serves to prevent ligand-independent activation of the receptor, and 
for localisation in the cell membrane (Watson et al., 1999). The intracellular domain 
consists of a tyrosine kinase domain which recruits various intracellular signalling 
proteins through phosphorylation (section 1.2.5 for more details) (Obermeier et al., 
1994; Obermeier, Halfter, et al., 1993; Obermeier, Lammers, et al., 1993; Stephens et 
al., 1994) (Figure 1.3).  
Each of the Trk receptors have several isoforms in the mouse due to differential 
splicing of exons that encode the receptors: two splice variants exist for TrkA (Clary 
and Reichardt, 1994), three for TrkB (Klein, Conway, et al., 1990; Kumanogoh et al., 
2008) and six for TrkC (Tessarollo et al., 1997), including full-length and truncated 
proteins (Figure 1.3). These splicing events can lead to either minor, or major changes 
in the function of the receptor. An example of a minor alteration are changes to short 
amino acid sequences in the extracellular, juxtamembrane regions. Lack of the 
juxtamembrane insert in TrkA or TrkB leads to activation only by NGF and BDNF, 
respectively (Clary and Reichardt, 1994; Strohmaier et al., 1996; Urfer et al., 1995), 
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however with the juxtamembrane inserts both receptors can be activated by NT3, and 
additional activation of TrkB by NT4 can occur (Boeshore et al., 1999; Clary and 
Reichardt, 1994; Meakin, 1997; Strohmaier et al., 1996).  
TrkC also has an isoform with a small insert in the tyrosine kinase domains which 
affects the substrate specificity, thus altering the intracellular signalling pathways 
(Garner and Larget, 1994; Guiton et al., 1995; Valenzuela et al., 1993). TrkB receptor 
splice variants result in truncated receptors that lack the intracellular kinase domain. 
Two truncated isoforms of TrkB exist in the CNS, TrkB.T1 and TrkB.T2 which differ 
only by the existence of an Shc-binding site in TrkB.T2 (Klein, Conway, et al., 1990). 
TrkC splice variants also include four truncated receptors that resemble the previously 
described truncated TrkB variants (Lamballe et al., 1991; Valenzuela et al., 1993) 
(Figure 1.3). The predominant theory for the function of these truncated receptors is 
that they regulate full length Trk receptor function, and are thought to act via a 
dominant-negative mechanism, forming non-functional heterodimers with full length 
receptors (Eide et al., 1996).  
Whilst both p75NTR and the Trk receptors bind neurotrophins, their extracellular 
domains are unrelated. Whereas the neurotrophins interact with the Ig2 domains 
within the Trk receptors (Holden et al., 1997; Ultsch et al., 1999; Urfer et al., 1995), 
they interact with the cysteine-rich domains in the p75NTR receptor (Baldwin et al., 
1992; Wiesmann and de Vos, 2001; Yan and Chao, 1991) (Figure 1.3). Furthermore, 
the intracellular domain of p75NTR does not contain a tyrosine kinase domain, and are 
unable to induce ligand-induced activation of intracellular signalling proteins (Roux 
and Barker, 2002).  
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Figure 1.3 Alternative splicing produces different sizes of neurotrophin receptors. Schematic of the known splice variants for the neurotrophin 
receptors. Full length p75NTR consists of four extracellular cysteine-rich domains (yellow) while the splice variant, s-p75NTR, only has one CR 
domain. Both variants of p75NTR contain an intracellular death domain (dark green). TrkA, TrkB and TrkC splice variants have similar extracellular 
domains with cysteine-rich clusters (C1, C2; red), three leucine-rich repeats (LRR1-3; blue), and two immunoglobulin-like domains (Ig1, Ig2; 
green), with the exceptions of one splice variant for TrkA (neuronal) and one for TrkB (full-length +) which contain a juxtamembrane insert. TrkB 
also has two truncated receptors; TrkB.T1 and TrkB.T2 that lack the tyrosine kinase (TK, purple) but have a small intracellular domain which is 
different between T1 and T2. Finally TrkC has five splice variants; one with a tyrosine kinase insert (TK+), and four truncated receptors. 
 
 
 
 
 
P
ag
e│
1
7
 
  Chapter 1 
Page | 18  
 
1.2.5. Signalling via Trk receptors 
 
Binding of the mature neurotrophins to the Trk receptors results in receptor 
dimerization (Jing et al., 1992), allowing transphosphorylation of the receptors 
tyrosine kinase domains within the activation loop (Cunningham et al., 1997; 
Cunningham and Greene, 1998). This results in further phosphorylation of tyrosine 
sites within the tyrosine kinase domain that then act as docking sites for intracellular 
adaptor proteins such as Src homologous and collagen-like (Shc) and phospholipase-
C (PLC) that are also phosphorylated by the Trk receptor intracellular domain 
(Obermeier et al., 1994; Obermeier, Halfter, et al., 1993; Obermeier, Lammers, et al., 
1993; Stephens et al., 1994). These adaptor proteins activate further signalling 
cascades such as RAS/mitogen-activated protein kinases (MAPKs), phosphoinositide 
3-kinase (PI3K) and phospholipase C γ (PLCγ) (Mitre et al., 2017).  
As the locations of neurotrophin expression can be far from the cell soma of Trk-
expressing neurons (discussed in section 1.2.3), it is important to note that ligand-
bound Trk receptors can be internalised through clathrin-mediated endocytosis 
(Grimes et al., 1996; Howe et al., 2001; Jullien et al., 2003). Application of 
monodansylcadaverine, a drug that inhibits clathrin-mediated endocytosis, results in 
an inhibition of Trk receptor internalisation (Du et al., 2003; Zheng et al., 2008). It is 
thought that macropinocytic endocytosis of the Trk receptors occurs, but only when 
there is an excess of the respective neurotrophin or Trk receptor, such as in the cases 
of genetically-modified animals or in vitro experiments, and is therefore not thought 
to occur under physiological conditions (Philippidou et al., 2011; Shao et al., 2002; 
Valdez et al., 2007).Within the endosomes, ligand-bound Trk receptors continue 
signalling (Grimes et al., 1996, 1997), and can also be retrogradely transported along 
microtubules to the cell soma (Ginty and Segal, 2002; Hendry, Stach, et al., 1974; 
Hendry, Stockel, et al., 1974). Trk receptors can also be trafficked into late endosomes 
for degradation into lysosomes.  
  Chapter 1 
Page | 19  
 
1.3. Mechanisms of neurotrophin cell survival/cell death 
 
1.3.1. Evidence of cell death caused by neurotrophin-withdrawal  
 
Following the identification of the four neurotrophins and their receptors, their role in 
supporting the survival of specific populations of sensory neurons has been 
investigated in considerable detail.  In vitro studies demonstrated that cultured TrkA, 
TrkB or TrkC-expressing sympathetic or sensory neurons died within forty-eight 
hours of neurotrophin withdrawal (Deckwerth and Johnson, 1993; Edwards and 
Tolkovsky, 1994; Martin et al., 1988). During death the cells had key morphological 
indicators of apoptosis; around twenty hours after neurotrophin withdrawal the DNA 
started to fragment (Deckwerth and Johnson, 1993; Edwards et al., 1991), and between 
eighteen to twenty-four hours, the nuclei shrunk and showed DNA condensation 
(Deshmukh and Johnson, 1997; Levi-Montalcini et al., 1969; Martin et al., 1988; 
Mesner et al., 1992). At this stage, microinjection of the prosurvival protein BCL-2 
rescued neurotrophin-dependent neurons that had undergone neurotrophin withdrawal 
(Allsopp et al., 1993; Batistatou et al., 1993; Garcia et al., 1992; Greenlund et al., 
1995; Mah et al., 1993; Troy et al., 1996). Neurons reach a commitment point twenty-
two hours after neurotrophin withdrawal, and the application of the respective 
neurotrophin could no longer rescue half of the cells (Deckwerth and Johnson, 1993; 
Edwards and Tolkovsky, 1994). Observations of morphological apoptosis were 
matched by biochemical analysis that demonstrated increased caspase activity, and 
cytochrome c release, after neurotrophin-withdrawal (Deshmukh et al., 1996; Neame 
et al., 1998; Stefanis et al., 1996; Troy et al., 1996) (discussed in section 1.1.3), 
supporting that neurotrophin withdrawal results in cell death via the intrinsic apoptotic 
pathway. Similarly, ablation of APAF-1, caspase-9 or caspase-3 prevented 
neurotrophin-withdrawal induced apoptosis in sensory and sympathetic neurons 
(Wright et al., 2007). Although overall RNA and protein synthesis levels dropped by 
30% twelve hours after neurotrophin withdrawal (Deckwerth and Johnson, 1993), key 
apoptotic genes, such as c-Jun that interacts with BCL-2 family proteins to regulate 
apoptosis (Lei and Davis, 2003), showed a marked increase from five hours after 
withdrawal (Estus et al., 1994; Freeman et al., 1994). Indeed, inhibiting RNA and 
protein synthesis, by application of inhibitors such as cycloxheximide, prevented 
neurotrophin-withdrawal induced death of neurons in vitro and in vivo (Martin et al., 
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1988; Milligan et al., 1994; Oppenheim et al., 1990; Scott and Davies, 1990). Thus, 
the loss of specific populations of neurons as a result of neurotrophin withdrawal 
seems to be an active process requiring transcription and protein synthesis.  
 
1.3.2. Neurotrophin/Trk knockout studies  
 
The in vivo relevance of the neurotrophin signalling system in cell survival during 
development has been convincingly established in homozygous loss-of-function 
mouse models (discussed below).  
 
1.3.2.1. NGF and TrkA 
 
Animals lacking NGF (Ngf-/-) die within the first few days after birth with no obvious 
abnormalities in any major organs, but with marked reduction in the size of 
sympathetic ganglia. This included innervation from the superior cervical ganglia 
(SCG) to the eye (Crowley et al., 1994). Similar results were obtained in TrkA-/- pups, 
where the SCG was completely absent (Fagan et al., 1996; Smeyne et al., 1994). The 
loss of neurons correlated with the finding that >95% of the cells in the SCG are TrkA 
positive (NGF dependent) (Dixon and McKinnon, 1994).  
In the same way, there was a 70-90% loss of sensory dorsal root ganglia (DRG) 
neurons in the Ngf and TrkA knockouts (Crowley et al., 1994; Smeyne et al., 1994). 
The DRG are a collection of sensory neuron cell bodies that lie bilaterally at each 
vertebral level of the spinal cord. The DRG are made up of several different sub-types 
of neurons including three main sub-divisions: Aδ, or peptidergic C-fibre, nociceptive 
neurons that express TrkA, Aβ mechanoceptors that express TrkB, and Aα and Aβ 
proprioceptive neurons that express TrkC (Duce and Keen, 1977; Harper and Lawson, 
1985; Lawson et al., 1974; Lawson, 1979; Mu et al., 1993). The DRG neurons lost in 
NGF homozygous knockout mice were the nociceptive neurons (Crowley et al., 1994; 
Smeyne et al., 1994), and as a consequence Ngf-/- or TrkA-/- mice demonstrated 
increased latency to respond to heat-induced pain, or pin-pricks (Crowley et al., 1994; 
Smeyne et al., 1994). As there was no loss of the DRG mechanoceptive or 
proprioceptive neurons in Ngf-/- and TrkA-/-, they exhibited normal motor activity and 
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placing reflexes (Crowley et al., 1994; Smeyne et al., 1994). Similar to the DRG, the 
trigeminal ganglia (TG) is a heterogeneous collection of sensory neuron cell bodies 
that differentially express Trk receptors (Mu et al., 1993). TrkA-/- and Ngf-/- mice 
showed loss of 70-90% of the small-diameter, nociceptive neurons in the trigeminal 
ganglia, resulting in a behavioural phenotype where there is loss of pain sensation in 
response to whisker pad pin-pricks (Smeyne et al., 1994).  
Other neuronal populations have also been demonstrated to be modestly affected by 
loss of NGF/TrkA signalling. There was a small, but non-significant reduction in the 
nodose ganglia neurons (Crowley et al., 1994), which contains the cell bodies of 
neurons that project to visceral organs such as the lungs (Conover et al., 1995; 
Hertzberg et al., 1994). Disruption of NGF/TrkA signalling led to a 20% reduction in 
the number of TrkA-expressing neurons in the CNS, such as the basal forebrain 
cholinergic neurons (Chen et al., 1997; Fagan et al., 1997; Sanchez-Ortiz et al., 2012; 
Smeyne et al., 1994; Svendsen et al., 1994) that project to the cerebral cortex, 
hippocampus and amygdala (Dreyfus, 1989). These changes occur during postnatal 
development, and so were not initially observed. The loss of this population of cells 
has been linked to memory deficits in heterozygous Ngf knockouts that survived 
postnatally (Chen et al., 1997). Other ganglia for the facial, acoustic and 
glossopharyngeal nerves appeared to not be affected by the loss of NGF/TrkA 
signalling (Smeyne et al., 1994).  
 
1.3.2.1.1. BDNF/NT4 and TrkB 
 
The effects of Bdnf, Ntf4, TrkB knockouts differ from those of Ngf/TrkA due to the 
differential pattern of expression of the ligands and their corresponding receptors. For 
example, as there is no detectable TrkB in the SCG, Ntf4-/- or Bdnf-/- knockouts did not 
demonstrate any loss of these neurons (Jones et al., 1994; Liu et al., 1995). What is 
striking is that Bdnf-/- and Ntf4-/- mice have clear differences in their phenotypes, 
despite both binding to TrkB. For example, Ntf4-/- mice could survive into adulthood 
with no obvious behavioural phenotypes (Conover et al., 1995), whilst Bdnf-/- or  
TrkB-/- pups died within the first few days of birth, with only a few surviving into the 
first postnatal week. Bdnf-/- or TrkB-/- knockout mice displayed no obvious physical 
deformities, and were a similar size to their littermates at birth, although those that 
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survive later showed retarded growth compared to their littermates (Erickson et al., 
1996; Ernfors, Lee and Jaenisch, 1994; Jones et al., 1994; Klein et al., 1993).  
Bdnf-/- or TrkB-/- mice had similar behavioural phenotypes in that they suffered from 
severe movement deficits such as difficulty righting and spinning, hunched stance, and 
ataxia, along with breathing abnormalities (Erickson et al., 1996; Ernfors, Lee and 
Jaenisch, 1994; Jones et al., 1994; Klein et al., 1993). TrkB-/-  pups were unable to feed 
as a result of these movement deficits, despite having normal gastrointestinal tracts 
(Klein et al., 1993).  
Over 95% of nodose-petrosal ganglia (NPG) neurons express TrkB (Huang et al., 
1999). Ntf4-/- or Bdnf-/- knockout mice demonstrated a loss of 50-60% of the NPG 
(Conover et al., 1995; Erickson et al., 1996; Ernfors, Lee and Jaenisch, 1994; Liu et 
al., 1995), whilst double knockouts of both Bdnf and Ntf4 demonstrate a 90% reduction 
in the number, and size of NPG (Conover et al., 1995; Erickson et al., 1996; Liu et al., 
1995). The loss of NPG neurons in the Bdnf/Ntf4 double knockout matched that of 
TrkB-/-  mice (Erickson et al., 1996). Similarly, the geniculate ganglia, containing cell 
bodies responsible for taste that innervate the gustatory epithelium, demonstrated a 
40-50% reduction in the number of neurons in either Bdnf-/- or Ntf4-/- pups (Conover et 
al., 1995; Erickson et al., 1996; Jones et al., 1994; Liu et al., 1995), in the Bdnf/Ntf4 
double knockout showed a loss of 95% of the geniculate ganglia cells (Conover et al., 
1995; Erickson et al., 1996; Fei and Krimm, 2013; Liu et al., 1995), which corresponds 
to the reduction of the geniculate ganglia in TrkB-/- pups (Fritzsch et al., 1997). This 
indicates that the NPG and geniculate contain different subpopulations of ganglia that 
are BDNF or NT4-dependent alone, and the double knockout suggests there is little 
redundancy between the two ligands. The loss of a similar number of NPG or 
geniculate ganglia neurons in the double knockout, compared to the TrkB knockout, 
indicates that these differential effects are still mediated by TrkB in these different 
subsets of the ganglia. Specific subsets of dopaminergic neurons are lost in the NPG 
of BDNF knockout mice innervate the carotid body, and they are important for 
effective ventilation, and cardiorespiratory reflexes (Erickson et al., 1996). This seems 
to be the main explanation for the severe respiratory abnormalities, and ultimately the 
lethality, observed in Bdnf or TrkB, but not Ntf4 knockouts.  
On the other hand, DRG neurons appear to be dependent upon both BDNF (Ernfors, 
Lee and Jaenisch, 1994), and NT4 (Liu et al., 1995), demonstrating a 30% vs a 15% 
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reduction in knockouts, respectively, while there is a 20-30% reduction in the number 
of DRG neurons in TrkB-/- mice. This indicates that there is overlap between NT4 and 
BDNF responsive neurons in the DRG. The neurons that were lost in these knockouts 
were found to correspond to the TrkB-expressing, large-diameter mechanoceptive 
neurons (Klein et al., 1993; Minichiello et al., 1995; Perez-Pinera et al., 2008). 
The vestibular ganglia, a collection of TrkB-expressing sensory neurons required for 
balance and locomotion (Ernfors et al., 1992; Robinson, 1996), appeared to only be 
dependent on BDNF, with reports of 80-90% reduction in the number of vestibular 
ganglia neurons in Bdnf-/- mice (Conover et al., 1995; Ernfors, Lee and Jaenisch, 1994; 
Jones et al., 1994). These neurons failed to innervate vestibular sensory epithelia 
(Ernfors, Lee and Jaenisch, 1994). However the vestibular ganglia were not affected 
in Ntf4-/- mice (Conover et al., 1995). Similarly there is no additive effect in the 
Bdnf/Ntf4 double knockout (Conover et al., 1995; Liu et al., 1995). This may be an 
explanation as to the severe movement deficits observed in Bdnf-/- and TrkB-/- mice, 
but not Ntf4-/- mice. Counter-intuitively, there has been only a reported loss of 60% of 
vestibular neurons in TrkB knockout mice (Minichiello et al., 1995; Schimmang et al., 
1995). There are also differential effects between NT4 and BDNF on survival of 
trigeminal ganglia. While NT4 doesn’t seem to be important in the survival of 
trigeminal ganglia neurons in knockout mice (Conover et al., 1995), Bdnf-/- mice 
exhibited a 30-40% reduction in the number of trigeminal neurons (Conover et al., 
1995; Ernfors, Lee and Jaenisch, 1994; Jones et al., 1994) that is matched in the 
Bdnf/Ntf4 double knockout (Conover et al., 1995; Liu et al., 1995). Similarly, TrkB 
knockouts demonstrate a 60% reduction in the number of trigeminal neurons (Klein et 
al., 1993)  
In vitro, and in vivo lesion experiments initially suggested that BDNF was important 
for the survival of CNS neurons, including motor neurons in particular (Alderson et 
al., 1990; Lindsay et al., 1985; Oppenheim et al., 1992; Sendtner et al., 1992). Given 
the widespread expression of BDNF across the CNS (Rauskolb et al., 2010), it was 
expected that BDNF would be responsible for the survival of CNS neurons. However 
knockout studies have indicated that there are few developmental deficits in the CNS 
of Bdnf-/- or Ntf4-/- mice (Jones et al., 1994). There appears to be delayed, but normal 
migration of cerebellar granule neurons in Bdnf-/- or Ntf4-/- animals, while the cortex, 
basal forebrain, substantia nigra and hippocampus appear normal (Jones et al., 1994; 
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Liu et al., 1995). Similarly, the loss of TrkB has not been found to link to obvious CNS 
abnormalities (Klein et al., 1993). However studies have found that in TrkB-/- mice 
that can survive for a few weeks postnatally, there is an increase in the number of 
pyknotic nuclei in the neocortex, striatum, thalamus and dentate gyrus (Alcantara et 
al., 1997). However, as these effects only occur late and in animals with compromised 
health status causality is difficult to establish with certainty. 
  
1.3.2.2. NT3 and TrkC 
 
Ntf3-/- and TrkC-/- mice usually die within the first few days of life, although some TrkC 
knockout pups can survive up to three weeks (Klein et al., 1994; Tessarollo et al., 
1994, 1997). Both TrkC and Ntf3 knockouts take nourishment from their mothers 
unlike the Ngf/TrkA, or Bdnf/Ntf4/TrkB knockouts outlined above, although TrkC-/- 
pups that survive are 25-50% of the body weight of their wild type littermates (Klein 
et al., 1994). Also unlike the other neurotrophins, both Ntf3-/- or TrkC-/-  mice exhibit 
severe cardiac deficits such as defects in the atrial and ventricular septum, and 
pulmonic stenosis (Donovan et al., 1996; Tessarollo et al., 1994, 1997), which could 
account for the perinatal lethality observed. Later studies have shown that NT3/TrkC 
signalling via the tyrosine kinase domain is important for the proliferation of cardiac 
myocytes (Donovan et al., 1996; Lin et al., 2000; Tessarollo et al., 1997). 
In the Ntf3-/- and TrkC-/- mice, there is a loss of specific subsets of sensory and 
sympathetic neurons. Importantly, the Ntf3 knockout consistently shows a more severe 
phenotype compared with TrkC-/- animals. For example, within the NPG, 30-50% of 
neurons are lost in Ntf3-/- pups (Ernfors, Lee, Kucera, et al., 1994; Farinas et al., 1994; 
Tessarollo et al., 1997), compared to 15% in TrkC-/- pups (Tessarollo et al., 1997). The 
number of neurons lost in the NPG in Ntf3-/- and TrkC-/- mice is not enough to result in 
any obvious breathing deficits. Similarly there is a 25-35% reduction in the number of 
neurons in the geniculate nucleus of Ntf3-/- pups, but only a modest, non-statistically 
significant reduction of 10% in TrkC-/- pups (Farinas et al., 1994; Tessarollo et al., 
1997). Along these lines, Ntf3-/- exhibit a 60-70% and a 20% reduction in the number 
of trigeminal and vestibular ganglia neuronal cell bodies, respectively (Ernfors, Lee, 
Kucera, et al., 1994; Farinas et al., 1994; Tessarollo et al., 1997; Tojo et al., 1995), 
versus 20% and 15% in TrkC-/-  knockouts, respectively (Farinas et al., 1994; 
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Tessarollo et al., 1997). Finally, the severe abnormal posture and limb movement in 
Ntf3-/- and TrkC-/- mice (Klein et al., 1994; Tessarollo et al., 1994) seems to be the 
result of the loss of large-diameter, TrkC-expressing proprioceptive neurons in the 
DRG (Klein et al., 1994; Matsuo et al., 1999; Tessarollo et al., 1997). In Ntf3-/- mice 
this is around 55-70% of DRG neurons (Ernfors, Lee, Kucera, et al., 1994; Fariñas et 
al., 1998; Tessarollo et al., 1997; Tojo et al., 1995), and 20% in TrkC knockouts (Klein 
et al., 1994; Tessarollo et al., 1997). The discrepancy between the phenotype of 
animals lacking Ntf3 or TrkC is particularly obvious in sympathetic ganglia. For 
example in the SCG, TrkC knockouts show no significant differences in the number 
of SCG neurons, but there is a 50-80% reduction in Ntf3 knockouts (ElShamy and 
Ernfors, 1996; Ernfors, Lee, Kucera, et al., 1994; Fagan et al., 1996; Farinas et al., 
1994). As in vitro NT3 can also activate the TrkA and TrkB receptors, it was initially 
proposed that the discrepancy between the phenotype of animals lacking either Ntf3 
or TrkC may reflect the activation of heterologous receptors by NT3 in the absence of 
TrkC (Davies et al., 1995). However, this possibility does not seem to hold true for all 
ganglia where detailed comparisons have been made using gene substitution 
experiments. For example, replacing BDNF by NT3 fails to rescue TrkB-expressing 
vestibular neurons suggesting a failure of NT3 to activate TrkB in vivo (Tessarollo, 
2004).  
 
1.3.3. Dependence receptors 
 
The observations summarised in section 1.3.2 further added weight to the notion that 
neurons are intrinsically programmed to die during development unless a diffusible 
survival factor, such as the neurotrophins, blocks their death (Jacobson et al., 1997; 
Oppenheim, 1991). Indeed, studies have detailed the pro-survival signalling of the 
ligand-bound Trk receptors via PI3K/Akt and Ras/MEK/MAPK pathways (Borasio et 
al., 1993; Crowder and Freeman, 1998; Nobes and Tolkovsky, 1995; Yao and Cooper, 
1995). However, there was a struggle to underpin this theory with a pathway for the 
default apoptotic state, and the question remained; what causes neurons to die in the 
first place and how could the selectivity of this phenomenon be explained? 
In 1998 the concept of dependence receptors was proposed (Bredesen et al., 1998). 
The term refers to receptors endowed with non-classical signal transduction in that 
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they signal both when ligand-bound and in the absence of the ligand. When ligand 
bound the receptors transduce positive signals to support cell survival, and in the 
absence of the cognate ligand the receptors actively transduce signals to initiate cell 
death. This new concept was initially developed in the context of tumour biology with 
the identification of the receptors deleted in colorectal cancer (DCC) and 
uncoordinated-5 homolog (UNC5H) (Llambi et al., 2001; Mehlen et al., 1998) that kill 
dividing cells in the absence of the corresponding ligand. 
 
1.3.4. TrkC as a dependence receptor 
 
In 2007, Servane Tauszig-Delamasure and colleagues demonstrated, using in vitro 
cells transfected with Trk receptors, that TrkC acts a dependence receptor. Their 
experiments involved transient transfection of full length rat TrkC (rTrkC) in human 
embryonic kidney 293 (HEK293T), and immortalised olfactory neuroblast 13.S.24 
cells (Tauszig-Delamasure et al., 2007). Transfected cells had increased levels of 
apoptosis, exhibited by increased levels of active caspase-3 and DNA condensation, 
and the addition of NT3 prevented this cell death in a dose-dependent manner. The 
authors determined that TrkC-induced apoptosis did not seem to involve the kinase 
activity of the receptor, as a kinase-dead mutant of TrkC (D679N) elicited similar pro-
apoptotic activity, indicating that other mechanisms were involved. Intriguingly, they 
also observed that TrkC-induced apoptosis was correlated with double cleavage of the 
TrkC intracellular domain by active caspase 3, and apoptosis could be blocked by 
preventing cleavage using the pan-caspase inhibitor carbobenzoxy-valyl-alanyl-
aspartyl-[O-methyl]-flouromethylketone (zVAD-fmk). To determine if the cleaved 
TrkC domain would cause cell death, they performed microinjections of the 
“dependence domain” released by cleavage (mapped as TrkC 496-641 in rat TrkC) 
into primary DRG neurons, and observed increased apoptosis (Tauszig-Delamasure et 
al., 2007).  
These results provided a novel explanation for how developing sensory and 
sympathetic neurons undergo apoptosis during development; the mere expression of 
the Trk receptors causes cell death when the ligand is not present. In this way, the 
number of cells innervating a target tissue can be controlled by secreting limited 
amounts of neurotrophins as superfluous neurons that do not get enough neurotrophin 
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die. This is referred to as the “neurotrophic hypothesis”. However, these new 
observations added to the neurotrophic hypothesis by demonstrating that it is the 
expression of the Trk receptors in the first place that causes neurons to be susceptible 
to cell death. These findings neatly explained the neuronal selectivity of neurotrophins 
as pro-survival factors, and also clarified in vivo observations discussed in section 
1.3.2 that Ntf3 knockout mice have an increased loss of sensory and sympathetic cells 
compared to TrkC knockouts.  
While around twenty dependence receptors have been identified, these receptors do 
not share obvious structural similarities, so knowledge of the mechanisms of one 
receptor cannot inform predictions about related receptors. However in 2013, Tauszig-
Delamasure’s group reported that the cleaved, intracellular, death domain of TrkC 
(termed TrkC-KF) is shuttled to the mitochondrial membrane by Cobra1, a cofactor 
for BRCA1 that relatively little is known about (Figure 1.4). TrkC-KF was then 
suggested to promote the activation of Bax, which resulted in the release of 
cytochrome c from the mitochondria, triggering the intrinsic pathway of apoptosis 
(Ichim et al., 2013). Altogether the findings by Tauszig-Delamasure et al. (2007) and 
Ichim et al. (2013) fit with the previous observations, for example that apoptosis 
induced by neurotrophin-withdrawal can be blocked by caspase inhibitors as this 
would be predicted to prevent caspase-mediated cleavage of TrkC.  
  
 
 
Figure 1.4 Suggested model of TrkC-induced cell death. Unbound TrkC intracellular domain is cleaved by caspase-3 at sites D495 and 
D641 to produce the TrkC killer fragment (TrkC-KF). Cobra-1 shuttles TrkC-KF to the mitochondrial membrane which allows the release 
of cytochrome c to induce apoptosis. Taken from (Ichim et al., 2013). 
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1.3.5. TrkA as a dependence receptor 
 
In the same set of experiments leading to the identification of TrkC as a dependence 
receptor, Tauszig-Delamasure reported that TrkA or TrkB did not behave as 
dependence receptors. However, a later study by Nikoletopoulou et al. (2010) 
identified TrkA, along with TrkC, as a dependence receptor using genetically-
modified mouse embryonic stem cells (ESCs). The benefit of ESCs over the 
HEK293T cells used by Tauszig-Delamasure is that these cells can readily be 
differentiated into homogenous populations of post-mitotic neurons in which to study 
neuron-specific processes in a more relevant system. In their experiments 
Nikoletopoulou et al. (2010) generated mouse ESCs expressing full length rat TrkA, 
TrkB or TrkC under the neuron-specific promoter microtubule associated protein tau 
(Mapt). A green fluorescent protein (GFP) cDNA was inserted in the second Mapt 
locus for ease of visualisation of targeted ESCs. In this model, the three Trk sequences 
were also terminally tagged with a hemagglutinin (HA) epitope, a nine amino acid-
long sequence that has been widely used and has not been reported to interrupt the 
activity of the protein it is tagged to (Jiang et al., 1996; Takeuchi et al., 2002). By 
having an HA tag on TrkA-C it was possible for Nikoletopoulou and colleagues to 
discriminate between endogenous and exogenous protein.  
 
Their genetically modified Mapt-HA-rTrkA, -rTrkB, -rTrkC and control (Mapt-EGFP) 
ESCs were differentiated into cortical-like neurons following a well-established 
protocol. In brief, ESCs were cultured for several passages before being placed on a 
non-adherent dish for eight days where they formed cellular aggregates (Bibel et al., 
2004, 2007). Retinoic acid was applied for the final four days of aggregation, and the 
aggregates dissociated and plated on the eighth day. Upon plating, the cells had a radial 
glial like morphology and were positive for radial glial markers such as brain lipid 
binding protein (BLBP), nectin-2 and PAX6. The presence of these markers decreased 
with time in culture, as these progenitors matured into a culture of 90-95% post-
mitotic, glutamatergic neurons. Less than 1% of neurons were positive for other 
neurotransmitters such as Isl-1, gamma-aminobutyric acid (GABA), tyrosine 
hydroxylase and choline acetyltransferase (ChAT), with the other 1% of cells being 
positive for non-neuronal glial-fibrillary acid (GFAP). The resulting neurons were 
shown to be similar to cortical neurons, and demonstrated both spontaneous and 
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depolarisation-induced action potentials after twelve days that could be blocked by 
tetrodotoxin (TTX) and bicuculline, alongside increased activity after the addition of 
glutamate. Maturation could also be marked by the appearance of spines 21 days after 
dissociation (referred to as day in vitro; DIV). Western blot analysis of wild type 
neurons using a pan-Trk antibody indicated that Trk protein could be detected from 
DIV7 onwards, and was later characterised as endogenous TrkB expression, similar to 
what is observed in the cortex (Bibel et al., 2004, 2007). 
 
The key observation by Nikoletopoulou and colleagues was that TrkA- and TrkC-
expressing ESC-derived neurons formed normally for the first few days in vitro, but 
were completely ablated between DIV 4-6. On the other hand TrkB-expressing 
neurons survived, even in the complete absence of BDNF. The death of neurons was 
marked by significantly increased levels of cleaved caspase-3 in the TrkA, and TrkC-
expressing neurons, while caspase activity remained unchanged in TrkB-expressing 
neuronal cultures. As predicted for a candidate dependence receptor, the death of 
TrkA- (and TrkC-) expressing neurons could be prevented by the addition of the 
cognate ligand NGF (and NT3 for TrkC). In addition to these in vitro experiments, the 
dependence receptor character of TrkA and TrkC could be verified in vivo using a 
method called tetraploid complementation. In this method tetraploid (4n) mouse 
blastomeres are combined with the Mapt-HA-rTrkA, -rTrkB or –rTrkC ESCs, which 
have a stronger lineage potency and therefore form the entire epiblast (Wang et al., 
1997). They noted that similar to their in vitro observations, expression of TrkA and 
TrkC led to massive loss of the nervous system in the embryos by 13.5 days post-
coitum (E13.5), despite no obvious loss of the nervous system at E11.5. Again, 
expression of TrkB did not result in cell death. Investigation of potential mechanisms 
of TrkA and TrkC-induced neuronal death indicated that kinase activity of the Trk 
intracellular domain was not required for neurotrophin-withdrawal induced death, 
although kinase activity was required for neurotrophin-induced survival 
(Nikoletopoulou et al., 2010).  
 
In addition to the generation of neurons to test for potential novel activities of the Trk 
receptors, the benefit of the system used by Nikoletopoulou and colleagues, is that by 
comparison with acute, transient transfection of HEK293T cells, the levels of Trk 
expression are controlled by an endogenous promoter and are much less likely to differ 
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widely between acutely transfected cells. This is a potentially serious problem with 
tyrosine kinase receptors as their autoactivation is well-documented when they are 
over-expressed in transfected cells (Nikoletopoulou et al., 2010), a possible reason 
why the death-inducing activity of TrkA was missed in the previous publication 
(Tauszig-Delamasure et al., 2007). In contrast, by virtue of using the HA tag, 
Nikoletopoulou et al. could demonstrate identical levels of Trk expression across the 
cultures.  
 
1.4. Aims  
 
Beyond previous work by Tauszig-Delamasure (2007) and Nikoletopoulou et al. 
(2010), very little is currently known about possible functions of the Trk receptors 
during development in the absence of activation by their ligands. Given that TrkA, but 
not TrkB, was identified as a dependence receptor when overexpressed in the nervous 
system (Nikoletopoulou et al., 2010), this thesis aimed to further investigate the roles, 
and possible differences between TrkA and TrkB during development. To achieve 
this, these receptors were overexpressed in all cells from the earliest stages of mouse 
development. TrkC was not included as there is already a heavy focus on the activity 
of TrkC by the groups of Servane Tauszig-Delamasure and Patrick Mehlen. To 
elucidate the mechanisms of TrkA and TrkB functions potentially identified in vivo, 
in vitro models were also generated that overexpressed TrkA and TrkB in neurons.  
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2 Methods 
 
2.1 Culturing mouse embryonic stem cells 
 
2.1.1 Mycoplasma testing 
 
Mycoplasma are a form of bacteria that can contaminate cell cultures. Contamination 
with these bacteria affects the growth rate of cultured cells; degrading host cell DNA, 
and outcompeting the host cells for nutrients (Nikfarjam and Farzaneh, 2012; Sokolova 
et al., 1998). As a consequence, mycoplasma contamination can affect the reliability 
of data derived from in vitro experiments. However, unlike other common cell culture 
contaminants, mycoplasma cannot be easily observed by an obvious increase in media 
turbidity (Young et al., 2010), and are difficult to identify through light microscopy 
due to their small size (0.2-0.3 µm), pleomorphism, and lack of cell wall (Razin, 2006). 
Due to these physical characteristics, mycoplasma are also able to pass through most 
filters, and are not sensitive to common antibiotics that act by disrupting bacterial wall 
synthesis. Therefore preventing, and detecting mycoplasma contamination is not 
trivial. As such there are estimates that anything from fifteen, and up to seventy percent 
(Coronato and Coto, 1991; Drexler and Uphoff, 2002; Olarerin-George and 
Hogenesch, 2015; Rottem and Barile, 1993) of cell lines worldwide are contaminated 
with mycoplasma. Whilst some anti-mycoplasma antibiotics do exist, there are reports 
of re-infection shortly after treatment, and these drugs can be cytotoxic to the host cells 
(Molla Kazemiha et al., 2011). For this reason all cell lines used in this thesis were 
routinely tested for mycoplasma contamination using a mycoplasma polymerase chain 
reaction (PCR) detection kit (Sigma-Aldrich) following the manufacturer protocol 
(Dobrovolny and Bess, 2011).   
 
2.1.2 Preparing gelatine-coated dishes 
 
2% stock solution of gelatine (Sigma-Aldrich) diluted in distilled water was prepared, 
and autoclaved. Whilst at 50°C, the solution was aliquoted into falcon tubes and stored 
at 4°C. When required, 2% gelatine was warmed at 37°C until liquid, and diluted in 
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double distilled water (ddH2O, Thermo Fisher Scientific) to create a 0.2% solution. 
Required culture dishes were covered in 0.2% gelatine, and incubated for a minimum 
of fifteen minutes at 37°C before use.  
 
2.1.3 Producing LIF 
 
Leukemia inhibitory factor (LIF) is a cytokine used as a media supplement in mouse 
embryonic stem cell (ESC) cultures to maintain mouse ESCs in a pluripotent, 
proliferative state; preventing spontaneous differentiation (Smith et al., 1988; Smith 
and Hooper, 1987; Williams et al., 1988).  
 
2.1.3.1  Culturing COS-7 cells 
 
COS-7 cells were quickly thawed in a 37°C water bath, and added to fresh cellular 
aggregate (CA) media (Dulbecco’s modified eagle media (DMEM; Thermo Fisher 
Scientific), 10% fetal bovine serum (FBS; BioSera), Glutamax (Thermo Fisher 
Scientific), non-essential amino acids (NEAA; Thermo Fisher Scientific),  
2-mercaptoethanol (Sigma-Aldrich)) in a 50 mL falcon tube (Corning). Cells were then 
centrifuged (Eppendorf 5810) at 180 relative centrifugal force (rcf) for three minutes. 
The supernatant was removed, and cells resuspended in CA media. Cells were then 
seeded onto 0.2% gelatine-coated 10 cm2 Nunc dishes (VWR) in 10 mL CA media 
and incubated at 37°C/7% CO2 until the cells reached around 70-80% confluency.  
COS-7 cells were passaged by washing with phosphate-buffered saline (PBS; Thermo 
Fisher Scientific), and incubated with 0.05% trypsin (Thermo Fisher Scientific) for 
three minutes at 37°C. Fresh CA media was then added, and the cells transferred to a 
falcon tube. Cells were centrifuged at 180 rcf for three minutes before aspiration of the 
supernatant, and the cell pellet was resuspended in fresh CA media. COS-7 cells were 
then seeded at a low density onto 0.2%-gelatine coated 10 cm2 Nunc dishes, and 
incubated at 37°C/7% CO2 until the cells reached 70-80% confluency. The day before 
transfection, cells were passaged again (as detailed above), and plated at a 1:10 split 
ratio.  
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2.1.3.2 Transfection of COS-7 cells with pLIF 
 
The next day a master mix of a LIF plasmid (10 μg per dish; plasmid gifted by 
Professor Meng Li, Cardiff University) and Lipofectamine 2000 reagent (20 μg per 
dish, Thermo Fisher Scientific) was made up in Opti-MEM (1 mL per dish, Thermo 
Fisher Scientific) and left at room temperature for fifteen minutes to allow the 
lipofectamine and plasmid to form nucleic acid-lipid complexes. Media was then 
removed from the dishes of COS-7 cells, and replaced with 5 mL Opti-MEM, and 1 
mL master mix, and incubated at 37°C/7% CO2 for 4-6 hours. After this time the 
transfection mixture was aspirated and replaced with 12 mL CA media, and the 
transfected cells incubated at 37°C/7% CO2 for four days to allow secretion of LIF into 
the media. The media was then pooled into 50 mL falcon tubes, and centrifuged for 
three minutes at 180 rcf. The supernatant was filtered through 20 μm minisart filters 
(Sigma-Aldrich) to remove any cellular debris, collected, and stored in 0.5 mL aliquots 
at -80°C until required.  
 
2.1.3.3  Testing LIF potency 
 
To test the potency of the produced LIF, wild type E14 mouse ESCs were plated at a 
density of one thousand cells per well in 0.2% gelatine-coated, 12-well Nunc plates 
(VWR). These were plated in CA media with 15% FBS. Cells were treated with a 
serial dilution (1:500-1:6.5x106) of LIF, and incubated at 37°C/7% CO2. The resulting 
quality of ESC culture was observed over a period of five days and compared to a no-
LIF control, and old LIF stock at 1:1000 dilution. If the new LIF at 1:1000 dilution 
resulted in a similar quality of ESC culture than the previous batch, and better than the 
no-LIF control, it was deemed suitable for use and tested for mycoplasma as outlined 
in section 2.1.1.  
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2.1.4 Culturing mouse embryonic fibroblasts 
 
2.1.4.1 Background 
 
Some mouse ESC lines, such as J1 ESCs, require culturing on mouse embryonic 
fibroblasts (MEFs) to prevent spontaneous differentiation. The mechanism by which 
MEFs improve ESC pluripotency is still undefined. However it is suspected that MEFs 
not only improve attachment of ESCs to the culture dish, but also that MEFs secrete 
various growth factors and molecules that support the survival, proliferation and 
pluripotency of mouse ESCs. Examples of identified secreted molecules from MEFs 
are transforming growth factor beta-1 (TGFβ) and Activin-A (Eiselleova et al., 2008; 
Tamm et al., 2013). 
 
2.1.4.2  Wild type MEFS 
 
C57BL/6J mice were time-mated, and plug checked the following morning.  
13.5-14 days post coitum (pc), pregnant females were culled by cervical dislocation, 
dissected, and embryos removed from the placenta. Embryos were washed in PBS, 
and the head, limbs, tail and organs removed and discarded. The remaining embryonic 
tissue was pooled in a 50 mL falcon tube, and washed twice with DMEM before 
transfer to a 10 cm2 petri dish (VWR) on ice, and chopped using a sterile razor blade. 
Cut tissue was transferred into a fresh 50 mL tube, and incubated at 37°C with 20 mL 
0.05% trypsin and DNase (20 µg/mL; Roche) for thirty minutes to dissociate the 
tissue. An additional 20 mL 0.05% trypsin was added, and the mixture incubated for 
a further thirty minutes at 37°C. Trypsin was inactivated by the addition of 10 mL 
FBS, and the tissue triturated with a 1 mL pipette before centrifugation at 180 rcf for 
fifteen minutes. The cell pellet was kept, whilst the supernatant was transferred to a 
separate 50 mL tube and centrifuged again to ensure that all cells had been collected. 
After aspirating the media, both cell pellets were resuspended in CA media 
supplemented with 1X penicillin-streptomycin (Thermo Fisher Scientific) to prevent 
bacterial contamination. The pooled cell suspension was passed through a 40 μm cell 
strainer (VWR) to remove any intact tissue. The cells were then seeded on 0.2% 
gelatine-coated 10 cm2 Nunc dishes at a ratio of 1.5 embryos per dish, and incubated 
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at 37°C/7% CO2. CA media was fully changed on alternate days. After reaching  
~90% confluency, MEFs were passaged as outlined in section 2.1.4.5, and seeded at a 
1:5 split ratio onto 0.2% gelatine-coated 10 cm2 Nunc dishes. When confluent, MEFs 
were passaged again and resuspended in CA media with 10% dimethyl sulfoxide 
(DMSO; Sigma-Aldrich), and frozen to -80°C in a Mr. Frosty freezing container 
(Thermo Fisher Scientific). After freezing, MEFs were stored in liquid nitrogen until 
required. 
 
2.1.4.3 Antibiotic-resistant MEFs 
 
Antibiotic-resistant MEFs were required when growing ESCs with antibiotics (see 
section 2.2.5), which would otherwise result in the death of wild type MEFs. 
Geneticin-resistant MEFs were purchased from ATCC, whilst immortalised 
puromycin-resistant MEFs were purchased from Stem Cell Technologies. 
 
2.1.4.4 Thawing MEFs  
  
Stock wild type, or antibiotic-resistant MEFs were quickly thawed in a 37°C water 
bath. Thawed MEFs were added to CA media before centrifugation at 180 rcf for three 
minutes. The supernatant was removed, and the cell pellet resuspended in fresh CA 
media. MEFs were then seeded onto 0.2% gelatine-coated T25 or T75 flasks (VWR) 
and incubated at 37°C/7% CO2. Cells were checked on a daily basis, and the media 
changed every 1-2 days.  
 
2.1.4.5 Passaging MEFs 
 
When confluent, MEFs were washed with PBS before incubation with 0.05% trypsin 
for three minutes at 37°C. MEFs were then resuspended in CA media, and transferred 
to 50 mL falcon tubes for centrifugation at 180 rcf for three minutes. After aspirating 
the supernatant, the cell pellet was resuspended in fresh CA media and MEFs plated 
on 0.2% gelatine-coated dishes.  
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2.1.4.6 Inactivating MEFs 
 
To prevent MEFs over-proliferating when used as a substrate for ESC culture, they 
were inactivated prior to use. To do this, MEFs were incubated with 10 µg/mL 
mitomycin (Sigma-Aldrich) for two hours, and subsequently washed twice with PBS. 
MEFs were left to recover in CA media at 37°C/7% CO2 for a minimum of one hour, 
and a maximum of three days. Before plating ESCs, CA media was replaced with fresh 
ES media (see section 2.1.5.2).   
 
2.1.5 Culturing J1 and E14 ESCs 
 
2.1.5.1 Background 
 
ESC lines exist that originated from different mice, and therefore have alternative 
genetic backgrounds. As a result, these lines can have different requirements for 
efficient culture. For example, two commonly used wild type ESC lines are J1 
(129S4/SvJae background) and E14 (129/Ola background) cells. Whereas J1 ESCs 
need to be cultured on MEFs to maintain their pluripotency, E14 ESCs can be cultured 
without MEFs on 0.2% gelatine-coated dishes (Smith, 1991). 
 
2.1.5.2 Thawing ESCs 
 
When culturing J1 ESCs, media from inactivated MEFs (section 2.1.4.6) was replaced 
with ES media (DMEM, NEAA, Glutamax, 2-mercaptoethanol, 15% FBS and LIF 
(produced in house, see section 2.1.3)). Wild type (ATCC), or genetically-modified J1 
or E14 ESCs were thawed quickly at 37°C and added to ES media in a 50 mL tube. 
The ESCs were then centrifuged at 180 rcf for three minutes, and the supernatant 
aspirated. The cell pellet was resuspended in ES media and three million cells seeded 
into either a T25 flask of inactivated MEFs for J1 ESCs, or 0.2%-gelatine coated T25 
flasks for E14 ESCs. Cells were then incubated at 37 ºC/7% CO2 until confluent, and 
the media changed every 1-2 days.  
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2.1.5.3 Passaging ESCs 
 
When ESCs reached 70% confluency, they were passaged following a well-
established protocol (Bibel et al., 2004, 2007). In brief, ESCs were washed with PBS 
before incubation with 0.05% trypsin for three minutes at 37°C. Following this, ESCs 
were resuspended in ES media, and transferred to a 50 mL tube, before centrifugation 
at 180 rcf for three minutes. The supernatant was removed, and the cell pellet 
resuspended in fresh ES media before plating onto a new flask of inactivated MEFS, 
or 0.2%-gelatine coated flasks for J1s and E14s, respectively. Whilst J1 ESCs were 
passaged at a 1:8-1:12 split ratio, E14 ESCs were passaged at a 1:3-1:6 split ratio.  
 
2.1.5.4 Freezing ESCs 
 
To store ESCs long term, stocks were frozen at early passages. To achieve this, ESCs 
were passaged as outlined in section 2.1.5.3, but after centrifugation, the cell pellet 
was instead resuspended in ES media with 10% DMSO. Cells were frozen down to  
-80°C in a Mr. Frosty freezing container and stored in liquid nitrogen until use.  
 
2.1.5.5 Alternative ESC culture media 
 
In this thesis the effects of different culture media on ESC quality was compared. 
Where stated, ESCs were passaged and maintained as above, but cultured in either 
2I+LIF media (100 mL Neurobasal (Thermo Fisher Scientific), 100 mL DMEM-F12 
(Thermo Fisher Scientific), 1 mL N2/BSA stock (1 mL 7.5% bovine serum albumin 
(BSA, Sigma-Aldrich) and 5 mL N2 supplement (Thermo Fisher Scientific)), 2 mL 
B27 without retinoic acid (Thermo Fisher Scientific), 2 mL Glutamax, 50 μM  
2-mercaptoethanol (Thermo Fisher Scientific), 1 μM PD0325901 (Axon MedChem), 
3 μM Chir99201 (Axon MedChem), 100 ng/mL recombinant LIF (Millipore)) or 
2I+LIF media supplemented with 15% FBS (2I LIF + FBS). Where targeted E14 cells 
were cultured on feeders, the protocol outlined in section 2.1.5.3 was followed. 
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2.1.6  Sub-cloning ESCs 
 
Where stated, ESCs were sub-cloned to isolate a population of ESCs with the desired 
characteristics, such as ESC cultures with less spontaneously differentiating cells. To 
do this, ESCs were thawed and expanded as outlined in sections 2.1.5.2 and 2.1.5.3. 
ESCs were then seeded onto 0.2%-gelatine coated 10 cm2 Nunc dishes at a 1:200 split 
ratio, and incubated at 37°C/7% CO2 for 5-9 days, until ESC colonies had formed that 
could be observed by eye. Media was changed every two days. The dishes were then 
washed with PBS before the addition of 0.01% trypsin (0.05% trypsin diluted 1:5 in 
PBS). Single colonies were aspirated using a pipette set at 20 µL, with a 200 μL tip, 
and transferred to individual wells of a 96-well plate (VWR). These individually 
picked colonies were incubated with 20 µL 0.05% trypsin for three minutes at 37°C 
before resuspending with 100 µL ES media. ESCs were then plated on inactivated-
MEFs on a 24-well plate (for J1 ESCs), or a 0.2% gelatine-coated 24 well plate (for 
E14 ESCs). ESCs were then incubated at 37°C/7% CO2, and media changed every two 
days until the cells reached 70% confluency. ESCs were subsequently passaged and 
expanded as outlined in section 2.1.5.3. 
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2.2 Generating mouse ESCs that overexpress TrkA or TrkB 
 
2.2.1 Rationale 
 
To generate an inducible expression system of TrkA or TrkB in ESCs (Figure 2.1), 
E14 and J1 Rosa26-CreERT2;Mapt-loxP-STOP-loxP-HA-rTrkA, or -rTrkB  mouse 
ESC lines were generated.  
In these ESCs the Trk receptors were expressed under the neuron-specific microtubule 
associated protein (Mapt) promoter (Binder et al., 1985; Jaisser, 2000). In this model, 
TrkA and TrkB were tagged with hemagglutinin (HA), a small sequence consisting of 
nine amino acids that is widely used and has not been reported to interrupt the activity 
of the protein it is tagged to (Nikoletopoulou et al., 2010). By having a HA tag, it is 
possible to discriminate between endogenous Trk expression and the exogenous 
tagged construct.  
However due to the presence of a loxP-STOP-loxP sequence preceding the Trk 
receptor sequences in this construct, they would not be expressed under physiological 
conditions. In order to express TrkA or TrkB, the loxP-flanked STOP needs to be 
excised, which can be achieved using a Cre recombinase enzyme. In the current model, 
the Cre recombinase was fused to a triple mutated human oestrogen receptor  
(Cre-ERT2) (Jaisser, 2000), and expressed under the ubiquitous Rosa26 promoter 
(Soriano, 1999). Through interactions with heat-shock protein 90 (Hsp90), Cre-ERT2 
is normally sequestered in the cytoplasm (Hayashi and McMahon, 2002; Mattioni et 
al., 1994; Nagy, 1999; Picard, 1994). However, upon Cre-ERT2 binding the synthetic 
ligand 4-hydroxytamoxifen (tamoxifen), Hsp90 is disrupted, and Cre-ERT2 
translocated into the nucleus (Feil et al., 1997; Tian et al., 2006) (Figure 2.1). When 
in the nucleus, the Cre enzyme can recombine the loxP-flanked STOP cassette (Jones-
Villeneuve et al., 1982). In this way, the expression of TrkA or TrkB in neurons could 
be temporally controlled by the addition of tamoxifen to cultures of these genetically 
modified ESCs (Hayashi and McMahon, 2002; Mattioni et al., 1994; Picard, 1994).  
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Figure 2.1 Tamoxifen-induced expression of TrkA or TrkB in ESCs.  A Cre recombinase-oestrogen receptor fusion 
protein (CreERT2; purple) is expressed under the ubiquitous Rosa26 promoter and remains in the cytoplasm (navy), thus 
preventing its binding to nuclear DNA. With the addition of tamoxifen to ESC cultures, the activated CreERT2 (red) 
protein translocates into the nucleus where it excises the loxP-flanked STOP cassette (orange) that immediately precedes 
the Trk receptor sequences (green), allowing temporal control of Trk receptor expression in ESCs. 
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2.2.2 Generating pMapt-loxp-STOP-loxP-HA-rTrkA and -rTrkB 
plasmids 
 
2.2.2.1 Preparation of Agar plates  
 
3.5% agar (Sigma-Aldrich) was dissolved in ddH2O and autoclaved. After cooling to 
50°C, agar was supplemented with either 50 μg/mL kanamycin (Sigma-Aldrich), or 
50 μg/mL ampicillin (Sigma-Aldrich). For details of when each antibiotic was used, 
see section 2.2.5. The agar was then poured into 10 cm2 petri dishes and left until the 
agar had set. Dishes were stored at 4°C for up to one month. One hour before use, agar 
plates were opened and placed face down in a 37°C incubator to remove any excess 
moisture. 
 
2.2.2.2 Preparation of L-broth 
 
2.5% L-broth (Sigma) was dissolved in ddH2O and autoclaved. Antibiotics were added 
(as outlined in section 2.2.2.1) once L-broth had cooled to room temperature. L-broth 
was stored at 4°C for up to two weeks.  
 
2.2.2.3 Digestion and purification  
 
2 μg of an existing plasmid (pSIEG) that contains a 1.5 kilobase (kb) loxP-STOP-loxP 
sequence was digested with EcoRI (NEB) and XbaI (NEB) (Figure 2.2) at 37°C for 
three hours. Subsequently the mixture was incubated with large Klenow DNA 
polymerase (NEB) and deoxynucleotide triphosphates (dNTPs, NEB) for one hour at 
37°C to blunt the ends. This was then incubated at 70°C to inactivate the enzymes. The 
digested, blunted 1.5 kb STOP fragment was purified following the microcentrifuge 
protocol of the QIAquick gel extraction kit (Qiagen) from step 2 of the protocol (the 
addition of QG buffer). This mixture was then electrophoresed on a 1% agarose 
(Thermo Fisher Scientific) gel supplemented with 0.2 μg/mL ethidium bromide 
(Sigma-Aldrich) for two hours. The corresponding 1.5 kb band was manually excised 
from the gel and transferred to a fresh 1.5 mL tube. The DNA was then extracted 
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following the microcentrifuge protocol of the QIAquick gel extraction kit from step 1 
of the protocol. 
Meanwhile, 2 μg of pMapt-HA-rTrkA or -rTrkB plasmids were linearised by digestion 
with PmeI (NEB) (Figure 2.2) at 37°C for three hours. The mixture was subsequently 
incubated with antarctic phosphatase (NEB) at 37°C for one hour to dephosphorylate 
vector ends, preventing self-ligation of the plasmid. After this, the enzymes were 
inactivated by incubation of this mixture at 70°C for fifteen minutes. The linearised 
plasmids were then electrophoresed on a 1% agarose gel supplemented with 0.2 μg/mL 
ethidium bromide for one hour. The corresponding band ~10 kb was manually excised 
from the gel, and placed into dialysing tubes (Sigma-Aldrich) filled with 300 µL TAE 
buffer (40 mM tris base (Thermo Fisher Scientific), 20 mM acetic acid (Sigma-
Aldrich), 1 mM ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich), in  distilled 
water) and electrophoresed for three to four hours, until the DNA could no longer be 
visualised in the gel. The resulting DNA solution was transferred to a 1.5 mL tube 
(Eppendorf) and precipitated with 50 µL 3 M sodium acetate (NaOAc, Sigma-
Aldrich), and 500 µL 100% isopropanol (Sigma-Aldrich) overnight at 4°C. The next 
day the mixture was centrifuged for fifteen minutes at 20000 rcf, and the supernatant 
removed. The DNA pellet was washed with 70% ethanol (VWR) and centrifuged for 
a further five minutes at 20000 rcf, and the supernatant was aspirated. The DNA pellet 
was then eluted in 30 µL buffer EB (Qiagen). 
 
2.2.2.4 Ligation 
 
3 μL of linearised, purified pMapt-HA-rTrkA or -rTrkB plasmid were each ligated to 
6 μL of the purified loxP-STOP-loxP fragment using quick T4 DNA ligase (NEB) for 
ten minutes at room temperature (Figure 2.2). 4 μL of the ligation mixture was then 
transformed into one shot TOP10 Escherichia coli (E.coli) (Thermo Fisher Scientific) 
by heat shock through immersion in a 42°C water bath for thirty seconds. After 
recovery in 300 μL super optimal broth with catabolite repression (S.O.C.) media 
(Thermo Fisher Scientific) for up to one hour at 37°C, bacteria were spread onto agar 
plates supplemented with ampicillin. Dishes were incubated overnight at 37°C to allow 
colony formation. 
  
Figure 2.2 Generation of pMapt-loxP-STOP-loxP-HA-rTrkA and -rTrkB vectors. A) Existing pMapt-HA-rTrkA and -rTrkB constructs 
were linearised by restriction digestion with PmeI enzyme. B) The loxP-STOP-loxP cassette was isolated from the pSIEG plasmid by digestion 
with EcoRI and XbaI, and then ligated into the linearised pMapt-HA-rTrkA and -rTrkB vectors. NLS – nuclear localisation signal, ORF – open 
reading frame, SV40 PA terminator – poly A terminator sequence. 
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2.2.2.5 Extracting DNA from bacterial colonies 
 
Bacterial colonies were picked the next morning using a 10 µL pipette, and 
individually added to 4 mL L-broth (Sigma-Aldrich) with 50 μg/mL ampicillin into 12 
mL plastic culture tubes (Fisher Scientific). Bacteria were incubated overnight at  
37°C on a shaker. DNA was then extracted from 1.8 mL samples of each bacterial 
culture using a miniprep kit (Qiagen) following the manufacturer protocol. The 
remaining bacteria were stored at 4°C until required.  
 
2.2.2.6 Identifying cultures with the desired plasmid 
 
To identify which bacterial clones contained the correct plasmid (insertion of the  
loxP-STOP-loxP cassette in the correct orientation), 2 μL of DNA, extracted via 
miniprep, was digested with HindIII (NEB) for one hour at 37°C. Digested DNA was 
then electrophoresed on a 1% agarose gel with 0.2 μg/mL ethidium bromide for one 
hour. Gels were imaged in a UV docking station (Biorad). Based on analysis of the 
digested band sizes (Chapter 3), the clones thought to have the required plasmid were 
amplified by incubating 100 μL of the remaining bacterial stock in 100 mL L-broth 
supplemented with 50 μg/mL ampicillin overnight in a 37°C shaker. DNA was then 
extracted from these bacteria using a maxiprep kit (Qiagen), following the 
manufacturer protocol. DNA was sequenced using Sanger sequencing (Eurofins) to 
confirm the sequence.  
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2.2.3 Targeting the Mapt locus  
 
2.2.3.1 Theory 
 
Clustered regularly interspaced short palindromic repeats (CRISPR) is a technique for 
genome-editing where a single-guide RNA (sgRNA) forms Watson-Crick base-pairs 
with target genomic DNA(Ran et al., 2013). This guides a Cas9 endonuclease to the 
site of the sgRNA, where Cas9 cleaves the double-stranded DNA, three base pairs up 
from a 5’ NGG protospacer adjacent motif (Figure 2.3). To repair these breaks in the 
DNA, cells undergo a homology-directed repair pathway when a template donor 
(construct) with sequences homologous to the damaged DNA is present, resulting in 
insertion of the construct (Ran et al., 2013).  
  
 
 
 
Figure 2.3 CRISPR genome editing. A single guide RNA (sgRNA) forms Watson-Crick base pairs with the target DNA. The sgRNA 
guides the Cas9 endonuclease to cleave both DNA strands (site indicated by red arrow and dashed line), three base pairs up from a NGG 
protospacer adjacent motif (PAM). This break in the DNA stimulates endogenous DNA repair mechanisms, which allows insertion of a 
construct with homologous sequences to the break site.  
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2.2.3.2 Generating sgRNA 
 
sgRNA for the Rosa26 and Mapt target sites were designed using an online tool 
(http://crispr.mit.edu/). The resulting sequences (Mapt: 
CTCCAGGCTTTGAACCAGTA and Rosa26: CTAGCAGTTTAAACAAAT) were 
incorporated into a 455 nucleotide sequence template (Figure 2.4), and ordered from 
IDT. The sgRNA fragment was then amplified through PCR using the reagents and 
cycle conditions outlined in Table 2.1. 
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TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATC
CGGTACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTT
CATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATT
AATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAG
AAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAA
AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTT
GGCTTTATATATCTTGTGGAAAGGACGAAACACCGNNNNNNNNNNN
NNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTA
GTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTCT
AGACCCAGCTTTCTTGTACAAAGTTGGCATTA 
Figure 2.4 Single-guide RNA template sequence. . The sequence of the entire 
sgRNA is indicated above. Black nucleotides indicate a U6 promoter. Green, bold 
nucleotides indicate the guide sequence which is determined by the target DNA. Blue 
nucleotides are the guide RNA scaffold. Red nucleotides indicate the termination 
signal.  
  
 
 
 
 
 
Table 2.1 Amplifying Rosa26 and Mapt sgRNA fragments  
 
Reagents 
Final 
Concentration 
PCR Conditions 
Nuclease-free water (Qiagen) Up to 50 μL 
 
98°C - 30 seconds 
98°C - 10 seconds 
58°C - 30 seconds 
72°C - 30 seconds 
72°C - 5 minutes 
 
5x Phusion high fidelity buffer (NEB) 1 x 
10 mM dNTPs (NEB) 0.2 mM 
Forward primer (Thermo Fisher Scientific) 
(TGTACAAAAAAGCAGGCTTTAAAG) 
0.5 μM 
10 μM reverse primer (Thermo Fisher 
Scientific) 
(TAATGCCAACTTTGTACAAGAAAG) 
0.5 μM 
gBlocks gene fragment (IDT) 1 ng 
Phusion DNA polymerase (NEB) 1 unit 
 
 
x35 cycles 
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The resulting PCR products were then blunted with large Klenow polymerase for one 
hour at 37°C, and gel purified following the microcentrifuge protocol of the QIAquick 
gel extraction kit. To allow further amplification, sgRNA were ligated into a generic 
cloning vector (TopoII-isomerase, Thermo Fisher Scientific) with salt solution 
(Thermo Fisher Scientific) at a 4:1:1 ratio respectively at room temperature for five 
minutes. 2 μL of the ligation mixture was then transformed into one shot TOP10  
E. coli through 30 second heat shock by immersion in a 42°C water bath, and left to 
recover in 300 μL S.O.C. media for one hour shaking at 37°C. The transformed E. coli 
were spread on agar dishes supplemented with 50 μg/mL kanamycin (Sigma-Aldrich) 
and left overnight at 37°C to allow the bacteria to form colonies. Colonies were picked 
using a 10 µL pipette tip, and individually added to 4 mL L-broth supplemented with 
50 μg/mL kanamycin in 12 mL plastic culture tubes. These were incubated at 37°C 
overnight, on a shaker. DNA was then extracted from 1.8 mL bacteria samples the next 
day using a miniprep kit (Qiagen), following the manufacturer protocol. Remaining 
bacteria were frozen at -80°C in 40% glycerol. To diagnose whether insertion of the 
sgRNA into the bacteria was successful, the DNA extracted via miniprep was digested 
using restriction enzymes BamHI (NEB) and XbaI (NEB) for three hours at 37°C, and 
electrophoresed on a 1% agarose gel supplemented with 0.2 μg/mL ethidium bromide 
for one hour. After selecting clones with bands corresponding to successful insertion 
(~5 kb, ~400 bp, and ~100 bp) the sequence was confirmed via Sanger sequencing. To 
amplify the plasmid, frozen bacterial stocks were added to 100 mL L-broth 
supplemented with 50 μg/mL kanamycin and incubated in a 37°C shaker overnight. 
The next day an endonuclease free, plasmid maxiprep (Qiagen) was performed, 
following manufacturer guidelines.  
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2.2.4 Targeting Rosa26  
 
2.2.4.1 Strategy 
 
Zinc finger nucleases (ZFNs) are composed of a nonspecific DNA cleavage domain 
of the FokI restriction endonuclease and a combination of zinc finger proteins that 
constitute the DNA binding domains. Each zinc finger can recognise three nucleotides, 
so that multiple zinc fingers can be assembled to recognise specific DNA sequences 
in target genes. ZFNs are used in heterodimer pairs to cleave the target site, as the FokI 
nuclease domain requires dimerization to create a double stranded break in the target 
DNA. As in CRISPR, this double stranded break induces the process of homology-
directed recombination (Beerli and Barbas, 2002; Beerli et al., 2000; Liu, Segal, et al., 
1997). The Rosa26 locus was targeted to generate J1 Rosa26-CreERT2, Rosa26-loxP-
STOP-loxP-HA-rTrkA and –rTrkB E14 ESCs. pRosa26-CreERT2 was gifted by 
Professor Francis Stewart (Dresden University), and pRosa26- loxP-STOP-loxP-HA-
rTrkA and –rTrkB plasmids generated by Dr. Xinsheng Nan (Cardiff University).  
 
2.2.4.2  Targeting ESCs with Rosa26 ZFNs 
 
In order to target the Rosa26 locus, the mRosa26 CompoZr Targeted Integration Kit 
(Sigma-Aldrich) was utilised. The three targeting constructs (pRosa26-CreERT2, 
pRosa26-loxP-STOP-loxP-HA-rTrkA, and -rTrkB) were cloned into the kit-provided 
donor plasmid, pZDonor-mRosa26, by Dr. Xinsheng Nan following the manufacturer 
protocol.  
 
2.2.5 Transfection of E14 & J1 ESCs 
 
J1 wild type cells underwent two rounds of transfection sequentially; the first round of 
transfections targeted the Rosa26 locus to establish a J1 Rosa26-CreERT2 line, and the 
second to Mapt to generate J1 Rosa26-CreERT2;Mapt-loxP-STOP-loxP-HA-rTrkA or 
-rTrkB ESCs (Table 2.2). As E14 Rosa26-CreERT2 cells had been previously generated 
by Dr. Xinsheng Nan, these ESCs only underwent one round of transfections to target 
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Mapt in order to generate the corresponding E14 Rosa26-CreERT2;Mapt-loxP-STOP-
loxP-HA-rTrkA or -rTrkB ESCs. J1 and E14 wild type ESCs were also transfected once 
to generate Mapt-loxP-STOP-loxP-HA-rTrkA or –rTrkB ESC lines without Cre.  
As E14 Rosa26-loxP-STOP-loxP-HA-rTrkA ESCs had been previously generated by 
Dr. Xinsheng Nan, the corresponding E14 Rosa26-loxP-STOP-loxP-HA-rTrkB ESCs 
were produced here.  
Before targeting, wild type ESCs were cultured and expanded as outlined in section 
2.1. The day prior to transfection, ESCs were passaged at a 1:5 split ratio onto a 
minimum of two T75 flasks. On the day of transfection, ESCs were washed once with 
PBS before the addition of 0.05% trypsin. Cells were incubated for three minutes at 
37°C before trypsin was inactivated by the addition of ES media. The cell suspension 
was then centrifuged at 180 rcf for three minutes before resuspension of the cell pellet 
in ES media, and counted using a nucleocounter (Chemometec) following the 
manufacturer protocol. 5 x106 dissociated ESCs were transferred to a 50 mL falcon 
tube per transfection, and centrifuged again at 180 rcf for three minutes. The pellet was 
then resuspended in 100 μL P3 transfection solution (82 μL Amaxa Buffer and 18 μL 
P3 supplement; Lonza) and 10 µL of respective DNA mixture. Where CRISPR 
targeting was required, the DNA mixture contained the corresponding sgRNA, 
targeting construct and Cas9 enzyme at a 1 µg: 10 µg: 1 µg ratio, respectively, and 
made up to a total volume of 10 μL. Where zinc finger targeting of the Rosa26 locus 
was used, 10 µg of the ZFN-plasmid (generated in section 2.2.4.2) was used.  
The entire suspension was then transferred to a cuvette (Lonza) and placed into a 4D-
Amaxa Nucleofector X-unit (Lonza) where the cells were transfected using the 
manufacturer program CG-104. After transfection, a drop of media was added to the 
cuvette using a Pasteur pipette (Lonza) and cells transferred to a new 50 mL falcon 
tube containing 10 mL ES media. Transfected cells were then seeded onto either  
0.2% Gelatine-coated 10 cm2 Nunc dishes if transfecting E14 ESCs, or on pre-prepared 
inactivated puromycin/geneticin-resistant (depending on the targeting construct; Table 
2.2) MEFs on 10 cm2 Nunc dishes if transfecting J1 ESCs. Varying volumes of 
transfected ESCs were plated, from 0.625-2.5 mL per dish. This was to ensure the 
optimal density for picking colonies. Dishes were then incubated at  
37°C/7% CO2. 24-48 hours later, the respective selection antibiotic was applied: 
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Geneticin (250 μg/mL) or puromycin (1.5 µg/mL). Media supplemented with the 
selection antibiotic was subsequently changed every two days. 
When individual ESC colonies were visible by eye, the dishes were washed with PBS 
before the addition of 0.01% trypsin (0.05% trypsin diluted 1:5 in PBS). Single 
colonies were aspirated using a pipette set at 20 µL, with a 200 μL tip, and transferred 
to individual wells of a 96-well plate that contained 20 µL 0.05% trypsin. ESCs were 
incubated in trypsin for three minutes before resuspending in 100 µL of ES media. 
Resuspended cells were then transferred to a 24-well plate (0.2% gelatine-coated for 
E14 ESCs, inactivated puromycin-/geneticin-resistant MEFs for J1s) and cultured in 
ES media with the respective selection antibiotic. Between 50-100 colonies were 
picked per transfection. ESCs were incubated at 37°C/7% CO2 on these 24-well plates, 
and media changed every two days (supplemented with antibiotic) until the cells in 
individual wells reached 70-80% confluency.  
Individual wells were then washed once with PBS before incubation with 100 µL  
0.05% trypsin for three minutes at 37°C. After the addition of 1 mL ES media. 1/10th 
of the cell suspension was transferred to a new 24-well plate (0.2% gelatine-coated for 
E14 ESCs, or with pre-prepared inactivated MEFs for J1 ESCs) for passaging as 
outlined in section 2.1, and the remaining cell suspension transferred to an Eppendorf 
tube for genomic DNA extraction (section 2.2.6).  
 
 
  
Table 2.2 List of generated ESC lines  
 
ESCs indicated with an asterisk were generated by Dr. Xinsheng Nan. 
Line 
Starting 
Mutation 
Targeting 
Method 
Targeting Construct Resistance MEFs Resulting ESC Line Reference 
E14 
Wild 
Type 
Zinc Finger Rosa26-CreERT2 Puromycin NA E14 Rosa26-CreERT2 
Chapter 3 
E14 Control * 
E14 
Wild 
Type 
CRISPR 
Mapt-loxP-STOP-loxP-
HA-rTrkA 
Geneticin NA 
E14 Mapt-loxP-STOP-loxP-HA-
rTrkA 
Chapter 3 
E14 No CreERT2 Control 
E14 
Wild 
Type 
CRISPR 
Mapt-loxP-STOP-loxP-
HA-rTrkB 
Geneticin NA 
E14 Mapt-loxP-STOP-loxP-HA-
rTrkB 
Chapter 3 
E14 No CreERT2 Control 
E14 
Rosa26-
CreERT2 
CRISPR 
Mapt-loxP-STOP-loxP-
HA-rTrkA 
Geneticin NA 
E14 Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkA 
Chapter 3 
E14 Experimental TrkA 
E14 
Rosa26-
CreERT2 
CRISPR 
Mapt-loxP-STOP-loxP-
HA-rTrkB 
Geneticin NA 
E14 Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkB 
Chapter 3 
E14 Experimental TrkB 
J1 
Wild 
Type 
Zinc Finger Rosa26-CreERT2 Puromycin 
Puromycin-
resistant 
J1 Rosa26-CreERT2 
Chapter 3 
J1 Control 
J1 
Rosa26-
CreERT2 
CRISPR 
Mapt-loxP-STOP-loxP-
HA-rTrkA 
Geneticin 
Geneticin-
resistant 
J1 Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkA 
Chapter 3 
J1 Experimental TrkA 
J1 
Rosa26-
CreERT2 
CRISPR 
Mapt-loxP-STOP-loxP-
HA-rTrkB 
Geneticin 
Geneticin-
resistant 
J1 Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkB 
Chapter 3 
J1 Experimental TrkB 
E14 
Wild 
Type 
Zinc Finger 
Rosa26-loxP-STOP-loxP-
HA-rTrkA-IRES-EGFP 
Puromycin NA 
E14 Rosa26-loxP-STOP-loxP-
HA-rTrkA-IRES-EGFP 
Chapter 4 
Blastocyst Injections * 
E14 
Wild 
Type 
Zinc Finger 
Rosa26-loxP-STOP-loxP-
HA-rTrkB-IRES-EGFP 
Puromycin NA 
E14 Rosa26-loxP-STOP-loxP-
HA-rTrkB-IRES-EGFP 
Chapter 4 
Blastocyst Injections 
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2.2.6 Genotyping ESCs and neurons 
  
2.2.6.1 Extracting DNA 
 
Cell suspensions in 1.5 mL tubes were centrifuged at 180 rcf for one minute, and the 
pellet resuspended in 500 µL DNA lysis buffer (10 mM Tris (Thermo Fisher 
Scientific) pH 8.0, 1 mM calcium chloride (CaCl2; Sigma-Aldrich), 100 mM sodium 
chloride (NaCl; Sigma-Aldrich), 0.5% sodium dodecyl sulfate (SDS; Sigma-Aldrich), 
5 mg/mL proteinase K (Promega)). Samples were then incubated at 50°C overnight. 
DNA was precipitated the next morning by the addition of 500 μL 100% isopropanol, 
and 50 μL 3 M NaOAc, inverted, and centrifuged at top speed at 20000 rcf for fifteen 
minutes at room temperature. Supernatant was carefully removed, and 500 μL 70% 
ethanol added. Samples were centrifuged for a further five minutes at 20000 rcf before 
resuspending the DNA pellet in 30 μL Tris-EDTA buffer (TE buffer; Qiagen).  
 
2.2.6.2 Genotyping PCR 
 
To test that the respective constructs were inserted into the correct region in ESCs, 
primer pairs were generated with a forward primer upstream of the construct’s Rosa26 
or Mapt 5’ homology arm, and a reverse primer in the construct itself. Therefore a 
polymerase chain reaction (PCR) would only amplify a product if the construct was 
inserted into the correct region. This was achieved using the Long-range Sequal Prep 
PCR kit (Thermo Fisher Scientific) following manufacturer guidelines with two points 
of note; 1) Enhancer A (provided in the kit) was used instead of enhancer B, and 2)  
1 μL of DNA mixture was used as a template. The PCR primers are outlined in Table 
2.3, and cycling (Table 2.3) carried out in a BIORAD T100 Thermal cycler. After 
amplification the mixture was supplemented with 4 μL DNA loading buffer (10 mM 
Tris-HCl (pH 7.5), 50 mM EDTA, 50% glycerol, 1 mg/mL bromophenol blue (Sigma)) 
and loaded onto a 1% agarose gel supplemented with 0.2 μg/mL ethidium bromide, 
and electrophoresed for one hour. Bands were detected using a UV docking station.  
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Table 2.3 Genotyping primers and PCR conditions for transfected ESCs 
Genotyping for 
insertion of: 
 
Forward Primer 
 
Reverse Primer 
 
PCR Conditions 
 
Rosa26-CreERT2 
 
 
TACGCCACAGGGAGTCCAAGAATG 
 
 
GACCGACGATGAAGCATGTTTAGC 
95°C   3 minutes 
95°C 30 seconds 
57°C 30 seconds         x 35 cycles  
68°C 4.5 minutes  
72°C  5 minutes 
 
 
Mapt-loxP-STOP-
loxP-HA-rTrkA 
 
 
 
CCCATGGCAGCTCACAAGTATC 
 
 
 
ATCCCGCTGGTTTTCCACAT 
95°C 3 minutes 
95°C 30 seconds 
60.3°C 30 seconds         x 10 cycles  
68°C 4.5 minutes  
95°C 30 seconds 
60.3°C 30 seconds                                   x25 cycles  
68°C 4.5 minutes (+ 10 sec/cycle) 
72°C  5 minutes 
 
 
Mapt-loxP-STOP-
loxP-HA-rTrkB 
 
 
 
CCCATGGCAGCTCACAAGTATC 
 
 
 
CCAAATTCCCAACGTCCCAGTACAAG 
95°C 3 minutes 
95°C 30 seconds 
60.3°C 30 seconds       x 10 cycles  
68°C 7 minutes  
95°C 30 seconds 
60.3°C 30 seconds                                  x25 cycles  
68°C 7 minutes (+ 10sec/cycle) 
72°C 5 minutes 
Rosa26-loxP-STOP-
loxP-HA-rTrkB 
CAAGCGGGTGGTGGGCAGGAATGCG TCGGCAGGAGCAAGGTGAGATGAC 
95°C 3 minutes 
95°C 30 seconds           
60°C 30 seconds          x 35 cycles 
68°C 2.5 minutes  
72°C 5 minutes 
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2.2.7 Karyotyping 
 
2.2.7.1 General considerations 
 
All cell lines detailed in this thesis were selected based on having the correct number 
of chromosomes. This was especially important where cells were being used to create 
transgenic mice. The karyotype of each ESC line was calculated as the percentage of 
cells with the correct number of chromosomes (forty in mice (Schnedl, 1971)).  
 
2.2.7.2 Karyotyping 
 
The day before karyotyping individual ESC clones were passaged at a 1:5 split ratio 
onto 0.2% gelatine-coated T25 flasks as outlined in section 2.1.5.3. Plates were 
incubated at 37°C/7% CO2 overnight. The next day demecolcine solution (0.1 µg/mL; 
Sigma-Aldrich) was added to the cells for two hours and cells placed back at  
37°C/7% CO2. Cells were then washed with PBS and incubated with 0.05% trypsin 
for three minutes at 37°C. Cells were resuspended in 5 mL ES media and transferred 
to a 15 mL falcon tube (Corning) for centrifugation at 340 rcf for three minutes. 
Supernatant was removed, and the cell pellet washed with PBS before centrifugation 
again at 340 rcf for three minutes. Cells were washed one further time with PBS, and 
the supernatant removed. Cells were then resuspended in 2 mL PBS and 6 mL 
hypotonic 0.0375 M potassium chloride (KCl; Sigma-Aldrich) solution, and incubated 
at 37°C for twelve minutes to allow the cells to swell. Samples were then centrifuged 
for five minutes at 244 rcf, and the supernatant aspirated. 3.5 mL methanol/acetic acid 
mixture (3:1 volume:volume ratio, -20°C; Sigma-Aldrich) was then added dropwise 
to the cells and left for twenty minutes at room temperature. Samples were centrifuged 
for five minutes at 244 rpm, and supernatant removed before a further 3.5 mL 
methanol/acetic acid mixture was added to the cells. Cells were centrifuged at 244 rcf 
for five minutes, and supernatant aspirated until around 0.1 mL was left. Cells were 
resuspended in this volume, and dropped from a height of around thirty centimetres 
onto polylysine adhesion slides (VWR). Two drops of cell suspension were added per 
slide. Slides were left to air dry, before adding 150 µL 4',6-diamidino-2-phenylindole 
(DAPI, 1:4000 in ddH2O, Sigma-Aldrich). Coverslips (24 mm x 50 mm; VWR) were 
placed on top of the cells and slides imaged immediately.  
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2.2.7.3 Imaging and analysis 
 
Slides were imaged using a fluorescence microscope at x40 magnification. Images 
were taken for a minimum of ten cells per clone (Figure 2.5). Chromosomes were 
counted using the cell counter plugin on ImageJ software. The chromosomes were 
counted for each cell, taking note of any abnormalities such as translocations. The 
percentage of cells with the correct number of chromosomes were then calculated. 
Clones with over 70% of cells with forty chromosomes were expanded and used for 
cell culture or generating transgenic mice.   
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Figure 2.5 Visualisation of chromosomes.  Representative image of forty, individual 
chromosomes (blue). Note that chromosomes are distinguishable from one another, 
and are not fused. 
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2.3 Differentiating ESCs into cortical-like neurons 
 
2.3.1 Preparing ESCs 
 
Targeted or wild type ESCs were differentiated following a well-established protocol 
(Bibel et al., 2004, 2007) (Figure 2.6). In brief, ESCs were passaged 4-6 times after 
thawing, as outlined in section 2.1.5.2. In the case of cells with a J1 background, ESCs 
were passaged a further two times on 0.2% gelatine-coated T75 flasks before 
differentiation. This was done to reduce the ratio of feeders to ESCs, as the presence 
of feeders can result in aggregates sticking to the dish and subsequently affect the 
quality of the differentiation.  
 
2.3.2 Generating cellular aggregates  
 
When ESCs were of a good quality (see publication for details (Bibel et al., 2004, 
2007)), they were passaged as outlined in section 2.1.5.3, but after centrifugation the 
cell pellet was resuspended in CA media. Cells were counted using the nucleocounter, 
and 4 x106 cells plated per 10 cm2 uncoated petri dish in 15 mL CA media. Dishes 
were incubated at 37°C/7% CO2 for eight days to allow formation of cellular 
aggregates (CAs). CA media was gently changed every two days using a 25 mL 
stripette to transfer CAs to a 50 mL falcon tube. CAs were left to settle, before the 
supernatant was carefully removed and 15 mL fresh CA media added. Cells were then 
gently transferred to a new 10 cm2 petri dish (Figure 2.6). Retinoic acid (5 µM; Sigma-
Aldrich) was added on media changes at day 4 and day 6 to trigger neuronal 
differentiation(Bain et al., 1996; Jones-Villeneuve et al., 1982). On the sixth day of 
aggregation, poly-DL-ornithine hydrobromide (PORN; Sigma-Aldrich) was diluted in 
Borate buffer (150 mM boric acid (Sigma-Aldrich), pH 8.3) and filtered to create a 
stock which could be kept up to one week at 4°C. This was then freshly diluted 1:5 in 
ddH2O (Thermo Fisher Scientific), and 0.5 mL plated per well in 12-well plates. Plates 
were incubated at 37°C/7% CO2 for twenty-four hours, and washed the next day three 
times with ddH2O. Wells were then coated in 8.3 µg/mL laminin (Thermo Fisher 
Scientific) for twenty-four hours at 37°C/7% CO2 until use.  
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2.3.3 Plating of neural progenitors 
 
On the eighth day of aggregation, CAs were dissociated by incubation with freshly 
prepared 0.05% trypsin (Sigma-Aldrich; diluted in PBS-0.05% EDTA) for three 
minutes at 37°C. Dissociated CAs were gently re-suspended in CA media before 
centrifuging at 180 rcf for three minutes. The cell pellet was resuspended and gently 
triturated in N2 media (DMEM-F12 (Thermo Fisher Scientific), 1 mM Glutamax,  
25 μg/mL Insulin (Roche), 1% N2 supplement, 1% NEAA, 50 µM 2-mercaptoethanol 
and 1X penicillin-streptomycin) before being passed through a cell strainer to remove 
any intact aggregates. Cells were counted using a nucleocounter, and plated in N2 
media onto the pre-prepared poly-DL-ornithine/laminin coated plates (section 2.3.2) 
at a density of 0.75-2 x106 cells depending on the density required for each experiment. 
N2 media was changed at two hours, and again one day after dissociation.  
Media was changed to complete media 2, 4, 8 and 12 days after dissociation (Bibel et 
al., 2007). To make complete media, 100X stock of the supplement was first prepared 
(Table 2.4). This stock was aliquoted and stored at -80°C for up to one year. Next, a 
BSA solution was prepared consisting of 1 g BSA (Sigma-Aldrich), 2 mg transferrin 
(Sigma-Aldrich) and 1.6 mg insulin (Roche) in 30 mL DMEM. Complete media was 
prepared on the day of use as outlined in Table 2.5. 
 
  
 
D                                                                  E                                                                                      
A                                                                  B                                                                  C                       
Cellular Aggregates  
(Day 0-4) 
Cellular Aggregates + 
R.A. (Day 4-8) 
Dissociated Neuronal Progenitors  
(DIV0-DIV2) 
Neurons  
(DIV2 onwards) 
ESCs on 0.2 % 
Gelatine 
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Figure 2.6 Neuronal differentiation of mouse ESCs. E14 ESCs were cultured on 0.2 % gelatine for 4-6 passages. J1 mouse ESCs were 
cultured on MEFs for 4-6 passages before culturing on A) 0.2 % gelatine for 2-3 passages to remove MEFs (red arrow: ESCs, blue arrow: 
dying cells, purple arrow: remaining MEFs). B) ESCs were passaged and 4 x106 cells added to a non-adherent petri dish in CA media to 
allow the cells to aggregate for eight days, C) retinoic acid (R.A.) was applied to the cellular aggregates (CAs) for the final four days. D) 
On the eighth day the CAs were dissociated, and plated onto poly-DL-ornithine/laminin coated dishes in N2 media. E) After two days in 
N2 media (DIV2), the cells were cultured in complete media which was changed at DIV4, DIV8 and DIV12.  
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Table 2.4 Preparation of 100X complete media supplement 
Reagents 
Final 
Concentration 
(μg/mL) 
For 200 mL 
of 100X 
stock (mg) 
L-alanine 2.00 40.0 
Biotin 0.10 2.0 
L-carnitine 2.00 40.0 
Ethanolamine 1.00 20.0 
D-galactose 15.00 300.0 
L-proline 7.76 155.2 
Putrescine 16.10 322.0 
Sodium pyruvate 25.00 500.0 
Sodium selenite 0.016 0.32 
Vitamin B12 0.34 6.8 
Zinc sulphate 0.19 3.9 
Catalase 2.56 51.2 
Glutathione 1.00 20.0 
Linoleic acid 1.00 20.0 
Linolenic acid 1.00 20.0 
Progesterone 0.006 0.12 
All-trans retinol 0.10 2.0 
Retinylacetate 0.10 2.0 
Tocopherol 1.00 20.0 
Tocopherolacetate 1.00 20.0 
All reagents sourced from Sigma-Aldrich.  
  
Dissolved in 
26.6 mL ddH2O 
Dissolved in 
26.6 mL Ethanol 
Diluted in 
172 mL 
DMEM 
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Table 2.5 Complete media reagents 
Reagents Volume (mL) 
DMEM 358 
Penicillin-Streptomycin (100x) 4 
100x Stock Supplement 4 
Superoxide dismutase (2.5 mg/mL) 0.4 
BSA Solution 30 
Glutamax (100x) 4 
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2.4 Animal husbandry 
 
Procedures, breeding and maintenance were carried out in accordance with Home 
Office Animals (Scientific Procedures) Act, ASPA, 1986 under PPL 30/3137. All 
animals were housed in a 10/14 hour light cycle with food (Global Rodent) and water 
available ad libitum. The temperature was maintained at 19-23°C and humidity 
between 45-65%. Animals were weaned around three to six weeks of age, depending 
on the line, and a maximum of five adult mice kept per cage. Embryonic ages were 
established by timed mating, and animals plug-checked the following morning to 
confirm breeding had occurred. Embryonic ages were confirmed according to Theiler 
staging criteria (Theiler, 2014). All mice were culled by cervical dislocation.  
 
2.5 Generation of TrkA- and TrkB-overexpressing mice 
 
2.5.1 Preparation of cells  
 
E14 Rosa26-loxP-STOP-loxP-HA-rTrkA ESCs were generated by Dr. Xinsheng Nan 
in our laboratory and the recombined and verified (see section 2.2.5) ESCs injected 
into blastocysts at the University of Cambridge. The resulting mice were subsequently 
transferred to Cardiff University (December 2016).  
E14 Rosa26-loxP-STOP-loxP-HA-rTrkB ESCs were generated as outlined in sections 
2.2.4. ESCs with the correct karyotype (section 2.2.7) were thawed and passaged 
according to the protocol described in section 2.1.5.3. The night before blastocyst 
injections occurred, the ESCs were passaged at a 1:3-1:5 split ratio. The next day ESCs 
were passaged and resuspended in 10 mL of CA media before being placed on ice for 
transfer to the site of blastocyst injection.  
 
2.5.2 Blastocyst injection  
 
Blastocyst injections to generate Rosa26-loxP-STOP-loxP-HA-rTrkB mice were 
carried out by Asif Jeelani as part of the JBIOS (Cardiff University) blastocyst 
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injection service. In brief, prior to injection, CD1 females were crossed with 
vasectomised CD1 males to induce pseudopregnancy. On the day of injection, the 
injection chamber and microscope stage were pre-cooled to 10°C, and the injection 
needle aligned. A single expanded blastocyst was then immobilised with a holding 
pipette using slight suction and individual ESCs aspirated into the injection needle. 
The needle was introduced into the blastocoel cavity and ESCs slowly expelled into 
the blastocyst before withdrawing the injection needle. Injected blastocysts were then 
implanted in to the uterus of anaesthetised pseudopregnant female mice. After transfer, 
the mouse was sutured and placed in a heat recovery unit for post-operative care 
according to ASPA guidelines. Females gave birth to litters and offspring were 
observed for any chimerism in coat colour. Any chimeric pups were crossed with wild 
type C57BL6/J mice, and their offspring genotyped. Pups were then continuously 
outbred to C57BL6/J mice for a minimum of three generations to reduce the potential 
for any off target mutations during transfection of ESCs affecting the mice.    
 
2.6 Genotyping mice 
 
2.6.1 Ear-notching  
 
Ear notches were taken for identification of transgenic mice in accordance with Home 
Office Animals (Scientific Procedures) Act, ASPA, 1986 and establishment 
regulations. Spare tissue from this procedure was then processed for genotyping. 
 
2.6.2 DNA extraction  
 
DNA was extracted from ear notches by incubation with 500 µL DNA lysis buffer 
overnight at 50°C. 500 µL 100% isopropanol and 50 µL 3 M sodium acetate was added 
to each sample and inverted before centrifugation at 20000 rcf for fifteen minutes at 
room temperature. Supernatant was aspirated, and the cell pellet washed with 70% 
ethanol. The samples were centrifuged for a further five minutes at  
20000 rcf before resuspending the DNA pellet in 30 μL TE buffer. The DNA 
concentration (ng/µL) was estimated using a BioSpectrometer® (Eppendorf).  
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2.6.3 Genotyping  
 
The DNA samples were used for genotyping using long-range sequal-prep PCR kit 
following the manufacturer protocol with enhancer A. The primers are outlined in 
Table 2.6, and thermal cycling (Table 2.6) carried out in a BIORAD T100 Thermal 
cycler. After amplification the mixture was supplemented with 4 μL DNA loading 
buffer and loaded onto a 1% agarose gel supplemented with 0.2 μg/mL ethidium 
bromide for gender, cre, MECP2 (as an internal control) and Rosa26 genotyping, or a 
3% agarose gel for Rosa26-loxP-STOP-loxP-HA-rTrkA and –rTrkB genotyping. 
Loaded gels were then electrophoresed for one hour and bands detected using a UV 
docking station. 
 
  
Table 2.6 Primers and PCR conditions for genotyping mice 
Genotyping 
For: 
Forward Primer Reverse Primer 
Band Size 
(bp) 
PCR Conditions 
Gender 
 
CTGAAGCTTTTGGCTTTGAG 
 
 
GGTTTCTTAAACCGTCACC 
 
X: 331 
Y: 302 
95°C    3 minutes 
95°C    30 seconds 
58.5°C    30 seconds      x 35 cycles  
68°C    4.5 minutes  
72°C    5 minutes 
Cre GGTTATGCGGCGGATCCGAAAAGAAA ACCCGGCAAAACAGGTAGTTATTCGGATCA 381 Same as above 
Rosa26 AAGGGAGCTGCAGTGGAGTA GTCCCTCCAATTTTACACC 275 Same as above 
MECP2 
Internal 
Control 
AAATTGGGTTACACCGCTGA CTGTATCCTTGGGTCAAGCTG 465 
Same as above 
 
Rosa26-loxP-
STOP-loxP-
HA-rTrkA 
CGCAGGGACTTCCTTTGTCCCAAATC GCTGGGAAGGAGACGCTGACTTG 
2823 
(mutant) 
1506 
(excised) 
95°C 3 minutes 
95°C 30 seconds 
60°C 30 seconds      x 35 cycles  
68°C 3 minutes  
72°C 5 minutes 
Rosa26-loxP-
STOP-loxP-
HA-rTrkB 
CGCAGGGACTTCCTTTGTCCCAAATC CCAAATTCCCAACGTCCCAGTACAAG 
2721 
(mutant)  
1404 
 (excised) 
Same as above 
P
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e│
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2.7 Basic morphological measurements 
 
After culling, all experimental embryos were weighed, and then imaged using a 
digipad (Medline) and dissecting light microscope (VWR). The body area was 
measured for each pup using ImageJ software.  
 
2.8 Histology 
 
2.8.1 Fixation 
 
Homozygous Rosa26-loxP-STOP-loxP-HA-rTrkA and –rTrkB males were time mated 
with heterozygous CMV-Cre females, and females plug checked the next morning. 
Between 11.5-18.5 days pc, mothers were culled by cervical dislocation, and embryos 
dissected out from the yolk sac in ice-cold PBS. Developmental stage was confirmed 
according to Theiler’s criteria (Graham et al., 2015). In the case of P0 pups, animals 
were culled by cervical dislocation on the morning of birth. Tail samples were taken 
for genotyping following the procedure outlined in section 2.6. At this stage, embryos 
≥ E13.5 had the skin removed to enable better fixation and processing. Embryos were 
incubated in 4% paraformaldehyde (PFA; Sigma-Aldrich) at 4°C. If embryos were ≤ 
E13.5 they were incubated in PFA overnight, or for two days if  
≥ E15.5. Following this, the PFA was replaced with 70% ethanol, and embryos stored 
at 4°C for a minimum of one day.  
 
2.8.2 Paraffin embedding 
 
Paraffin wax (Sigma-Aldrich) was heated to 60°C, and embryos were simultaneously 
processed on a roller as outlined in Table 2.7.  
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Table 2.7 Paraffin processing of embryos 
Step Reagent Time (hour) Temperature 
1 95% Ethanol 1 Room Temperature 
2 95% Ethanol 1 Room Temperature 
3 100% Ethanol 1 Room Temperature 
4 100% Ethanol 1 Room Temperature 
5 100% Ethanol 1 Room Temperature 
6 Xylene1 1 Room Temperature 
7 Xylene 1 Room Temperature 
8 Paraffin Wax  1 60°C 
9 Paraffin Wax 1 60°C 
 
1 – purchased from Sigma-Aldrich 
 
 
22 x 22 mm plastic moulds (VWR) were filled with pre-warmed paraffin wax and left 
at 60°C for ten minutes to allow bubbles to settle. Embryos were then placed in these 
moulds in the required orientation, and transferred to a -20°C cold plate. Once the 
paraffin started to solidify, a cassette (Sigma-Aldrich) was placed on top of the mould 
and more paraffin wax poured on top. Once the paraffin had solidified, the blocks were 
transferred to 4°C until use. 
 
2.8.3 Microtome and staining 
 
Blocks were mounted on the microtome (Leica RM2245) and 10 µm transverse 
sections were sliced. Sections were floated in a 42°C water bath and transferred onto 
superfrost plus slides (VWR). Slides were left to dry at 50°C overnight and stored at 
room temperature. Slides were then transferred to the Bioimaging Hub and 
haematoxylin and eosin stainings were performed by Derek Scarborough (Cardiff 
University, Bioimaging Hub) before being collected. 
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2.8.4 Imaging and quantification  
 
Structures of interest were identified via light microscopy. Images were taken of 
structures using a digipad.  
Ganglia volumes were estimated following the Cavalieri method (Coggeshall, 1992). 
In brief, images of stained sections were taken at pre-determined intervals across the 
entire ganglia. The area of each ganglia section was measured in ImageJ, and averaged 
to give ā. This value was then used to calculate the volume using equation 1, where t 
is the section thickness, and s is the total number of sections the ganglia can be 
observed on. 
 
Equation 1. 𝑮𝒂𝒏𝒈𝒍𝒊𝒂 𝑽𝒐𝒍𝒖𝒎𝒆 (𝑽𝒓𝒆𝒇) =  ā ×  t ×  s  
 
To calculate the number of neurons per ganglia, cell bodies were counted in ganglia 
sections at pre-determined intervals, and averaged to give a value for Q-. This value 
was then used to calculate the total number of neurons in each ganglia using equation 
2. aRef. was the average section area per ganglia, h was the section thickness.  
 
 Equation 2. 𝑵𝒆𝒖𝒓𝒐𝒏𝒂𝒍 𝑪𝒐𝒖𝒏𝒕 (𝑵𝒗) =
𝑸−
(𝒂𝑹𝒆𝒇.×𝒉)
  . 
 
Estimates of volume and counts per ganglia were then averaged across the left and 
right ganglia for each embryo. Statistics were calculated in IBM SPSS statistics 
software (version 25) for Windows. Data were tested for normality, and the relevant 
test applied (stated in each figure).  
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2.9 iDISCO 
 
2.9.1 Fixation  
 
To complete iDISCO (Immunolabelling-enabled three-dimensional imaging of 
solvent-cleared organs) analysis, homozygous Rosa26-loxP-STOP-loxP-HA-rTrkA 
males were time-mated with heterozygous CMV-Cre females, and females plug 
checked the next morning. 15.5 days pc, mothers were culled by cervical dislocation, 
and embryos dissected out from the yolk sac in ice-cold PBS. Developmental stage 
was confirmed according to Theiler’s criteria (Graham et al., 2015). Embryos were 
then left for five minutes in ice-cold PBS to drain blood from the umbilical cord to 
reduce background flourescence. Tail samples were taken for genotyping, and 
embryos fixed in 4% PFA for two days at 4°C.  
 
2.9.2 iDISCO: immunolabelling and clearing 
 
Embryos were immunolabelled and cleared according to the January 2015 version of 
the protocol by Renier et al. (2017) (see Table 2.8 for outline of procedure). In brief, 
fixed embryos were transferred to 20 mL glass vials (Thermo Fisher Scientific) and 
washed with PBS three times to remove excess PFA before dehydration at room 
temperature (RT) in methanol/PBS in 20% increments, from 0% up to 100% methanol. 
Embryos were then incubated overnight at 4°C in a solution of 5% hydrogen peroxide 
(H2O2; Sigma-Aldrich). Samples were then washed with 80% methanol before 
gradually washing in decreasing methanol/PBS solutions in 20% increments, 
supplemented with 0.2% Triton X-100 (TX; Sigma-Aldrich). Embryos were incubated 
overnight at 37°C in 0.2% Triton X-100, 20% DMSO and 0.3 M glycine diluted in 
PBS.  
For blocking, the embryos were incubated for two days at 37°C in a solution of 0.2% 
Triton X-100, 20% DMSO and 6% donkey serum (Sigma-Aldrich) in PBS. Embryos 
were then washed in PtWH (0.2% Tween, 10 µg/mL Heparin in PBS) twice for one 
hour before incubation for two days at 37°C with primary antibody (α-TrkA (1:300) 
R&D) in 5% DMSO, 3% donkey serum in PtWH. To remove excess antibody, 
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embryos were washed for one day in PtWH, before incubation with secondary 
antibody (Donkey anti-goat Alexa Fluor 546 (Thermo Fisher Scientific)).  Samples 
were kept in the dark after the addition of secondary antibody. Embryos were then 
washed for two days at room temperature in PtWH before clearing with 50% 
tetrahydrofuran (THF; Sigma-Aldrich) in water overnight at room temperature. It is 
important that after this stage the steps are carried out in glass vials as THF can react 
with plastic. The next morning, embryos were incubated in 80% THF for one hour, 
before two washes with 100% THF for one hour each. This was removed and the 
embryos kept in dichloromethane (DCM; Sigma-Aldrich) until the embryos sank to 
the bottom. Embryos were incubated in DiBenzyl Ether (DBE; Sigma-Aldrich) for two 
hours. At this stage the vials need to be filled completely to prevent oxidation. After 
replacing with fresh DBE, embryos were stored in the dark at room temperature for up 
to a few months for imaging. 
   
 
Table 2.8 iDISCO protocol 
Day 1 Day 2 Day 3 Day 4 
Temp. Time Solution Temp. Time Solution Temp. Time Solution Temp. Time Solution 
RT 30 min. PBS RT 30 min. 
80% 
MeOH/PBS 
37°C 2 Days 
0.2% TX/20% 
DMSO/6% Donkey 
Serum/PBS 
" " " 
RT 30 min. PBS RT 30 min. 
80% MeOH/                   
0.2% TX/PBS 
 
RT 30 min. PBS RT 30 min. 
60% MeOH/                    
0.2% TX/PBS 
RT 30 min. 
20% MeOH/   
PBS 
RT 30 min. 
40% MeOH/                     
0.2% TX/PBS 
RT 30 min. 
40% MeOH/   
PBS 
RT 30 min. 
20% MeOH/                       
0.2% TX/PBS 
RT 30 min. 
60% MeOH/   
PBS 
RT 30 min. 0.2% TX/PBS 
RT 30 min. 
80% MeOH/   
PBS 
RT 1 hour 0.2% TX/PBS 
RT 30 min. 100% MeOH RT 1 hour 0.2% TX/PBS 
RT 1 hour 100% MeOH 37°C Overnight 
0.2% TX/20% 
DMSO/0.3 M 
Glycine/PBS 
RT 3-6 hours 100% MeOH 
 
4°C Overnight 
5% H202/     
MeOH 
P
ag
e│
7
7
 
   
 
 
 
 
 
 
 
 
Day 5 Day 6 Day 7 Day 8 Day 9 
Temp. Time Solution Temp. Time Solution Temp. Time Solution Temp. Time Solution Temp. Time Solution 
RT 1 hour 
0.2% Tween/10 
µg/mL            
Heparin/PBS 
(PtWH) 
" " " RT  10 min. PtWH 37°C 2 Days 
Secondary 
Antibody/3% 
Donkey 
Serum/PtWH 
" " " 
RT 1 hour PtWH 
 
RT  15 min. PtWH Keep in the dark from now on 
37°C 2 Days 
Primary 
Antibody/5% 
DMSO/3% 
Donkey 
Serum/PtWH 
RT  30 min. PtWH 
  
 
RT  1 hour PtWH 
RT  2 hours PtWH 
RT  Overnight PtWH 
P
ag
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Day 10 Day 11 Day 12  
Temp. Time Solution Temp. Time Solution Temp. Time Solution 
RT 10 min. PtWH RT 2 hours PtWH RT 1 hour 80% THF/ H2O 
RT 15 min. PtWH RT 2 hours PtWH RT 1 hour 100% THF 
RT 30 min. PtWH RT 2 hours PtWH RT 1 hour 100% THF 
RT 1 hour PtWH -every 2 hours until end of the day- RT 
<1 hour (until 
embryo sinks) 
DCM 
RT 2 hours PtWH RT Overnight 
50% THF/ 
H2O 
RT 
<2 hours (until 
embryos clear) 
DBE 
RT 2 hours PtWH 
 
RT Store DBE 
-every 2 hours until end of the day- 
 
RT Overnight PtWH 
P
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2.9.3 Creating the imaging chamber 
 
Imaging chambers were 3D printed using the 5mm, or 8mm .sti files (Renier et al., 
2017). These chambers were printed with Visijet M3 Crystal by Printit-3D 
(http://www.printit-3d.com/). The chamber was secured to a microscope slide (VWR) 
with Kwik-sil epoxy (WPI) which is compatible with DBE.  
 
2.9.4 Imaging  
 
Embryos were transferred to the chamber, and the chamber filled with DBE and 
covered with a glass coverslip. Embryos were imaged with confocal microscopy (LSM 
780, Zeiss) using Zen black software (Zeiss). Z stack imaging allowed optical sections 
of the embryos, and the tiles stitched together. A 3D composite image was generated 
by using ‘max intensity projection’ in the Zen Black software. 
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2.10 Immunohistochemistry 
 
2.10.1 Fixation and embedding 
 
Homozygous Rosa26-loxP-STOP-loxP-HA-rTrkA males were time mated with 
heterozygous CMV-Cre females, and females plug checked the next morning.  
13.5 days pc, mothers were culled by cervical dislocation, and embryos dissected out 
from the yolk sac in ice-cold PBS. Developmental stage was confirmed according to 
Theiler’s criteria (Graham et al., 2015). Tail samples were taken for genotyping 
following the procedure outlined in section 2.6. Heads were separated from the body, 
and skin removed. Embryos were incubated in 4% PFA at 4°C overnight. The next 
day embryos were transferred to 30% sucrose (Fisher Scientific) solution in 15 mL 
falcon tubes, and incubated at 4°C until embryos sank to the bottom. At this point, 
embryos were transferred to moulds filled with optimum cutting temperature (O.C.T.) 
compound (VWR) and placed on dry ice to set. Embedded embryos were then 
transferred to -80°C.  
 
2.10.2 Sectioning and staining 
 
Embedded embryos were sectioned at 20 μm thickness on a cryostat (LM3050S) and 
placed on polysine slides. Slides were stored at -80°C.  
Slides were washed with PBS once before incubation with PBST-S (0.1% TX, 10% 
donkey serum (Sigma-Aldrich) in PBS) for one hour at room temperature. Slides were 
then incubated overnight at 4°C with anti-cleaved caspase-3 (CST) antibody diluted 
1:400 in PBST-S. The next day, slides were washed three times with PBS before 
incubation with a secondary antibody (donkey anti-rabbit Alexa Fluor 647; Fisher 
Scientific) diluted 1:1000 in PBST-S, for one hour at room temperature. Slides were 
washed again three times with PBS before incubation with DAPI (1:4000 diluted in 
ddH2O) for five minutes. Slides were washed one further time with PBS, followed by 
ddH2O before being left to dry at room temperature. Coverslips were then mounted 
onto the slides using DAKO mounting medium (Agilent Technologies).  
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2.10.3 Imaging and analysis 
 
Slides were imaged using confocal microscopy. Images were taken at pre-determined 
intervals across the entire ganglia. Where regions of interest were larger than the field 
of view, tile scans were obtained and stitched together. To count the number of cleaved 
caspase-3 positive cells, images were thresholded in ImageJ, and the number of 
positive cells counted using the cell counter plugin. Counts were averaged across the 
individual ganglia, and this was again averaged across the left and right ganglia for 
each embryo. This was then calculated as a fold increase compared to controls.  
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2.11 Western blotting  
 
2.11.1 Protein extraction 
 
Limbs were washed with PBS before the addition of ice-cold protein lysis buffer  
(50 mM Tris-HCl (Sigma-Aldrich), 150 mM sodium chloride, 1 mM EDTA, 1% 
Triton X-100, 0.2% Sodium deoxycholate (Sigma-Aldrich)) supplemented with the 
following enzymes: 1.5 mM aprotinin (Sigma-Aldrich), 100 mM 1-10 phenantroline 
(Sigma-Aldrich), 100 mM 6-aminohexanoic acid (Sigma-Aldrich), 1% protease 
inhibitor cocktail (Sigma-Aldrich), 1% phosphatase inhibitor cocktail (Sigma-
Aldrich) and sodium orthovanadate (Sigma-Aldrich). The limbs were then crushed 
using pestles (VWR) and incubated for thirty minutes on ice. Samples were vortexed 
every five minutes during this time. Samples were then centrifuged at 20000 rcf for 
ten minutes at 4°C, and the supernatant stored at -80°C until use.  
 
2.11.2 Quantifying protein 
 
The concentration of protein in each sample was determined by the use of a PierceTM 
BCA assay kit (Thermo Fisher Scientific) following the manufacturer protocol. 
Protein samples were diluted between 1:10-1:200 depending on the expected 
concentration. Triplicates were performed to ensure the calculated concentrations 
were accurate. Plates were incubated at 37°C for thirty minutes before absorbance 
analysis using a microplate reader (FLUOstar® Omega microplate reader) at 562 nm 
excitation wavelength. The concentration of the protein in each sample was quantified 
using a standard curve.  
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2.11.3 Sample preparation 
 
Samples were diluted to 1 μg/μL in lysis buffer supplemented with 4x lithium dodecyl 
sulfate buffer (LDS; 106 mM Tris HCl, 106 mM Tris Base, 0.74 mM LDS (Sigma-
Aldrich), 0.5 mM EDTA, 1 M glycerol, 0.2 mM Brilliant Blue (Sigma-Aldrich),  
0.175 mM Phenol Red (Sigma-Aldrich)) and 50 mM dithiothreitol (DTT; Invitrogen) 
to a total volume of 31 μL per well/sample, and incubated for ten minutes at 70°C.  
 
2.11.4 Western blot and membrane transfer 
 
30 μL of sample was electrophoresed on NuPAGETM NovexTM 4-12% Bis-Tris gels 
(Thermo Fisher Scientific) at 120 V for 1.5 hours in running buffer (50 mM  
2-(N-morpholino)ethanesulfonic acid (MES; Sigma-Aldrich), 50 mM Tris base,  
0.1% SDS, 1 mM EDTA, pH 7.3). After electrophoresis the gel was removed and 
protein transferred to a nitrocellulose membrane (GE Healthcare) using semi-dry 
transfer machines (GE Healthcare). Here the membrane and blotting papers were 
soaked in transfer buffer (25 mM Bicine (Sigma-Aldrich), 25 mM Bis-Tris (Sigma-
Aldrich), 1 mM EDTA, 20% methanol). Transfer was then carried out at 17 V for one 
hour. After transfer the membranes were washed once with TBS-T (24.7 mM Tris 
base, 137 mM NaCl, 2.6 mM KCl, 0.1% Tween-20 (Sigma-Aldrich), pH 7.5). 
 
2.11.5 Primary and secondary antibodies 
 
Membranes were then incubated with blocking buffer (1% BSA, 5% blocking reagent 
(Biorad) in TBS-T) for one hour at room temperature, before incubation with primary 
antibody (Table 2.9) diluted in blocking solution overnight at 4°C. The membranes 
were washed three times with TBS-T for twenty minutes before incubation with 
secondary antibodies (Table 2.9) diluted in blocking solution for one hour at room 
temperature. Membranes were washed again with TBS-T three times for twenty 
minutes.  
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Table 2.9 Antibodies used for western blot 
 
 
2.11.6 Detection and stripping 
 
Membranes were incubated with 1 mL LumiGLO® Reserve Chemiluminescent 
Substrate kit (KPL) at room temperature for two minutes. The LumiGLO® was 
removed and signal detected using a ChemiDocTM MP system together with Imagelab 
software (Biorad).  
After developing the membranes were washed for ten minutes in TBS-T before 
incubation with stripping buffer (Sigma-Aldrich) for fifteen minutes at room 
temperature. Membranes were washed three further times for ten minutes in TBS-T 
and then the process continued from section 2.11.5 for the internal control (GAPDH).  
 
 
Antibody Type Dilution Species Company 
Catalogue 
Number 
αHA mAb 1:2000 Rat 
Roche (via 
Sigma-Aldrich) 
ROAHAHA 
αpan-Trk pAb 1:2000 Rabbit Santa Cruz sc-11 
αGAPDH pAb 1:5000 Chicken Abcam ab83956 
αrat-HRP pAb 1:4000 Goat R&D HAF005 
αrabbit-HRP pAb 1:4000 Goat Promega W4011 
αchicken-HRP IgY 1:15000 Goat Abcam ab6877 
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3. Generating an in vitro model of TrkA- and TrkB- 
overexpressing neurons 
 
3.1. Introduction 
 
The observation by Nikoletopoulou et al. (2010) that TrkA acts as a dependence 
receptor provided a plausible explanation as to why NGF-dependent neurons die 
during development. However the mechanisms of TrkA-induced cell death remain 
undefined. In order to further elucidate the mechanisms of TrkA-induced cell death, 
mouse ESCs were generated as in the Nikoletopoulou et al. (2010) paper, but with two 
key differences; 1) the presence of a loxP-flanked STOP cassette preceding the Trk 
receptors, preventing expression without Cre-dependent recombination, and 2) a 
CreERT2 sequence under the ubiquitous Rosa26 promoter, where the Cre recombinase 
activity is induced by addition of Tamoxifen (Figure 3.1).   
 
Figure 3.1 Comparison of Nikoletopoulou et al. (2010) and current strategies. A) 
In the previous publication, HA-tagged (purple) TrkA and TrkB (green) are expressed 
under the Mapt locus constitutively. The BM40 signal sequence is indicated in 
(orange) before HA. B) The current strategy has a loxP-flanked STOP cassette 
preceding the Trk receptor sequences, so that it cannot be expressed under 
physiological conditions. In this case, expression of TrkA and TrkB is induced by the 
addition of Tamoxifen to the ESC culture, which activates the CreERT2 protein 
(expressed under the ubiquitous Rosa26 locus) to excise the STOP cassette.  
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These ESCs were differentiated into homogenous populations of glutamatergic, 
cortical-like neurons (Bibel et al., 2004, 2007), as used in the Nikoletopoulou et al. 
(2010) paper. In this way, the expression of TrkA and TrkB could be temporally 
controlled during differentiation of ESCs into mature neurons. The benefit of neuronal 
models derived from mouse embryonic stem cells (ESCs), compared to primary 
cultures, is that due to the pluripotency and proliferation potential of ESCs, an 
unlimited number of any cell type can be produced, provided there is an established 
differentiation protocol. This is advantageous in that there is an unlimited supply of 
material for analysis without the need for sacrificing animals. 
This in vitro model was generated with the aim of testing:  
1) The effects of delayed TrkA expression in post-mitotic neurons, 
2) The biochemical mechanisms of TrkA-induced cell death, 
3) Whether, and at what point, TrkA-induced cell death in neurons could be 
rescued by NGF addition. 
This chapter firstly outlines the production of the pMapt-loxP-STOP-loxP-HA-rTrkA 
and -TrkB targeting plasmids, and the generation and validation of the required ESC 
lines. 
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3.2. Generation of pMapt-loxP-STOP-loxP-HA-rTrkA and -
rTrkB vectors 
 
The targeting constructs were first generated (outlined in section 2.2.2). The pMapt-
loxP-STOP-loxP-HA-rTrkA and -rTrkB plasmids were produced by linearising the 
pMapt-HA-rTrkA and -rTrkB plasmids (as used in Nikoletopoulou et al.’s 2010 paper 
with PmeI, and a 1.5 kb loxP-STOP-loxP sequence ligated into this location (Figure 
3.2). The plasmid ligation mixture was then transformed into E. coli, and DNA 
extracted from individual colonies for restriction analysis using HindIII. HindIII 
restriction sites in the pMapt-loxP-STOP-loxP-HA-rTrkA (Figure 3.3) and rTrkB 
(Figure 3.4) plasmids were different, and so are depicted in separate figures.  
In the original pMapt-HA-TrkA plasmid, HindIII restriction gives rise to three DNA 
fragments; >10 kb, 2.2 kb, and 600 bp (Figure 3.3, A). However after ligation of the 
loxP-STOP-loxP cassette into the linearised pMapt-HA-rTrkA plasmid in the correct 
orientation, HindIII digestion resulted in five separate DNA fragments; >10 kb, 3.7 
kb, 60 bp, 40 bp, and 600 bp (Figure 3.3, B). Alternatively in the pMapt-HA-rTrkB 
plasmid, HindIII restriction results in two DNA fragments; >10 kb, and 2.2 kb (Figure 
3.4A). When there was ligation of the loxP-STOP-loxP cassette in the correct 
orientation, HindIII digestion resulted in four DNA fragments; >10 kb, 3.7 kb, 60 bp, 
and 40 bp (Figure 3.4B). The bands >100 bp band could be visualised after separation 
by electrophoresis on an agarose gel, in order to identify the bacterial samples that 
contained the correct plasmid (Figure 3.3, D, and Figure 3.4, D).  The plasmid DNA 
sequence was then confirmed by Sanger sequencing, and the bacteria amplified. DNA 
was extracted from these bacteria by maxiprep to obtain a high concentration of the 
required plasmid.  
 
 
 
 
 
  Chapter 3 
Page | 89  
 
 
Figure 3.2 Generation of pMapt-loxP-STOP-loxP-HA-rTrkA and -rTrkB 
plasmids. A) The existing plasmid contained a BM40 sequence (orange) preceding a 
HA-tagged (purple) rat TrkA or TrkB (green) sequence, flanked by two homology arms 
for the mouse Mapt gene (blue). The plasmid was linearised using the restriction 
enzyme PmeI (red). In this break, the loxP-flanked STOP cassette (pink), excised from 
another construct using EcoRI and XbaI (red) was ligated to form the new plasmid.  
B) Agarose gel (1%) electrophoresis of the digested loxP-STOP-loxP sequence. The 
desired STOP cassette sat at 1.5kb (indicated by an arrow), and was purified from the 
gel to separate it from the plasmid backbone (~6kb band). C) The pMapt-HA-rTrkA 
or -rTrkB plasmids (indicated by TrkA or TrkB here) when digested with PmeI only 
gave rise to one ~12kb fragment after electrophoresis on an 1% agarose gel as there is 
only one PmeI restriction site.  
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Figure 3.3 Restriction analysis of pMapt-loxP-STOP-loxP-HA-rTrkA plasmid. A)  The HindIII restriction sites in pMapt-HA-rTrkA plasmid 
gave rise to three DNA fragments; >10 kb, 2.2 kb, and 600 bp. B) When there was ligation of the loxP-STOP-loxP cassette into the linearised 
pMapt-HA-rTrkA plasmid in the correct orientation, HindIII digestion would result in five DNA fragments; >10 kb, 3.7 kb, 60 bp, 40 bp, and  
600 bp. C) When the STOP cassette had been inserted in the wrong orientation, HindIII restriction would result in five DNA fragments; >10 kb, 
2.2 kb, 40 bp, 1.5 kb, and 600 bp. D) Example 1% agarose gel of HindIII digested plasmids. Numbers indicate different E. coli clones. TrkA 
indicates an example of HindII digestion of the existing pMapt-HA-rTrkA plasmid. Black squares by the clone number indicates samples with 
incorrect orientation of the STOP cassette, and red asterisks mark clones with correct orientation of the STOP cassette. The band sizes of interest 
are indicated by a black arrow.  
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Figure 3.4 Restriction analysis of pMapt-loxP-STOP-loxP-HA-rTrkB plasmid. A)  The HindIII restriction sites in pMapt-HA-rTrkB plasmid 
gave rise to two DNA fragments; >10 kb, and 2.2 kb. B) When there was ligation of the loxP-STOP-loxP cassette in the correct orientation, HindIII 
digestion resulted in four DNA fragments; >10 kb, 3.7 kb, 60 bp, and 40 bp. C) When the STOP cassette had been ligated in the wrong orientation, 
HindIII restriction would result in four DNA fragments; >10 kb, 2.2 kb, 40 bp, 1.5 kb and 600 bp. D&E) Example 1% agarose gel of HindIII 
digested plasmids. Numbers indicate plasmids from E.coli clones when trying to generate the D) pMapt-loxP-STOP-loxP-HA-rTrkB plasmids. 
Black squares by the clone number indicates samples with incorrect orientation of the STOP cassette, and red asterisks mark clones with correct 
orientation of the STOP cassette. The lane labelled TrkB indicates an example of HindII digestion of the existing pMapt -HA-rTrkB.  
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3.3. Generating R26-CreERT2;Mapt-LSL-TrkA and -TrkB ESCs 
 
Wild type mouse ESCs can be of different genetic backgrounds, and are initially 
derived from different mice. As it has been noted that there can be an effect of genetic 
background on results, two lines of both Rosa26-CreERT2;Mapt-loxP-STOP-loxP-HA-
rTrkA and -rTrkB (hereby referred to as R26-CreERT2;Mapt-LSL-TrkA or –TrkB) 
ESCs were generated; one on an E14 background, and the other on a J1 background. 
J1s are derived from male 129/terSv mice and require culture on mouse embryonic 
fibroblasts to maintain pluripotency (Li et al., 1992), whilst E14s are derived from 
male 129/Ola mice and can be cultured without fibroblasts (Hooper et al., 1987).  This 
was to ensure that the results obtained with one cell line could be replicated, therefore 
validating the findings. Mouse ESCs of different genetic backgrounds can behave 
differently, for example as indicated by the results of histone H3 lysine 9 acetylation  
(Hezroni et al., 2011).  
 
3.3.1. E14 background 
 
In order to excise the loxP-flanked STOP cassette, we required an ESC line that 
expressed CreERT2. As E14 Rosa26-CreERT2 ESCs were readily available, where 
CreERT2 is expressed ubiquitously, these ESCs were targeted with the pMapt-loxP-
STOP-loxP-HA-rTrkA and pMapt-loxP-STOP-loxP-HA-rTrkB constructs (section 
3.2), aided by CRISPR-guided targeting (section 2.2.3). Genotyping PCR confirmed 
a targeting success rate of between 25-35% (Figure 3.5), and clones were karyotyped 
to ensure they had the correct number of chromosomes (>70% of cells with forty 
chromosomes). The results indicated that the ESC lines outlined in Table 3.1 were 
suitable to continue with for experiments.   
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Table 3.1 E14 R26-CreERT2;Mapt-LSL-TrkA and -TrkB ESC lines 
 
ESCs Line Clone 
Karyotype 
(%) 
E14 Rosa26-CreERT2;Mapt-loxP-STOP-loxP-HA-rTrkA #36 70 
E14 Rosa26-CreERT2;Mapt-loxP-STOP-loxP-HA-rTrkA #208 70 
E14 Rosa26-CreERT2;Mapt-loxP-STOP-loxP-HA-rTrkB #13 75 
E14 Rosa26-CreERT2;Mapt-loxP-STOP-loxP-HA-rTrkB #16 75 
  
  
 
 
 
 
Figure 3.5 Genotyping PCR determining insertion of the pMapt-loxP-STOP-loxP-HA-rTrkA and -rTrkB constructs into the endogenous 
Mapt gene of ESCs. Expected location of the pMapt-loxP-STOP-loxP-HA-rTrkA and -rTrkB constructs in the endogenous Mapt gene in ESCs. 
Arrows marked #1-3 indicate genotyping primer pair locations (details in methods section 2.2.6), with the arrow direction indicating whether it 
is forward or reverse primer. Pair #1 and #2 are used to genotype Mapt-lox-STOP-loxP-HA-rTrkA ESCs, whilst pair #1 and #3 are used to 
genotype Mapt-loxP-STOP-loxP-HA-rTrkB ESCs. 
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3.3.2. J1 Background 
 
As J1 Rosa26-CreERT2 ESCs were unavailable, wild type J1s were targeted in two 
stages; first with a pRosa26-CreERT2 zinc finger nuclease targeting kit (section 2.2.4), 
and once a J1 Rosa26-CreERT2 line had been established they were targeted with the 
pMapt-loxP-STOP-loxP-HA-rTrkA and -rTrkB plasmids. 
 
3.3.2.1. Testing the effects of antibiotic-resistant MEFs on antibiotic 
selection  
 
During targeting, antibiotics were applied to select for cells that had integrated the 
construct, and therefore expressed the antibiotic resistance gene contained within the 
plasmid. Whereas the pRosa26-CreERT2 construct contained a selection cassette to 
puromycin, the pMapt-loxP-STOP-loxP-HA-rTrkA and -rTrkB constructs contained a 
selection cassette to neomycin. However, any ESCs that did not contain the construct 
would die upon exposure to antibiotics.  
Though the concentrations of both puromycin and neomycin for effective selection 
had been tested on both E14 and J1 ESCs grown on gelatine, it was observed that from 
150 picked J1 clones, none had the correct construct. This was due to the concentration 
of antibiotic being too low, resulting in a higher proportion of surviving non-targeted 
clones. The sensitivity of J1 ESCs to different concentrations of puromycin or 
neomycin when grown on antibiotic-resistant MEFs of different densities was tested 
(Figure 3.6, neomycin results not shown). The results indicated that when grown on 
antibiotic-resistant MEFs, J1s were less susceptible to antibiotic-induced death. A new 
concentration of 1.5 μg/mL puromycin and 250 μg/mL for MEFs was selected for 
targeting of J1 ESCs. 
 
  
 
Figure 3.6 J1 ESCs were more resistant to puromycin selection when cultured on puromycin-resistant MEFs. One thousand J1 ESCs 
            were plated on either 2.5 x105 (A-D), or 5 x105 (E-H) puromycin-resistant MEFs/well. ESCs were either grown (A, E) without any 
antibiotics, or with (B, F) 1 μg/mL, (C, G) 1.5 μg/mL, or (D, H) 2 μg/mL puromycin. ESC colonies (noted by shiny borders and clusters of 
cells) are indicated by green arrows, and MEFs by yellow arrows. Scale Bars: 200 μm.  
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3.3.2.2. Production of J1 Rosa26-CreERT2 ESCs 
 
Wild type J1 ESCs were targeted with the pRosa26-CreERT2 construct as outlined in 
section 2.2. Genotyping confirmed a targeting success rate of 49%, and clones were 
karyotyped to ensure they had the correct chromosomal number. The lines detailed in 
Table 3.2 were determined to be suitable to continue with for the second round of 
targeting.  
 
Table 3.2 J1 Rosa26-CreERT2 ESC Lines 
 
 
 
 
 
 
 
3.3.2.3. Generation of J1 R26-CreERT2;Mapt-LSL-TrkA and -TrkB 
ESCs 
 
J1 Rosa26-CreERT2 ESCs were then targeted with the pMapt-loxP-STOP-loxP-HA-
rTrkA and -rTrkB constructs as outlined in section 2.2.5. Genotyping confirmed a 
targeting success rate of 10% for both the TrkA and TrkB constructs. Positive clones 
were karyotyped to ensure they had the correct chromosomal number. The clones 
outlined in Table 3.3 were deemed suitable for experiments.  
 
ESCs Line Clone Karyotyping (%) 
J1 Rosa26-CreERT2 CL1 77 
J1 Rosa26-CreERT2 CL24 77 
J1 Rosa26-CreERT2 CL20 73 
J1 Rosa26-CreERT2 CL12 92 
J1 Rosa26-CreERT2 CL27 77 
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Table 3.3 J1 Rosa26-CreERT2;Mapt-LSL-TrkA and -TrkB ESC lines 
 
 
3.4. Tamoxifen-induced recombination in ESCs and ESC-derived 
neurons 
 
To ensure that TrkA and TrkB receptor expression was dependent on tamoxifen 
treatment, 0.8 μg/mL of tamoxifen was applied to E14 R26-CreERT2;Mapt-LSL-TrkA 
and -TrkB ESCs (Figure 3.7, A and B). E14 genetically modified ESCs were the first 
available lines, and so are focused on for the preliminary tests outlined in this chapter.  
Genotyping PCR of treated ESCs demonstrated that there was complete excision of 
the STOP cassette in the DNA of selected ESC clones. Furthermore there was no 
expression of the exogenous Trk receptors without tamoxifen treatment. As tamoxifen 
can be cytotoxic (Majumdar et al., 2001), one question was what stage of the in vitro 
differentiation procedure, application time, and concentration of tamoxifen would 
allow efficient recombination of the STOP cassette in neurons without affecting the 
quality of the neuronal culture. To do this, the E14 R26-CreERT2;Mapt-LSL-TrkA 
clone #36 was differentiated into neurons (section 2.3 (Bibel et al., 2007)), and 
0.1 μg/mL tamoxifen added at either day 6 (48 hours), or day 8 of the cellular 
aggregation procedure (2 hours, or 48 hours). These timings were selected to fit with 
media changes within the differentiation procedure. It was observed that there were 
many non-neuronal cells in this differentiation (Figure 3.7, D and E), although there 
were enough neurons to extract DNA (See section 3.6 for further details). There was 
ESCs Line Clone Karyotyping (%) 
J1 
Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkA 
A12 75 
J1 
Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkA 
A8 75 
J1 
Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkB 
B15 70 
J1 
Rosa26-CreERT2;Mapt-loxP-
STOP-loxP-HA-rTrkB 
B18 70 
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full deletion of the STOP cassette in the DNA of cells in all test conditions (Figure 3.7, 
C). Additionally, incubation with tamoxifen at the ESC, cellular aggregate, neural 
progenitor, nor mature neuronal stages resulted in toxicity to the neurons (Figure 3.7, 
D and E), and deletion of the STOP cassette was complete in all cases.  
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R26-CreERT2;Mapt-LSL-TrkA                             R26-CreERT2;Mapt-LSL-TrkA +TAM 
R26-CreERT2;Mapt-LSL-TrkA 
R26-CreERT2;Mapt-LSL-TrkB 
R26-CreERT2;Mapt-LSL-TrkA 
D                                                           E 
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Figure 3.7 Tamoxifen treatment resulted in Cre-mediated recombination of the 
loxP-flanked STOP cassette in the DNA of ESCs and ESC-derived neurons.  
A) E14 R26-CreERT2;Mapt-LSL-HA-rTrkA, or B) -rTrkB ESCs were treated with 0.8 
μg/mL tamoxifen for 48 hours. DNA was then extracted at DIV2 and a genotyping 
PCR reaction, run on a gel, tested for deletion of the 1.5 kb loxP-flanked STOP 
cassette. Numbers above each lane refer to ESC lines derived from different clones. 
Replicates are from different dishes of Tamoxifen-treated ESCs. The negative control 
was an E14 Rosa26-CreERT2 line. C) The STOP cassette was removed in neurons 
when 0.1 μg/mL tamoxifen was added, at either D6 CAs for 48 hours, or to neural 
progenitors immediately after dissociation of D8 CAs for either 2 or 48 hours. DNA 
was extracted from the neurons two days after treatment, and a genotyping PCR 
reaction run on the gel demonstrated here. The negative control was a E14 R26-
CreERT2 line and the positive control was DNA from tamoxifen treated E14 R26-
CreERT2;Mapt-LSL-HA-rTrkA clone #36 in figure A. D) Example of tamoxifen 
untreated neuronal culture derived from E14 R26-CreERT2;Mapt-LSL-HA-rTrkA clone 
#208, and example image of E) neurons derived from tamoxifen-treated ESCs. Insets 
are 200% magnification. Scale bars: 100 μm.  
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3.5. Expression of TrkA and TrkB protein  
 
Next it was confirmed whether excision of the STOP cassette in the DNA of 
tamoxifen-treated ESCs or neurons related to expression of the respective Trk receptor 
at the protein level. To do this, ESCS were treated with tamoxifen (0.8 μg/mL;  
48 hours as ESCs), and differentiated. Protein samples were then extracted from E14 
Rosa26-CreERT2;Mapt-LSL-TrkA and -TrkB neurons from D8 of cellular aggregation 
to DIV8 (8 days after plating neuronal progenitors) (section 2.11). Western blot 
analysis indicates that HA-tagged TrkA and TrkB protein is present after tamoxifen 
treatment, but without tamoxifen no HA-tagged TrkA and TrkB protein could be 
detected (Figure 3.8). This confirms that the system is reliable.  
  
  Chapter 3 
Page | 105  
 
 
 
 
Figure 3.8 Tamoxifen treatment resulted in expression of HA-tagged TrkA and 
TrkB protein in ESC-derived neurons. A) R26-CreERT2;Mapt-LSL-TrkA, and  
B) R26-CreERT2;Mapt-LSL-TrkB ESCs were treated with 0.8 μg/mL tamoxifen for 
two days before neuronal differentiation. The resulting neurons were checked for 
expression of the HA-tagged TrkA and TrkB proteins (~140 kDa) by western blot 
using αHA antibody. DIV refers to days in vitro; the age of neurons after dissociation 
of the cellular aggregates. Loading control bands are GAPDH (~38 kDa). 
 
 
 
R26-CreERT2;Mapt-LSL-TrkA 
R26-CreERT2;Mapt-LSL-TrkB 
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3.6. Differentiation of R26-CreERT2;Mapt-LSL-TrkA and -TrkB 
ESCs into neurons 
 
3.6.1. Differentiation into cortical-like neurons 
 
To differentiate targeted ESCs into homogeneous, glutamatergic, cortical-like 
populations of neurons a well-established protocol was utilised (Bibel et al., 2004, 
2007) that is routinely used for mouse ESCs of different genetic backgrounds such as 
J1 and E14 (Figure 3.9, A, B), even with genetic modifications such as E14 Rosa26-
CreERT2 (Figure 3.9, C). However as mentioned above, the R26-CreERT2;Mapt-LSL-
TrkA and -TrkB ESCS did not consistently produce homogenous neuronal cultures 
with either a E14, or J1 background (Figure 3.9, D and E), even when tamoxifen was 
not added for the respective Trk receptor to be expressed. As it had been confirmed 
that Trk expression is not leaky, this indicated that it was an issue with the cell lines 
themselves, and not an unknown effect of the Trk receptors. The resulting “neuronal” 
cultures included a comparatively high number of non-neuronal cells, and the few 
neurons that were generated clumped together in clusters. These neurons could not be 
cultured for more than a few days without dying due to rapid expansion of the dividing, 
non-neuronal cells. The neuronal cultures were not improved even after tailoring 
aspects of the ESC culture protocol such as time between passages and seeding density 
(not shown) to improve the quality of ESCs before differentiation which has been 
found to correlate with neuronal quality (Bibel et al., 2004) .  
Careful observation of cellular aggregates (CAs) demonstrated that there were 
differences in their formation (Figure 3.10). While wild type E14 and J1 ESCs formed 
large, light, aggregates with clearly defined boundaries (Figure 3.10A, Figure 3.10B) 
at D8, R26-CreERT2;Mapt-LSL-TrkA and -TrkB aggregates had a bubbly border, and 
were smaller, and denser (Figure 3.10D, Figure 3.10E). E14 R26-CreERT2 (Figure 
3.10C) and E14 Mapt-LSL-TrkA (Figure 3.10F) ESCs on the other hand formed CAs 
that were in between those of wild types and R26-CreERT2;Mapt-LSL-TrkA and –TrkB 
ESCs.  
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Furthermore, the yield of neural progenitors (the number of cells obtained after 
dissociating D8 cellular aggregates) has been found to be linked to neuronal culture 
quality (Bibel et al., 2007). Whereas wild type J1 or E14 ESCs resulted in 20-35 x106 
neural progenitors per dish of aggregates, both E14 and J1 R26-CreERT2;Mapt-LSL-
TrkA and -TrkB ESCs consistently produced yields of <15 x106 neural progenitors per 
dish of aggregates.  
 
 
  Chapter 3 
Page | 108  
 
 
Figure 3.9 Differentiation of ESCs into neurons.Cortical-like neurons can be 
derived from both A) J1 and B) E14 wild type ESCs. Images shown are 8 days after 
dissociation of aggregates (DIV8).  Neuronal cultures derived from C) E14 Rosa26-
CreERT2 are also able to differentiate into homogenous populations of neurons (DIV8). 
However R26-CreERT2;Mapt-LSL-TrkA ESCs on either a D) J1 or E) E14 background 
(DIV8) show many non-neuronal cells, clusters of neuronal somas and thick, cable 
like axons by DIV8. F) E14 Mapt-LSL-TrkA ESCs were able to differentiate into 
homogenous populations of neurons. All neurons were plated at 0.75 x106 density. 
Axons are indicated by orange arrows, soma by purple arrows, and non-neuronal cells 
by blue arrows. Scale bars: 100 μm.  
 
D 
J1 R26-CreERT2;Mapt-LSL-TrkA 
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Figure 3.10 D8 cellular aggregates of different ESC lines. D8 Cellular aggregates 
from wild type A) E14 or B) J1 ESCs form large, round aggregates with a dense dark 
centre (red arrow) with a lighter gradient (green arrow) towards clearly defined borders 
(purple arrow). There are few free-floating, dying (white) cells (blue arrow). C) E14 
Rosa26-CreERT2 ESCs also seem to form nice aggregates by D8, although they are 
smaller in size, and denser in the centre. However the borders are still clear. D) E14 
R26-CreERT2;Mapt-LSL-TrkA (clone #36), or E) -TrkB (clone #13), and F) J1 R26-
CreERT2;Mapt-LSL-TrkA (clone A12) form dense aggregates with undefined edges 
(yellow arrow), with lots of dying cells. Scale bars: 200 μm.  
E14 WT                                                           J1 WT 
E14 Rosa26 –CreERT2                                     E14 R26-CreERT2;Mapt-LSL-TrkA 
E14 R26 –CreERT2;Mapt-LSL-TrkB                 J1 R26-CreERT2;Mapt-LSL-TrkA 
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3.6.2. Differences between ESC clones 
 
The inability to produce homogenous neuronal cultures with R26-CreERT2;Mapt-LSL-
TrkA and -TrkB ESCs also did not vary with the clone (Figure 3.11), nor was it 
improved by sub-cloning. Again, yields of neural progenitors from different clones 
and subclones were consistently < 15 x106 per dish of aggregates. As there was no 
observable difference between the J1 or E14 lines, the efforts detailed in this chapter 
to improve neuronal cultures show example differentiations from E14 R26-
CreERT2;Mapt-LSL-TrkA clones #36 and #208. 
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Figure 3.11 Comparison of neuronal culture quality using different ESC clones. 
Neurons at DIV8 from A) R26-CreERT2;Mapt-LSL-TrkA clone #36 and B) clone #208, 
C) R26-CreERT2;Mapt-LSL-TrkB clone #13 and D) clone #16. Non-neuronal cells are 
indicated by blue arrows. Scale bars: 100 μm. Insets are 200% magnification. 
 
 
 
 
 
 
 
 
 
E14 R26 –CreERT2;Mapt-LSL-TrkA #36         E14 R26-CreERT2;Mapt-LSL-TrkA #208 
E14 R26 –CreERT2;Mapt-LSL-TrkB #13         E14 R26-CreERT2;Mapt-LSL-TrkB #16 
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3.6.3. Adapting ESC culture media 
 
As mentioned previously, neuronal differentiation is strongly dependent upon the 
quality of the ESC culture upon starting the differentiation process, particularly as 
spontaneously differentiating ESCs will not give rise to neuronal cells and contaminate 
the culture with non-neuronal cells (Bibel et al., 2007; Wu et al., 2012). This is similar 
to well documented findings that a high number of ESC passages, which affects 
chromosomal stability (Rebuzzini et al., 2015), and karyotype may affect 
differentiation potential (Zhang et al., 2016). As the quality of ESC culture has been 
linked to neuronal differentiation homogeneity (Bibel et al., 2007), it was tested 
whether different ESC culture conditions could improve the differentiation of the 
targeted ESCs. Whilst the ability to generate cultures of wild type neurons of different 
backgrounds indicated that this was not an issue with tissue culture reagents or 
application of the protocol, fresh stocks of reagents were prepared, and the targeted 
cell lines differentiated by another person within the lab who routinely used this 
protocol. However this yielded the same results. Another possibility was that the LIF 
generated in house was not effective at preventing cells from differentiating. Whilst 
the ESCs looked morphologically like they were undifferentiated, it is possible that 
the molecular machinery with in house LIF may have pushed the ESCs towards 
differentiating into a non-neuronal cell type. However, using commercial recombinant 
LIF also did not improve neuronal differentiation quality (image not shown). 
Next, the effects of ES Media as described by Bibel et al. (2007) was compared to 
another established ES culture media;  serum-free 2I +LIF media (Silva et al., 2008) 
(section 2.1.5.5). 2I+LIF media is serum-free, and whilst it may lack the unidentified 
nutrients and growth factors thought to be provided by serum, it also bypasses the 
variability between batch numbers. However in this thesis, different batches of bovine 
calf serum used in ES media was tested for their effect on ESC culture quality, and the 
same, single batch then used throughout. The second major difference between ESC 
and 2I+LIF media is that 2I+LIF includes inhibitors of glycogen synthase kinase-3 
(GSK-3) and mitogen-activated protein kinase (MAPK)/extracellular signal related 
kinases (Erk) 1 and 2 pathway. Inhibiting the MAPK/Erk pathway prevents the growth 
of primed epiblast stem cells (EpiScs) (Silva et al., 2008), a specified lineage that ESCs 
can differentiate into but maintain a similar morphology to ESCs to the untrained eye, 
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while inhibiting GSK-3 stimulates ESC self-renewal (Ying and Smith, 2017). 2I+LIF 
media supplemented with 15% FBS, referred to as 2I +LIF +15% FBS, was also tested.  
ESCs cultured in 2I +LIF +15% FBS appeared to be the best quality in comparison to 
ES or 2I +LIF media in terms of morphology (shiny borders, small, uniform ESCs, 
few differentiating ESCs) and proliferated quickly (1-2 days). However these ESCs 
still gave rise to poor quality neuronal cultures (Figure 3.12). The yield of neural 
progenitors was again an indicator of poor differentiation, with each media type 
ultimately producing <15 x106 progenitors per dish of CAs. 
  
 
Figure 3.12 Adapting ESC media improved ESC, but not neuronal quality. Clone #208 ESCs and the resulting neuronal cultures at DIV4 
(NPs) when cultured in (A, D) ES media, (B, E) 2I + LIF media, or (C, F) 2I + LIF + 15% FBS. Spontaneously differentiating cells are indicated 
by red arrows, and non-neuronal cells indicated by blue arrows. Scale bars: 100 μm. Insets are 200% magnification. 
A                                                                       B                                                                         C 
 
 
 
 
 
 
 
 
 
 
D                                                                       E                                                                         F 
ES Media (ESCs)                                                    2I + LIF media +15 % FBS (ESCs)                       2I + LIF media (ESCs) 
ES Media (NPs)                                                      2I + LIF media +15 % FBS (NPs)                         2I + LIF media (NPs) 
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3.6.4. Culturing targeted E14 ESCs on MEFs  
 
Although ESCs with E14 background are classically cultured on gelatine-coated 
dishes (Hooper et al., 1987), it is possible that culturing targeted ESCs on mouse 
embryonic fibroblasts (MEFs) could improve the quality of the ESCs, and 
subsequently their ability to differentiate. Although the exact mechanism by which 
MEFs improve ESC pluripotency is undefined, it is thought that the secretion of 
growth factors and small molecules that are known to be important in proliferation, 
such as activin-A and transforming growth factor beta (TGFβ), may play a role 
(Eiselleova et al., 2008; Ogawa et al., 2006; Tamm et al., 2013). Whilst culturing 
targeted ESC clones #36 and #208 on MEFs improved the morphological quality of 
the ESC culture (section 3.6.4) (Figure 3.13), these cells were still unable to generate 
cultures with a higher proportion of neurons than non-neuronal cells (Figure 3.13).  
Furthermore, combining both 2I+LIF+15% FBS media and culture on MEFs did not 
improve neuronal culture (Figure 3.14). Similarly, the neuronal progenitor yield in all 
treatment conditions was <10 x106 per dish of CAs.
  
A                                                                          B                                                                          C 
 
 
 
 
 
 
 
 
 
 
D                                                                         E                                                                           F 
#36 - MEFs                                                              #36 – MEFs  Gelatine                                           #36 - DIV3  
#208 - MEFs                                                            #208 – MEFs  Gelatine                                         #208 - DIV3  
Figure 3.13 Targeted E14 ESC quality is improved by grown on MEFs but does not affect resulting neuronal culture.   
R26-CreERT2;Mapt-LSL-TrkA clone #36 (A-C) or clone #208 (D-F) ESCs on (A, D) feeders, (B, E) after two passages on gelatine, and (C, F) 
DIV3 neurons. Scale bars: 100 μm. Insets are 200 % magnification. 
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Figure 3.14 Targeted E14 ESC quality is improved by growth on MEFs in combination with 2I+LIF+15% FBS media.  R26-CreERT2;Mapt- 
LSL-TrkA clone #36 (A-C) ESCs grown on feeders before passaging twice on gelatine with A) ES media, B) 2I + LIF + 15% FBS media, or  
C) 2I + LIF media. Scale bars: 100 μm. Insets are 200% magnification. 
 
MEFs  Gelatine (ES media)                                MEFs  Gelatine (2I + LIF + 15 % FBS)            MEFs  Gelatine (2I + LIF)  
A                                                                         B                                                                          C 
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3.7. Summary 
 
This chapter outlined the adaptation of the pMapt-HA-rTrkA and –rTrkB plasmids, 
used by Nikoletopoulou et al. (2010), by the addition of a loxP-flanked STOP cassette 
preceding the HA sequence (Figure 3.1). Analysis by restriction digestion with HindIII 
indicated bacterial clones that had the expected band sizes for insertion of the  
loxP-STOP-loxP cassette (Figure 3.3, and Figure 3.4). The plasmid was then 
completely sequenced by Sanger sequencing, and sections of sequence were compared 
to all known sequences by use of the basic local alignment search tool (BLAST, 
National Institute of Health).  
The generated plasmids were then transfected into Rosa26-CreERT2 mouse ESCs of 
two genetic backgrounds; J1 and E14 (Section 3.3), to generate novel mouse ESC lines 
(Table 3.1and Table 3.3). Application of tamoxifen to the E14 R26-CreERT2;Mapt-
LSL-TrkA and –TrkB ESCs resulted in complete excision of the loxP-flanked STOP 
cassette (Figure 3.7), which corresponded with expression of HA-tagged TrkA and 
TrkB protein (Figure 3.8). Furthermore, HA-tagged protein could not be detected in 
untreated cells, indicating that there was no leaky expression of the Trk receptors. This 
supports that cells not treated with tamoxifen could act as a valid control line. While 
these cultures had numerous non-neuronal cells (Figure 3.8), these would not 
contribute to the detection of HA-tagged protein due to HA-TrkA and HA-TrkB being 
expressed under the neuronal-specific Mapt promoter. It subsequently became evident 
that R26-CreERT2;Mapt-LSL-TrkA and -TrkB ESCs could not be differentiated into 
homogenous neuronal cultures using the well-established differentiation protocol 
described by Bibel et al. (2004) (Figure 3.9). A few days after dissociation of CAs 
there were many non-neuronal cells which continued to proliferate (Figure 3.9). As 
neurons are post-mitotic, non-neuronal cells quickly overtake the cultures and 
outcompete neurons for nutrients and space. As a result, in these cultures neurons 
could only be cultured for a maximum of eight days before dying. As the endogenous 
levels of Trk receptors increase slowly during the course of this neuronal 
differentiation protocol, it therefore turned out not to be possible to rigorously compare 
the levels of endogenous versus exogenous Trk in these ESC-derived neurons (see 
Bibel et al., 2004 & 2007, and Nikoletopoulou et al., 2010).  
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It was observed that the difficulty in generating homogenous neuronal cultures was 
not a shortcoming of the differentiation procedure itself, as pure cultures could be 
derived from both wild type, and alternative genetically-modified ESC lines of both 
J1 and E14 genetic backgrounds (Figure 3.9). Furthermore, the dissimilarities in 
differentiation potential between wild type, and R26-CreERT2;Mapt-LSL-TrkA and -
TrkB ESCs were distinctly visible by D4 of the cellular aggregation process. Instead 
of forming large, light, aggregates with clearly defined boundaries like their wild type 
counterparts, the R26-CreERT2;Mapt-LSL-TrkA and -TrkB aggregates had a bubbly 
border, and were smaller, and more dense (Figure 3.10). Additionally, there were more 
dying cells observed during the aggregation process, and a lower yield of neural 
progenitor cells at D8. These observations indicate that the difficulty in differentiation 
started during aggregation, as there were no obvious issues with proliferation. Efforts 
to improve the quality of ESC cultures using alternative media (Figure 3.12) or 
culturing ESCs on MEFs (Figure 3.13Figure 3.14) also did not improve the 
differentiation capacity. Therefore these genetically-modified cells were not further 
used in this thesis. Possible reasons for the difficulty in differentiating these ESCs are 
discussed further in section 7.2. 
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4. Generation of in vivo TrkA- and TrkB-overexpression 
models 
4.1. Introduction 
 
To elucidate the role of TrkA overexpression in vivo, it was of interest to determine 
whether the ubiquitous expression of TrkA would affect mouse development. As TrkA 
overexpression under the control of the Mapt promoter has been previously reported 
to induce widespread apoptosis across the nervous system and the premature death of  
embryos (Nikoletopoulou et al., 2010), a different strategy was used. This chapter 
describes the generation of a mouse model where HA-tagged TrkA is expressed under 
the ubiquitous Rosa26 promoter (Soriano, 1999), allowing the effects of TrkA 
expression to be determined in all cell types throughout development. The construct 
contains an IRES-EGFP sequence to allow visualisation of TrkA expression. 
Constitutive expression of TrkA was prevented by the inclusion of a loxP-flanked 
STOP cassette in these mice, and thus allowing the maintenance of a stable colony. 
Given the reported differences between the phenotype of mice overexpressing TrkA 
and TrkB, a similar mouse line was generated allowing the conditional expression of 
TrkB.  
 
  
 
Figure 4.1 Comparison of the current in vivo strategy with previous work.  A) In Nikoletopoulou et al. (2010) HA-tagged (purple) TrkA and 
TrkB (green) are expressed under the Mapt locus constitutively. The BM40 signal sequence is indicated in orange. The constructs also contain an 
IRES-EGFP sequence (black) to allow visualisation of Trk-expressing cells. B) The current strategy has a loxP-flanked STOP cassette preceding 
the Trk receptor sequences, so that they cannot be expressed under physiological conditions, thus allowing the stable breeding and maintenance of 
these mouse lines. In order to drive expression of HA-TrkA and HA-TrkB, these mice can be crossed with various Cre driver lines to allow excision 
of the STOP cassette. The Cre driver lines can be selected according to experimental requirements in terms of location and timing of desired TrkA, 
or TrkB expression.  
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4.2. Generation of TrkA and TrkB ESCs 
 
Rosa26-loxP-STOP-loxP-HA-rTrkA-IRES-EGFP (herein referred to as R26-LSL-
TrkA) ESCs were generated previously by Dr. Xinsheng Nan. To generate the 
corresponding TrkB ESCs, wild type E14 ESCs were first targeted with pRosa26-loxP-
STOP-loxP-HA-rTrkB-IRES-EGFP constructs (as outlined in section 2.2.5) to 
generate the corresponding R26-LSL-TrkB ESCs.  Genotyping confirmed correct 
targeting (outlined in section 2.2.6), and clones were karyotyped to ensure they had 
the correct number of chromosomes (Table 4.1). Clones with >70% karyotype were 
selected (section 2.2.7) and tested for mycoplasma (section 2.1.1).  
 
Table 4.1 Rosa26-loxP-STOP-loxP-TrkB-IRES-GFP Clones 
 
 
4.3. Generation of TrkA- and TrkB-overexpressing mice 
 
Both R26-LSL-TrkA and –TrkB mice were generated by injections of genetically 
modified mouse ESCs into blastocysts (as outlined in section 2.5). R26-LSL-TrkA 
mice were generated through a collaboration with Cambridge University, and the 
corresponding –TrkB mice were generated by the JBIOS unit at Cardiff University. 
Born pups were observed for chimerism (Figure 4.2). Chimeric coats were generated 
by the fact that E14 ESCs were derived from the mouse strain 129/Ola, which have an 
agouti or chinchilla coat colour (Hooper et al., 1987), while the injected blastocysts 
were derived from C57BL/6J mice. Therefore chimeric offspring from these injections 
indicate that the injected, mutant ESCs are contributing to some of the cells that make 
up the mouse. These chimeras were bred with C57BL/6J mice, and had germline 
ESCs Line Clone Karyotype (%) 
E14 Rosa26-loxP-STOP-loxP-TrkB-IRES-EGFP B50 79 
E14 Rosa26-loxP-STOP-loxP-TrkB-IRES-EGFP B13 80 
E14 Rosa26-loxP-STOP-loxP-TrkB-IRES-EGFP B44 73 
E14 Rosa26-loxP-STOP-loxP-TrkB-IRES-EGFP B46 83 
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transmission of the R26-LSL-TrkA and -TrkB gene, which was confirmed by 
genotyping PCR. These mice were backcrossed with C57BL/6J for a minimum of four 
generations. Backcrossing reduces the chances of pups inheriting off-target genetic 
mutations that may have occurred during targeting of the original ESCs. 
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1 
2 
3 
4 
Figure 4.2 Chimeric pups.  Representative image of 
chimeric offspring from R26-LSL-TrkB blastocyst 
injections. A) Numbers 1-4 indicate the different mouse 
pups. The coat colour of mice 2-4 is solid black, indicating 
that they are not chimeras. The patchy coat colour 
(indicated by red arrow) of mouse 1 indicates that it is a 
chimera; made up of both R26-LSL-TrkB ESCs (Agouti), 
and wild type cells from the injected blastocyst (Black). 
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4.4. Breeding and maintenance of R26-LSL-TrkA and –TrkB mice 
 
R26-LSL-TrkA and –TrkB mice did not demonstrate any obvious phenotype, were 
fertile, and gave birth to litters of a reasonable size (Table 4.2). Furthermore these 
mice seemed to have normal mothering ability, and the offspring were viable based 
on the observation that there was no abnormal loss of pups prior to weaning (Table 
4.2). R26-LSL-TrkA had a normal lifespan of >1 year in animal housing. Due to the 
late generation of R26-LSL-TrkB mice, it has only been possible to observe 
homozygotes up to 8 months of age. However at the time of writing there were no 
observable phenotypes or effect on survival. It is important to note that the litter size 
reported in Table 4.2 for C57BL/J wild types is lower than normally expected (around 
eight pups per litter). This may be a reflection of a heavy breeding regimen.  
 
Table 4.2 Breeding of wild type, and R26-LSL-TrkA and –TrkB mice 
 C57BL/6J R26-LSL-TrkA 
(het x het) 
R26-LSL-TrkB 
(het x het) 
Average Litter Size at P0 (N) 5.4 (5) 7.4 (9) 6.1 (7) 
Average Litter Size at Weaning 
(N) 
5.2 (5) 6.9 (9) 5.6 (7) 
Weaning Age  P21-P28 P21-P28 P21-P28 
  N = number of litters. 
 
4.5. Cre-mediated recombination using a ubiquitous Cre driver 
 
CMV-Cre (C57BL/6J background) (Schwenk et al., 1995) animals were bred with  
R26-LSL-TrkA and -TrkB to allow excision of the  STOP cassette. In CMV-Cre mice, 
Cre expression, driven by the human cytomegalovirus (CMV) promoter, is randomly 
inserted into the X chromosome (Schwenk et al., 1995). As males (XY) only inherit 
their single X chromosome from their mother, crosses were used where R26-LSL-TrkA 
or -TrkB homozygous males were crossed with CMV-Cre heterozygous females. 
Using this breeding scheme both male and female offspring could inherit CMV-Cre 
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(Figure 4.3), allowing analysis of any gender based discrepancies in the results. Using 
this breeding scheme it is also important to note that all animals would inherit the R26-
LSL-TrkA or -TrkB gene from the homozygous father, allowing relevant littermate 
controls to be analysed where CMV-Cre was not inherited (Figure 4.3). 
  
 
 
                                   Figure 4.3 Breeding scheme and expected offspring 
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4.6. Efficiency of Cre-mediated recombination 
 
Deletion of the STOP cassette in offspring from R26-LSL-TrkA and -TrkB 
homozygous male and CMV-Cre heterozygous female crosses was determined by 
genotyping PCR of tails from culled litters (or ear notches in >P14 pups) (Figure 4.4A 
and B). The PCR for the R26-LSL-TrkA and -TrkB genes produced a 2.8 and 2.7 kb 
product (denoted floxed-STOP band), whilst deletion of the 1.5 kb STOP cassette 
produced a 1.4 and 1.3 kb product (denoted Δ band).  However in some cases, where 
offspring inherited both the CMV-Cre and R26-LSL-TrkA or -TrkB genes, no deletion 
could be observed as revealed by the lack of a detectable Δ band (Figure 4.4A and B). 
Additionally, some mice exhibited partial recombination indicating that not all cells 
had excision of the STOP cassette characterised as indicated by the presence of both 
the floxed-STOP, and Δ bands. This inefficiency in deletion was observed in both 
male and female offspring (Figure 4.4A, and B). Offspring were categorised into three 
groups (Table 4.3); <95% deletion (determined by the presence of the floxed-STOP, 
Δ bands, and Cre), >95% deletion (determined by the complete absence of a floxed-
STOP band, and only visualisation of the Δ band, along with Cre), or age, sex-matched 
littermate controls (only visualisation of the floxed-STOP band, no Cre). To reduce 
variability in the data, only offspring with complete (>95%) excision of the STOP 
cassette (herein referred to as TrkA- or TrkB-overexpressing) were used for analysis, 
and those with <95% deletion were not included. 
 
Table 4.3 Grouping of experimental/control offspring based on PCR  
 
  Presence(+)/Absence(-) of PCR Band  
  Floxed-STOP  Δ  Cre  
N
a
m
e
 
TrkA- or TrkB- overexpressors - + + 
Controls (age, and sex-matched) + - - 
<95% Deletion (not analysed) + + + 
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Figure 4.4 Examples of genotyping PCR bands. Examples of genotyping PCR for 
offspring of A) R26-LSL-TrkA and B) R26-LSL-TrkB homozygous males crossed with 
CMV-Cre heterozygous females. The floxed-STOP band around 2.8 and 2.7 kb, 
represents the intact R26-LSL-TrkA or –TrkB gene. Δ indicates the resulting 1.4 and 1.3 
kb band that appears when the 1.5 kb floxed-STOP sequence has been excised in –TrkA 
and –TrkB embryos. The expected 381 bp band indicates whether CMV-Cre has been 
inherited. The control band around 275 bp indicates an internal control for Rosa26 to 
indicate that the PCR reaction had worked. #1-7 indicates different samples. Red 
triangles indicate mice that inherited Cre and R26-LSL-TrkA or TrkB with >95% 
excision. Black triangles indicate animals that inherited Cre and R26-LSL-TrkA or TrkB 
and only a percentage of cells had complete excision. Blue triangles indicate embryos 
that inherited both genes and had no excision of the loxP-flanked STOP cassette. 
Orange squares indicate R26-LSL-TrkA and –TrkB mice that did not inherit Cre 
(referred to as controls). Controls were sex-matched to experimental animals. 
TrkB 
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B 
 
 
 
TrkB-litter 
TrkA-litter 
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4.7. Detection of TrkA and TrkB protein 
 
The result of the excision of the STOP cassette observed via genotyping PCR was also 
examined at the protein level. To this end hind limb protein extracts were separated 
by SDS gel electrophoresis and examined after membrane transfer using antibodies to 
the HA tag. Tagged TrkA or TrkB could only be detected in the limbs of TrkA- (Figure 
4.5B) or TrkB-overexpressors (Figure 4.6B), and not in controls animals not 
expressing Cre (Figure 4.5B, and Figure 4.6B). Using the pan-Trk antibody that 
recognises a conserved sequence in the carboxyterminal of TrkA, TrkB and TrkC, 
there was a massive increase in the levels of Trk-immunoreactive material in Trk-
overexpressing embryos compared with lysates of control animals (Figure 4.5A, 
Figure 4.6A). This is not surprising given the very low levels of Trk expression in the 
developing limbs (Hallbook et al., 1995; Klein, Martin-Zanca, et al., 1990), possibly 
reflecting the developing limb innervation. 
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Figure 4.5 Western blot analysis of E18.5 TrkA- litters. Representative 
western blots of E18.5 limbs from TrkA-overexpressing embryos (#5-#7) 
compared to controls (#1-#4) using an A) αpan-Trk antibody that detects TrkA-
C. Expected band size for pan-Trk – 110-140 kDa. Numbers #1-7 indicates 
different embryos from different litters. B) HA-tagged exogenous TrkA in 
limbs of E11.5 and E15.5 litters. Expected HA band size – 110-140 kDa. 
αGAPDH is used as a loading control ~38 kDa. Size of bands is indicated by 
the kDa ladder on the right hand side. 
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Figure 4.6 Western blot analysis of E18.5 TrkB- litters. Western blot analysis of 
E18.5 limbs from TrkB-overexpressing embryos (#5-#9) compared to controls (#1-
#4) using an A) α pan-Trk antibody that detects TrkA-C (expected band size –  
110-140 kDa), and B) αHA antibody that detects only the HA-tagged exogenous TrkB 
(expected band size – 110-140kDa). αGAPDH is used as a loading control (~38 kDa). 
Numbers #1-9 indicates different embryos from different litters. Size of bands is 
indicated by the kDa ladder on the right hand side.  
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4.8. Detection of GFP early in embryonic development 
 
It is well-established that Rosa26 is expressed in all cell types (Friedrich and Soriano, 
1991; Zambrowicz et al., 1997), and that CMV-Cre is active from the earliest stages 
of development and in embryonic stem cells (Schwenk et al., 1995). To confirm that 
TrkA/TrkB were expressed at early developmental stages, expression of IRES-EGFP 
at E6.5 was analysed (Figure 4.7B and Figure 4.7C) in embryos with >95% deletion 
of the STOP cassette, as determined by genotyping PCR (Figure 4.7A).  
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Figure 4.7 STOP cassette excision in E6.5 Embryos. A) Genotyping PCR for E6.5 
TrkA (#1-2), and TrkB (#3-7) litters. The floxed-STOP band around 2.7-2.8 kb 
represents the intact R26-LSL-TrkA or –TrkB sequence. Δ indicates the the resulting 
1.3-1.4 kb band that appears when the 1.5 kb loxP-STOP-loxP sequence has been 
excised. #1-7 indicates different samples. Red triangles indicate embryos with >95% 
excision. Black triangles indicate offspring where only a percentage of cells had 
complete excision. Orange squares indicate R26-LSL-TrkA and –TrkB controls.  
B,C) Representative images of GFP flourescence across E6.5 embryos; B) embryo #3, 
and C) embryo #1. Scale bars: 50 μm.  
A 
B                             #3       C                             #1 
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4.9. Summary 
 
This chapter outlined the generation and characterisation of novel in vivo mouse lines 
conditionally expressing TrkA and TrkB  under the control of the ubiquitous Rosa26 
promoter (Mao et al., 2001; Soriano, 1999; Zambrowicz et al., 1997) (Figure 4.1). 
STOP cassette excision in TrkA- and TrkB-overexpressing embryos was evident as 
early as E6.5 (Figure 4.7). Exploitation of the IRES-GFP sequence in the transgene, 
demonstrated that STOP cassette excision at E6.5 could be associated with increased 
EGFP levels across the entire embryo compared to controls (Figure 4.7). The 
widespread, regular pattern of EGFP fluorescence across the entire E6.5 TrkA- and 
TrkB-overexpressing embryos supports the idea that expression of TrkA and TrkB 
under the Rosa26 promoter is ubiquitous, and occurs during early developmental 
stages i.e. shortly after blastocyst implantation. As constitutive TrkA expression in 
neurons has been reported to result in widespread loss of the nervous system, the 
ability to generate a line constitutively expressing TrkA may not be feasible. Preceding 
the TrkA or TrkB sequences with a STOP cassette prevented constitutive expression 
of TrkA or TrkB, allowing maintenance and breeding of a stable transgenic mouse 
line. No indications were found for expression of the Trk constructs in the absence of 
Cre-mediated recombination (Figure 4.5 and Figure 4.6). The control lines designated 
R26-LSL-TrkA and –TrkB could be maintained as homozygotes without any detectable 
viability of fertility problems.   
Although any Cre-driver line can be used in combination with the lines generated here, 
a CMV-Cre driver line where a CMV-Cre construct was randomly inserted into the  
X chromosome, was utilised. As males (XY) inherit their only X chromosome from 
their mother, the breeding schemes used involved CMV-Cre heterozygous females to 
ensure that both male and female offspring inherited CMV-Cre. In this way, TrkA- or 
TrkB-overexpressing offspring of both genders could be studied, to control for any 
potential gender differences (Figure 4.3). However, for reasons that are unclear, 
complete excision of the STOP cassette was not evident in some embryos that 
inherited both the CMV-Cre and R26-LSL-TrkA or -TrkB genes (Figure 4.4). 
Therefore, only animals with >95% excision of the STOP cassette, as determined by 
genotyping PCR, were included for analysis for the remainder of this thesis. These 
mice were designated TrkA- or TrkB-overexpressing, and age, sex-matched, littermate 
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R26-LSL-TrkA or –TrkB mice were designated as controls. Partial excision of stop 
cassette has observed before by others using the CMV-Cre line (Fan et al., 2015; 
Schwenk et al., 1995). 
The experimental strategy described in the above appeared to work as anticipated as 
the HA tag could only be detected in TrkA- or TrkB-overexpressing embryos (Figure 
4.5B and Figure 4.6B). Furthermore TrkA- or TrkB- protein, as detected by a pan-Trk 
antibody, was also elevated in comparison to controls (Figure 4.5A, and Figure 4.6A), 
supporting the idea that there is overexpression of TrkA and TrkB. Although the 
GAPDH loading controls do indicate a slight variation in the amount of protein loaded 
on the gel, the binary pattern of presence or absence of the protein is striking. The 35 
and 45 kDa fragments detected by western blotting are most likely proteolytic products 
of the Trk receptors (Chao and Bothwell, 2002). 
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5. Analysis of TrkA-overexpressing embryos 
 
5.1. Introduction 
 
As outlined in chapter 4, a mouse model was generated that conditionally expressed 
TrkA. This in vivo model was generated with the aims of exploring the consequences 
of ubiquitous TrkA expression from the earliest stages of development with a focus 
on embryonic lethality, gross morphology and cell death. This was achieved by 
crossing with a CMV-Cre line. As outlined in chapter 4, only mice with >95% deletion, 
referred to as TrkA-overexpressing, were analysed. Controls were designated as sex-
matched, littermate R26-LSL-TrkA mice that did not inherit the CMV-Cre gene.   
 
5.2. Survival of TrkA-overexpressing mice  
 
Given that TrkA has been previously reported to act as a “dependence receptor”, we 
first explored if its ubiquitous expression would result in widespread death of embryos 
during development. Survival of TrkA-overexpressing embryos was recorded at 
various embryonic and postnatal ages through genotyping PCR (Figure 5.1). Amongst 
ten litters analysed postnatally, only one TrkA-overexpressing pup survived until P14. 
Litters were observed from birth twice daily, and no remains of pups were found that 
could be genotyped, indicating that TrkA-overexpressing pups must have been 
cannibalised within a few hours or days of birth. A Kruskal-Wallis test indicated there 
was a statistically significant difference in the percentage of surviving TrkA-
overexpressing embryos across age (χ2(5) = 12.677, p = 0.027). Dunn’s pairwise tests 
were carried out for the groups (adjusted using Bonferroni correction), and found a 
significant difference between the percentage of TrkA-overexpressing pups at P14 
compared to all other ages (Figure 5.1). The one TrkA-overexpressing pup that did 
survive postnatally was much smaller than their littermates, and had to be culled at 
P15 due to being small and sick.   
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Figure 5.1 Genotype of TrkA-litters during development.  The percentage of 
surviving CMV-Cre;R26-LSL-TrkA offspring with >95% deletion (purple, termed 
TrkA-overexpressors), CMV-Cre;R26-LSL-TrkA mice with <95% deletion (grey, 
termed partial TrkA-expressors), and R26-LSL-TrkA (green, termed controls) animals 
per litter during different developmental stages.  The percentage of TrkA-
overexpressing mice per litter is stable during embryonic development, but dropped 
dramatically between P0-P14 (* - p <0.05, Kruskal-Wallis test with Dunn’s pairwise 
comparisons). N = number of litters at each age.  
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5.3. Morphological analysis  
  
TrkA-overexpressors were examined for the presence of morphological deficits with 
the expectation that TrkA-overexpressing animals may show increased cell death 
across all cell types, and may therefore be demonstrably smaller than littermate 
controls. However no gross morphological differences between TrkA-overexpressors 
and controls were observed across development (Figure 5.2). Measurements of body 
size and weight were recorded across E11.5-P0, and a two-way ANOVA conducted 
examining the effect of age and genotype on body size of the TrkA-litters (Figure 
5.3A).  A statistically significant interaction between the effects of genotype and age 
(F(1,40) = 4.904, p = 0.033) was detected. Examining this interaction using 
Bonferroni pairwise comparisons revealed a slight, but significant reduction in the 
body area of TrkA-overexpressors (M = 174.73 mm2, SD ± 11.74) and their sex-
matched littermates (M = 188.54 mm2, SD ± 11.40) at E18.5 (p = 0.007, Figure 5.3A). 
However there was no significant difference between TrkA-overexpressing embryos  
(M = 49.23 mm2, SD ± 5.98) and their littermates (M = 49.88 mm2, SD ± 6.54) at 
E13.5 (p = 0.885, Figure 5.3A). As expected during development, there was a 
significant increase in body area between E13.5 and E18.5 embryos regardless of 
genotype (p < 0.001, Figure 5.3A). However the reduction in body area at E18.5 was 
not matched by any significant difference in the weight of P0 TrkA-overexpressors  
(M = 1.55 g, SD ± 0.11), and their sex-matched, littermate controls (M = 1.63 g,  
SD ± 0.12) (t(18) = 1.446, p = 0.165; Figure 5.3B). The weight of P0 offspring was 
obtained from six litters, with an average litter size of 4.7  
(SD ± 1.2) pups. 
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Figure 5.2 Morphology of TrkA-overexpressing embryos at 
E13.5 and E18.5. Representative images of TrkA-overexpressing 
male embryos at E13.5 and E18.5, compared to littermate controls. 
Scale bars are 1.5 mm for E13.5 embryos, and 3 mm for E18.5 
embryos.  
 
Control TrkA-overexpressing 
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Figure 5.3 Size and weight of TrkA-overexpressing embryos.  A) The 
area of embryos at E13.5 and E18.5 is similar between TrkA-
overexpressing embryos (purple) and their littermates (green). NS – not 
significant, ** - p <0.01, *** - p < 0.001 (two-way ANOVA with post-hoc 
Bonferroni pairwise comparisons). B) The weight of pups at P0 is similar 
between TrkA-overexpressing embryos and their littermates. Data from six 
litters, average litter size = 4.7 (SD ± 1.2). NS – not significant (independent 
t-test). Error Bars - standard deviation. N = number of embryos analysed 
per group.  
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To further analyse the morphology of TrkA-overexpressing litters, haematoxylin and 
eosin staining was performed on transverse sections of offspring from E11.5-P0. It 
was observed that the general morphology of the eye, spinal cord, cerebellum and nose 
appeared to be normal in terms of size, and structure at E18.5 between genotypes 
(Figure 5.4). To quantify if there were any changes to the number of CNS neurons, 
cortices were dissected from litters at E18.5, and dissociated. The total number of 
neurons was counted, and there appeared to be no significant difference in the number 
of cortical neurons between TrkA-overexpressors (M = 2.34 x106 neurons,  
SD ± 0.83) and the sex-matched littermate controls (M = 2.25 x106 neurons,  
SD ± 0.81) (t(5) = -0.154, p = 0.884; Figure 5.5). This altogether indicates that whilst 
TrkA-overexpressing pups die soon after birth, the overexpression of TrkA across all 
cell types throughout development did not result in generalised cell death. 
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Figure 5.4 The eye, hippocampus, spinal cord and nose in E18.5 of control versus 
TrkA-overexpressing embryos.  Representative images of the eye (A,B), 
hippocampus (C,D), spinal cord (E,F), and nose (G,H) in E18.5 TrkA-overexpressing 
embryos (B,D,F,H) compared to littermate controls (A,C,E,F). Scale bars: 300 μm, 
except B,C where scale bars are 200 μm.   
TrkA-overexpressing Control 
A                                    B 
 
 
 
 
 
C                                    D 
 
 
 
 
 
E                                     F 
 
 
 
 
 
 
G                                    H 
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Figure 5.5 Number of cortical neurons in E18.5 TrkA-litters.  Number of neurons 
in dissociated cortices of TrkA-overexpressing mice (purple) compared to controls 
(green). N = number of embryos analysed from two litters. Error bars - standard 
deviation. NS – not significant (independent t-test).  
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5.4. iDISCO analysis 
 
The observation that TrkA-overexpressors died in the first few days postnatally, but 
did not have any obvious morphological phenotype, indicated that TrkA over-
expression may cause the loss of specific populations of cells that are critical for 
postnatal survival. As this phenotype (as outlined in the introduction) has been 
previously reported in mice lacking both Ngf alleles, sympathetic and sensory ganglia 
were examined in detail. The plausibility of this hypothesis was first examined in 
whole mounts of TrkA-litter  heads using 3D imaging of immunolabelled solvent-
cleared whole embryos (short iDISCO(Renier et al., 2017)) using antibodies to TrkA. 
This antibody was first validated with E12 wild-type embryos (Figure 5.6). As 
expected, this antibody specifically marked known TrkA-expressing structures such 
as the trigeminal, dorsal root, and superior cervical ganglia (Figure 5.6A). Using this 
method, the differences between the earlier, and later formed dorsal root ganglia 
(DRG) could also be observed (Figure 5.6B). iDISCO was therefore next used to 
explore a possible loss of ganglia and/or nerves using E15.5 TrkA-overexpressing 
embryos compared to controls.  
iDISCO using a TrkA antibody in E15.5 TrkA-overexpressing embryo heads 
demonstrated that there was a consistent loss of the trigeminal, superior cervical and 
dorsal root ganglia in TrkA-overexpressing embryos compared to their littermates 
(Figure 5.7). As expected, there was also widespread TrkA staining across the head of 
TrkA-overexpressing mice not limited to neuronal structures. This staining pattern 
was not observed in littermate controls, where TrkA staining was restricted to specific 
neuronal structures.  
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Figure 5.6 Validation of TrkA iDISCO staining. Representative images of iDISCO 
staining using a TrkA antibody in E12 wild type embryos. A) The whole embryo 
(indicated by dotted white boundary) can be visualised using iDISCO, without the 
need for sectioning. TrkA antibody seems to be specific, and compatible with this 
method, as only known TrkA-expressing cells can be visualised. These include the 
trigeminal ganglia (white arrow), the superior cervical ganglia (yellow arrow), and the 
dorsal root ganglia. The expected developmental gradient can be observed (more 
mature ganglia: purple arrow, younger ganglia blue arrow). Scale bar: 500 μm. The 
grey box indicates the area taken for higher magnification images in B) magnified 
images of the dorsal root ganglia demonstrate characteristic TrkA staining patterns. 
Scale bar: 100 μm.  
 
A                                                              B 
  
        
Figure 5.7 TrkA iDISCO staining of TrkA-overexpressor versus littermate control. Representative images of iDISCO staining 
using a TrkA antibody in E15.5 A) control versus B) TrkA-overexpressing mice. Note the general TrkA staining outside the 
nervous system of TrkA-overexpressing embryos, while in the littermate control there is specific neuronal staining, including the 
indication of ganglia e.g. the trigeminal ganglia (dotted white line in A, missing ganglia indicated by white arrow in B). Ectopic 
TrkA staining can also be identified in areas such as the whisker pad (red dotted line). Scale bars: 500 μm.  
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5.5. Volume of sensory and sympathetic ganglia 
 
Given the iDISCO observations that sensory and sympathetic ganglia in the head may 
be affected in TrkA-overexpressing embryos at E15.5, haematoxylin and eosin 
stainings were performed on transverse sections of TrkA-litters at E11.5, E15.5, E18.5 
and P0. Ganglia that appeared to be lost via iDISCO were selected for analysis, 
including the superior cervical (sympathetic; SCG), dorsal root (sensory; DRG, C1) 
and trigeminal ganglia (sensory; TG). As these ganglia endogenously express TrkA, 
the analysis also included ganglia expressing little (sensory; nodose-petrosal ganglia, 
NPG, (Wetmore and Olson, 1995)) or no (sensory, vestibular ganglia, VG, 
(Schecterson and Bothwell, 1994)) endogenous TrkA. E11.5-P0 time points were 
chosen as they correspond with the periods of formation, and naturally occurring cell 
death across these ganglia ((Coughlin et al., 1977; White et al., 1998); for more detail 
see section 7.4).  
Two-way ANOVA revealed that there was a significant interaction of age and 
genotype in ganglia that endogenously express TrkA, such as the SCG  
(F(2,27) = 13.817, p <0.001), DRG (F(2,23) = 4.669, p = 0.02) and TG  
(F(2,24) = 34.761, p <0.001, Table 5.1). Bonferroni pairwise comparisons revealed 
that the volume of the SCG in TrkA-overexpressing mice was not significantly 
different at E15.5 compared to littermate controls (p = 0.546), but at E18.5 and P0 the 
volume of the SCG was significantly reduced compared to littermates (p<0.001, Table 
5.1, Figure 5.8A, and Figure 5.8B). Comparisons also indicated that the DRG volume 
was not significantly different between TrkA-overexpressors and sex-matched 
littermates at early stages such as E11.5 (p = 0.972) and E15.5 (p = 0.930, Table 5.1), 
but were significantly reduced compared to littermates by E18.5 (p = 0.001, Figure 
5.8C, and Figure 5.8D). Similarly, there was no significant difference between 
genotypes in the trigeminal ganglia at E11.5 (p = .618, Table 5.1), while there was a 
significant reduction in the trigeminal ganglia volume in TrkA-overexpressing 
embryos compared to littermates at E15.5 and E18.5 (p<0.001, Table 5.1, Figure 5.8E, 
Figure 5.8F).  
In the NPG, where a fraction of sensory neurons have been reported to endogenously 
express TrkA (Wetmore and Olson, 1995), there was no significant interaction of age 
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and genotype (F(2,30) = 2.323, p = 0.115), however there was a main effect of 
genotype (F(1,30) = 5.517, p = 0.026), and pairwise comparisons revealed that at 
E18.5 there was a slight, but significant reduction in the NPG volume (p = 0.021, Table 
5.1) in TrkA-overexpressors (Figure 5.9A) compared to the sex-matched littermates 
(Figure 5.9B). However at E15.5 (p = 0.712), and P0 (p = 0.058) there was no 
significant difference between the genotypes. Meanwhile in the vestibular ganglia 
which has no endogenous TrkA expression (Schecterson and Bothwell, 1994), one 
way ANOVA analysis of the volume of the vestibular ganglia at E18.5 indicated that 
there was no significant difference between TrkA-overexpressing embryos (Figure 
5.9C) and littermate controls (F(1,8) = 1.758, p = 0.222, Figure 5.9D, Table 5.1).  
  
  Chapter 5 
Page | 150  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 The superior cervical, dorsal root, and trigeminal 
ganglia in E18.5 TrkA litters.  Representative images of the 
superior cervical (A,B), C1 dorsal root (C,D), and trigeminal (E,F) 
ganglia in E18.5 TrkA-overexpressing embryos (B,D,F) which 
appear to be reduced in size compared to their sex-macthed, 
littermate controls (A,C,E). Ganglia are indicated by black, dotted 
lines. Scale bars A-D: 100 μm, scale bars E-F: 200 μm.  
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Figure 5.9 The nodose-petrosal and vestibular ganglia in E18.5 
TrkA-litters.  Representative images of the nodose-petrosal (A,B), and 
vestibular (C,D) ganglia in E18.5 TrkA-overexpressing embryos (B,D) 
appear to be similar in size compared to their sex-matched, littermate 
controls (A,C). Ganglia are indicated by black, dotted lines.  
Scale bars: 100 μm.  
A                                                 B 
 
 
 
 
 
 
 
C                                                D 
TrkA-overexpressing Control 
  
 
Table 5.1 Volume of sensory and sympathetic ganglia in TrkA-litters  
  E11.5  E15.5 E18.5 P0 
 Control 
x104 μm3 
(±SD) (N) 
TrkA-over 
expressing 
x104 μm3 
(±SD) (N) 
Remaining 
% vs. 
Control (p) 
Control 
x104 μm3 
(±SD) (N) 
TrkA-over 
expressing 
x104 μm3 
(±SD) (N) 
Remaining 
% vs. 
Control (p) 
Control 
x104 μm3 
(±SD) (N) 
TrkA-over 
expressing 
x104 μm3 
(±SD) (N) 
Remaining 
% vs. 
Control (p) 
Control 
x104 μm3 
(±SD) (N) 
TrkA-over 
expressing 
x104 μm3 
(±SD) (N) 
Remainin
g % vs. 
Control 
(p) 
Sensory Ganglia 
Dorsal 
Root (C1) 
386 
(±107) 
(5) 
340 (±54) 
(4) 
88% NS 1061 
(±350) 
(4) 
504 (±114) 
(7) 
47% NS 5890 
(±5373) 
(4)
  
940  
(±414) 
(5) 
16% ** 
NA 
Trigeminal  4581 
(±697) 
(5) 
3820 
(±2400) 
(3) 
85% NS 11229 
(±2785)
(5) 
3781 
(±1587) 
(8) 
34% *** 24562 
(±937) 
(4)
   
7059 
(±3046)
(5) 
29% ***  
NA 
Vestibular 
NA NA 
2145 
(±205) 
(4) 
1981 
(±184)
(6)
  
92% NS 
NA 
Nodose-
petrosal 
NA 
1080 
(±116)
(5) 
1178 (±287) 
(8) 
109% NS 2314 
(±397) 
(6) 
1691 
(±363)
(7) 
73% * 2578 
(±793) 
(5) 
2004 (634) 
(5) 
77% NS 
Sympathetic Ganglia 
Superior 
Cervical 
NA 
2225 
(±338)
(5) 
2027 (±804) 
(9) 
91% NS 5108 
(±180) 
(4) 
2811 
(±415)
(5) 
55% *** 5023 
(±751) 
(5) 
2536 (±324) 
(5) 
50% *** 
 
Volume counts were determined from haematoxylin and eosin stainings as detailed in section 2.8. N= number of embryos analysed, indicated in superscript 
brackets, from a minimum of three litters per time point. Two of each ganglia were counted per embryo and averaged. NS - not significant, * - p < 0.05,  
** - p < 0.01, *** - p < 0.001 compared to littermate controls (two-way ANOVA with Bonferroni pairwise comparisons, except the vestibular ganglia where 
one-way ANOVA was performed).  
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5.6. Neuronal counts in sensory and sympathetic ganglia 
 
To determine whether the reduction in ganglia volume was due to a loss of neurons, 
or if the reduction could be explained by events preceding the time of naturally 
occurring cell death, counts were performed on these ganglia across E11.5-P0 as 
outlined in section 2.8.4.  
A two-way ANOVA was performed for the number of neurons in the SCG, which 
revealed a significant interaction between genotype and age (F(2,26)= 7.762,  
p = 0.002), of which there was a significant main effect of age (F(2,26) = 5.789,  
p = 0.008) and genotype (F(1,26) = 10.960, p = 0.003). Probing of this interaction with 
Bonferroni pairwise comparisons revealed that at E15.5 there was no significant 
difference in the number of SCG neurons between genotypes (p = 0.218), although 
there was a significant reduction in the number of SCG neurons in E18.5 (p = 0.005) 
and P0 (p = 0.001) TrkA-overexpressors compared to sex-matched littermate controls. 
Pairwise comparisons also indicated that while the number of neurons in the SCG of 
control animals significantly increased between E15.5-E18.5 (p = 0.002), as is 
expected of normal development, there was no further increase in the number of 
neurons in the SCG across age in the TrkA-overexpressing embryos (p = 1.000, Figure 
5.10A).   
In the dorsal root (F(2,23) = 15.081, p <0.001), and trigeminal (F(2,24) = 27.028,  
p <0.001) ganglia there was a significant interaction of age and genotype. Bonferroni 
pairwise comparisons indicated that there was no difference in the number of neurons 
between genotypes in the E11.5 dorsal root (p = 0.243) or trigeminal (p = 0.350), 
ganglia, but in both ganglia by E15.5 and E18.5 this was statistically significant  
(p <0.001) (Figure 5.10C).  
Two-way ANOVA showed there was also a significant interaction between age and 
genotype for the nodose-petrosal ganglia (F(2,30) = 3.983, p = 0.029). Bonferroni 
pairwise comparisons revealed that while the number of neurons in the NPG was not 
significantly different between genotypes at E15.5 (p = 0.195, Figure 5.11B) and 
E18.5 (p = 0.114, Figure 5.11B), there was a significant decrease in the number of 
NPG neurons between TrkA-overexpressing neurons and littermate controls at P0  
(p = 0.023, Figure 5.11B). By contrast, in the vestibular ganglia at E18.5 one-way 
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ANOVA showed there was no significant difference in the number of neurons between 
TrkA-overexpressors and littermates (F(1,8) = 0.557, p = 0.477, Figure 5.11A).   
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  Figure 5.10 Number of neurons in the superior cervical, trigeminal and 
dorsal root ganglia in TrkA-overexpressing embryos.  A) The number of 
neurons in the A) superior cervical, B) trigeminal and C) dorsal root ganglia 
of TrkA-overexpressing embryos (purple) compared to littermate controls 
(green) over development. Neuronal counts were determined on sections 
stained with haematoxylin and eosin. Number of embryos analysed in each 
group are the same as outlined in Table 5.1, from a minimum of three litters 
per age. Two of each ganglia were counted per embryo and averaged. NS - 
not significant, * - p < 0.05, ** - p < 0.01, *** - p < 0.001 compared to 
littermate controls (Two-way ANOVA with Bonferroni pairwise 
comparisons). 
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Figure 5.11 Number of neurons in the nodose-petrosal and vestibular 
ganglia of TrkA-overexpressing embryos over development. A) Number 
of neurons in the vestibular ganglia of TrkA-overexpressing embryos 
(purple) compared to littermate controls (green) at E18.5. NS – not 
significant (one-way ANOVA). B) Number of neurons in the nodose-
petrosal ganglia of TrkA-overexpressing embryos compared to littermate 
controls over development. NS - not significant, * - p < 0.05, ** - p < 0.01, 
*** - p < 0.001 compared to littermate controls (Two way ANOVA with 
Bonferroni pairwise comparisons). Neuronal counts were determined on 
sections stained with haematoxylin and eosin. Number of embryos analysed 
are the same as outlined in Table 5.1, from a minimum of three litters per 
age. Two of each ganglia were counted per embryo and averaged.  
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5.7. Apoptosis in sensory and sympathetic ganglia 
 
To confirm that the reduction in the number of neurons in these ganglia was due to 
apoptosis, immunohistochemistry was performed on E13.5 TrkA-overexpressing 
embryos using antibodies to cleaved (active) caspase-3. Both the trigeminal (Figure 
5.12; F(1,6) = 58.043, p<0.001) and dorsal root ganglia (C1) (Figure 5.13;  
F(1,6) = 25.740, p = 0.002) of TrkA-overexpressing embryos demonstrated a 
significantly increased number of cleaved caspase-3 positive cells, indicating that there 
were higher levels of apoptosis in the sensory and sympathetic ganglia of TrkA-
overexpressing mice compared to their littermates.   
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Figure 5.12 Caspase-3 activation in the trigeminal ganglia of TrkA-
litters at E13.5. Representative images of cleaved caspase-3 staining (red) 
in the trigeminal ganglia of A) control littermates and B) TrkA-
overexpressing embryos. The ganglia are indicated by white dotted lines. 
Scale bars: 100 μm. C) Quantification of cleaved caspase-3 staining. Values 
were normalised to controls. N = number of embryos analysed, from two 
litters. *** - p <0.001 (one-way ANOVA).  
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Figure 5.13 Caspase-3 activation in the dorsal root ganglia of TrkA-
litters at E13.5. Representative images of cleaved caspase-3 staining in C1 
dorsal root ganglia in A) littermate controls, and B) TrkA-overexpressing 
mice at E13.5. The ganglia are indicated by the white dotted lines. Scale 
bars: 50 μm. C) Quantification of cleaved-caspase 3 counts. Values were 
normalised to control. N = number of embryos analysed from two litters.  
** - p <0.01 (one-way ANOVA).  
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5.8. Summary 
 
This chapter outlined the consequences of ubiquitously overexpressing TrkA from the 
earliest stages of mouse development. The most obvious results of this genetic 
manipulation was the early postnatal death of nearly all pups soon after birth (Figure 
5.1). The results also indicated that in spite of the early and ubiquitous expression of 
this receptor, development proceeded normally as TrkA-overexpressing embryos 
appeared to have no gross morphological defects (Figure 5.2), except for a slight, but 
significant reduction in overall body area (Figure 5.3A). This reduction in body area 
came late in development at E18.5, and was not present at E13.5 (Figure 5.3A), 
indicating that the effects of TrkA-overexpression occur late in development. 
Furthermore, the gross morphology across various CNS tissues such as the 
hippocampus, eye, nose and spinal cord in TrkA-overexpressing embryos remained 
remarkably normal during development (Figure 5.4). More specific analyses using the 
iDISCO staining technique revealed a clear and complete loss of structures that 
endogenously express TrkA in the head of E15.5 TrkA-overexpressing embryos, such 
as the trigeminal and superior cervical ganglia (Figure 5.7).  
This analysis also revealed areas of intense TrkA staining in structures that do not 
normally express TrkA, such as the whiskers (Martin-Zanca et al., 1990), yet the 
morphology of these structures appeared normal (Figure 5.7). The notion that TrkA-
overexpression may lead to selective death of neurons endogenously expressing TrkA 
was confirmed by detailed histological examination of the specific ganglia. 
Quantification of the volume and the number of neurons indicated a loss of cranial 
sensory and sympathetic ganglia that endogenously express TrkA. Histological 
analysis of the SCG, of which >95% of neurons are reported to endogenously express 
TrkA (Schecterson and Bothwell, 1994), showed that there was a significant reduction 
in the volume of the SCG by E18.5 (Figure 5.8A, Figure 5.8B, Table 5.1), as a result 
of a reduction in the number of neurons (Figure 5.10A). The notion that TrkA 
overexpression closely follows the pattern of naturally occurring cell death is further 
supported by the observation that gangliogenesis did not seem to be affected. Indeed 
during the period of SCG formation (between E13-E18) (Coughlin and Collins, 1985), 
there was no significant difference between TrkA-overexpressing and control embryos 
in the volume of the SCG at E15.5 (Table 5.1), nor the number of neurons (Figure 
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5.10A), indicating that TrkA-induced cell death may only occur in post mitotic 
neurons. Given the early postnatal death of the most pups, older SCG could not be 
analysed. 
Analysis of the volume and neuronal numbers of other sensory ganglia confirmed that 
ganglia that endogenously express TrkA are affected in TrkA-overexpressing mice 
(Table 5.1). This included the C1 dorsal root (DRG; Figure 5.8B and Figure 5.8C), 
and trigeminal (TG; Figure 5.8D and Figure 5.8E) ganglia, which are a collection of 
mixed TrkA-C-expressing sensory ganglia. While 45% of DRG neurons endogenously 
express TrkA (Wetmore and Olson, 1995), around 75% of neurons express TrkA in 
the TG (Huang et al., 1999). Correspondingly, the DRG and TG had a reduction of 
62% DRG neurons (Figure 5.10C) and 75% TG neurons (Figure 5.10B) at E18.5 in 
TrkA-overexpressing embryos compared to sex-matched littermate controls. These 
figures are similar to those previously reported in Ngf-/- mice, of 70-90% loss of TG 
and DRG neurons (Chen et al., 1997; Crowley et al., 1994; Fagan et al., 1996; Smeyne 
et al., 1994). As in the SCG, the DRG and TG were not significantly different at E11.5 
or E15.5 (Table 5.1, Figure 5.10B, Figure 5.10C) during the period of ganglia 
formation (E12- E14.5 for DRG (White et al., 1998), E9.5-E13.5 for TG (Huang et al., 
1999)) in TrkA-overexpressing embryos compared to their littermates, further 
supporting the idea that apoptosis caused by TrkA overexpression follows the pattern 
of normally occurring neuronal death. This was reflected by a three-fold increase in 
cleaved caspase-3 staining in both the trigeminal (Figure 5.12) and dorsal root (Figure 
5.13) ganglia over and above on-going cell death observed in control embryos.  
Given the lack of phenotype outside of ganglia endogenously expressing TrkA, it was 
of interest to determine whether TrkA overexpression had any effect on ganglia not 
endogenously expressing TrkA in most neurons. A small, but statistically significant 
decrease in the number of NPG neurons could be observed in TrkA-overexpressing 
embryos (Figure 5.11A), possibly corresponding to the small number of TrkA-
expressing, NGF-dependent in these ganglia (Wetmore and Olson, 1995). No such 
decrease could be observed in the vestibular ganglia (Figure 5.11B), which do not 
usually express TrkA (Schecterson and Bothwell, 1994).  
In summary, ubiquitous TrkA overexpression during mouse development does cause 
cell death, and the early postnatal death of the pups, but the death is limited to cell 
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types endogenously expressing TrkA during normal development. This restricted 
phenotype is reminiscent of embryos lacking Ngf (see section 7.4.3). 
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6. Characterisation of TrkB-overexpressing mice 
6.1. Introduction 
 
Chapter 5 detailed how ubiquitous expression of TrkA during development resulted in 
perinatal lethality, and the loss of NGF-dependent neurons. As TrkA and TrkB are 
related receptors, but previous reports have indicated that TrkB may not act as a 
dependence receptor (Nikoletopoulou et al., 2010; Tauszig-Delamasure et al., 2007), 
it was of interest to explore the consequences of also overexpressing TrkB using a 
similar approach (Chapter 4). As with TrkA-overexpressors, only mice with >95% 
deletion of the STOP cassette were selected for analysis. Likewise the embryos 
designated controls were sex-matched, littermates without excision of the stop cassette 
preceding TrkB.  
 
6.2. Survival of TrkB-overexpressing mice 
 
Unlike was the case with TrkA, there was no significant decrease in the percentage of 
TrkB-overexpressing embryos over development as determined by a one-way 
ANOVA (F(4,10) = 0.546, p = 0.706) (Figure 6.1). As only mice with >95% deletion 
were included for analysis the high values for the standard deviation is to be expected 
due to the variability in Cre-excision efficiency. Postnatal TrkB-overexpressing 
animals did not show any obvious phenotypes. Furthermore TrkB-overexpressing 
pups not only survived normally, but were fertile and able to give birth to litters (N = 
2 litters, M = 6.5 pups per litter).  
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Figure 6.1 Genotype of TrkB-litters during development. The percentage of 
surviving CMV-Cre;R26-LSL-TrkB animals with >95% deletion (purple stripes, 
termed TrkB-overexpressors), CMV-Cre;R26-LSL-TrkB mice with <95% deletion 
(grey block, termed partial TrkB-expressors), and R26-LSL-TrkB offspring (green 
stripes, termed controls) per litter at different developmental ages is shown. The 
percentage of TrkB-overexpressing offspring per litter is stable over embryonic and 
postnatal development. N = number of litters analysed. No significant difference 
between percentage of TrkB-overexpressing animals over time (one-way ANOVA).  
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6.3. Morphological analyses  
 
TrkB-overexpressing embryos were indistinguishable from controls (Figure 6.2), and 
a two-way ANOVA performed on body size at both E13.5 and E18.5 (Figure 6.3A) 
did not reveal any significant interaction between age and genotype (F(1, 25) = 1.925,  
p = 0.178). Similarly, there was no significant main effect of genotype  
(F(1,25) = 0.448, p = 0.509), a result confirmed by Bonferroni pairwise comparisons. 
As expected, there was a significant main effect of age (F(1,25) = 2634.785, p <0.001) 
regardless of genotype as embryos obviously grew in size between E13.5 to E18.5.  
An independent t-test also revealed that there was no significant difference in the 
weight of TrkB-overexpressors (M = 1.26 g, SD ± 0.17) and controls  
(M = 1.28 g, SD ± 0.10) at E18.5 (t(11) = 0.373, p = 0.717; Figure 6.3B). The weight 
of E18.5 pups was obtained from two litters, with an average litter size of 7.5  
(SD ± 4.9) pups. In support of the lack of any clear morphological differences, TrkB-
overexpressing mice did not display any obvious phenotype, including in particular 
balance or breathing or feeding deficits (for discussion see section 7.5.4).   
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Figure 6.2 Morphology of TrkB-overexpressing embryos at E13.5 and E18.5.  
Representative images of male TrkB-overexpressing embryos at E13.5 and E18.5, 
compared to controls. Scale bars are 1.5 mm for E13.5 embryos, and 3 mm for E18.5 
embryos.  
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Figure 6.3 Size and weight of TrkB-overexpressing embryos. A) The 
area of embryos at E13.5 and E18.5 is similar between TrkB-overexpressing 
embryos (purple) compared to their littermates (green). NS -  not significant, 
*** - p <0.001 (two-way ANOVA with Bonferroni pairwise comparisons). 
B) The weight of embryos at E18.5 is similar between TrkB-overexpressing 
animals and sex-matched, littermate controls. Data from two litters, average 
litter size = 7.5 (SD ± 4.9).  NS – not significant (independent t-test). Error 
bars - standard deviation. N = number of embryos analysed per group.  
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The TrkB-overexpressing embryos were further analysed by performing haematoxylin 
and eosin stainings on transverse sections of TrkB-overexpressing embryos and sex-
matched, littermate controls between E13.5 and E18.5. The general morphology of a 
number of structures including the nose, eye, spinal cord, and hippocampus appeared 
to be normal in terms of general appearance and size in TrkB-overexpressing embryos. 
Side-by-side comparisons with controls at E18.5 failed to reveal any differences in the 
morphology of most structures (Figure 6.4). To quantify if there were any changes to 
the number of CNS neurons, cortices were dissected from E18.5 litters, dissociated 
and the total number of cells counted. No statistically significant difference was 
observed in the number of cells dissociated from the cerebral cortex between TrkB-
overexpressing pups (M = 3.96 x106, SD ± 0.80) and controls (M = 4.33 x106,  
SD ± 0.41) (t(5) = 0.720, p = 0.504; Figure 6.5). Taken together, these results indicate 
that the overexpression of TrkB across all cell types throughout development did not 
result in any gross morphological phenotypes.  
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Figure 6.4 The eye, hippocampus, spinal cord, and nose structures in 
E18.5 TrkB-overexpressing embryos. Representative images of the eye 
(A,B), hippocampus (C,D), spinal cord (E,F), and nose (G,H) in E18.5 TrkB-
overexpressors (B,D,F,H) compared to sex-matched, littermate controls 
(A,C,E,F). Scale bars: 300 μm, except B,C where scale bars are 200 μm.  
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Figure 6.5 Number of cortical neurons in E18.5 TrkB-litters.  Number 
of neurons in dissociated cortices of TrkB-overexpressing mice (purple) 
compared to controls (green). N = number of embryos analysed from one 
litter. Error bars - standard deviation. NS – not significant (independent t-
test). 
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6.4. Volume of sensory and sympathetic ganglia 
 
The superior cervical (SCG), dorsal root (DRG), nodose-petrosal (NPG), trigeminal 
(TG), and vestibular (VG) ganglia of TrkB-overexpressing embryos and control 
littermates were analysed at E13.5 and E18.5, the same developmental period as with 
TrkA-overexpressing embryos.  
Quantification of ganglia volume revealed that in the SCG there was no significant 
difference in ganglia volume between the two genotypes at E18.5 (F(1,7) = 1.849,  
p = 0.216; Figure 6.6A and Figure 6.6B, Table 6.1). Two way ANOVA analysis 
indicated that there was a significant interaction of genotype and age in the volume of 
the NPG (F(1,11) = 57.272, p  <0.001) Bonferroni pairwise comparisons indicated that 
there was a significant reduction in the volume of the NPG between TrkB-
overexpressing (Figure 6.7A) and controls (Figure 6.7B) both at E13.5 (p = 0.031), 
and E18.5 (p <0.001) (Table 6.1). Furthermore, while there was no significant 
interaction between genotype and age in volume of the vestibular ganglia  
(F(1,11) = 1.393, p =0.263), there was a main effect of genotype (F(1,11) = 24.44,  
p <0.001). Bonferroni pairwise comparisons revealed that there was a significant 
decrease in the volume of vestibular ganglia at both E13.5 (p = 0.033), and at E18.5  
(p = 0.001) (Table 6.1) in TrkB-overexpressors (Figure 6.7D) compared to the sex-
matched, littermate controls (Figure 6.7C).  
In the dorsal root ganglia volume there was no significant interaction between 
genotype and age (F(1,11) = 3.472, p = 0.089). However there was a significant main 
effect of genotype (F(1,11) = 7.59, p = 0.019), and Bonferroni pairwise comparisons 
revealed that while the DRG volume was not different between genotypes at E13.5  
(p = 0.576), by E18.5 there was a significant reduction in the DRG volume in TrkB-
overexpressing embryos (Figure 6.6D) compared to controls (p = 0.004, Figure 6.6C, 
Table 6.1). Similarly, there was a significant main effect of both genotype  
(F(1,11) = 31.567, p <0.001) and age (F(1,11) = 262.746, p <0.001) in the trigeminal 
ganglia with a significant interaction between the two factors (F(1,11) = 5.449,  
p = 0.04). Bonferroni pairwise comparisons demonstrated no significant difference 
between TrkB-overexpressing embryos and controls in trigeminal ganglia volume at 
E13.5 (p = 0.057), while there was a significant reduction the trigeminal ganglia 
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volume at E18.5 in TrkB-overexpressors (Figure 6.6F) compared to sex-matched, 
littermate controls (p<0.001, Figure 6.6E, Table 6.1).   
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Figure 6.6 The superior cervical, dorsal root, and trigeminal ganglia in E18.5 
TrkB-overexpressing-embryos. Representative images of the superior cervical 
(A,B), C1 dorsal root (C,D), and trigeminal (E,F) ganglia in E18.5 TrkB-
overexpressing embryos (B, D, F) compared to littermates (A, C, E). Ganglia are 
indicated by black, dotted lines. Scale bars A-D: 100 μm, scale bars E-F: 200 μm.  
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Figure 6.7 The nodose-petrosal and vestibular ganglia in E18.5 TrkB-
overexpressing embryos. Representative images of the nodose-petrosal (A,B), and 
vestibular (C,D) ganglia in E18.5 TrkB-overexpressing embryos (B, D) compared to 
littermates (A, C). Ganglia are indicated by black, dotted lines. Scale bars: 100 μm.
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Table 6.1 Volume of sensory and sympathetic ganglia in TrkB-litters  
  E13.5  E18.5 
 
Control 
x104 μm3  
(±SD) (N) 
TrkB-
overexpressing 
x104 μm3  
(±SD) (N) 
Remaining 
% vs. 
Control (p) 
Control 
x104 μm3  
(±SD) (N) 
TrkB-
overexpressing 
x104 μm3  
(±SD) (N) 
Remaining % 
vs. Control 
(p) 
Sensory Ganglia 
Dorsal 
Root (C1) 
832 
(±36) 
(3) 
610 
(±141) 
(3) 
73% NS 
2458 
(±415) 
(4) 
1311 
(±682) 
(5) 
53% ** 
Trigeminal 
8693 
(±989) 
(3) 
6447 
(±396) 
(3) 
74% NS 
21370 
(±2074) 
(4) 
15933 
(±901)
(5) 
75% ** 
Vestibular 
1187 
(±158) 
(3) 
826 
(±172) 
(3) 
70% NS 
1570 
(±146) 
(4) 
982 
(±219)
(5)
 
63% *** 
Nodose 
943 
(±140) (3) 
666 
(±213) (3) 
71% * 
1626 
(±159) 
(4) 
251 
(±25)
(5) 
15% *** 
Sympathetic Ganglia 
Superior 
Cervical 
NA 
4707 
(±123) 
(4) 
4480 
(±311)
(5) 
95% NS 
 
Volume counts were determined from haematoxylin and eosin stainings as detailed in section 2.8.4. N - numbers of embryos analysed per group from a 
minimum of two litters per age, indicated in superscript brackets. Two of each ganglia were counted per embryo and averaged. NS - not significant,  
* - p < 0.05, ** -p < 0.01, *** - p < 0.001 compared to littermate controls (two-way ANOVA with Bonferroni pairwise comparisons, except superior cervical 
ganglia where a one-way ANOVA was performed).  
P
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6.5. Neuronal counts in sensory and sympathetic ganglia 
  
To determine whether the reduction in ganglia volume was due to a reduction of 
neuronal number, neurons were counted in these ganglia at E13.5 and E18.5 as 
outlined in section 2.8.4.  
Two-way ANOVAs revealed a significant interaction of age and genotype in the NPG 
(F(1,11) = 24.565, p <0.001), VG (F(1,11) = 5.264, p = 0.042), and DRG  
(F(1,11) = 4.967, p =0.048). Bonferroni pairwise comparisons indicated that there was 
no significant difference in the number of neurons between TrkB-overexpressors and 
controls at E13.5 in the NPG (p = 0.115), VG (p = 0.172), and DRG (p = 0.728) 
indicating that ganglia initially formed normally. However by E18.5 TrkB-
overexpressing embryos showed a significant decrease in the number of neurons in 
the NPG (p <0.001, Figure 6.9A), VG (p <0.001, Figure 6.9B), and DRG (p = 0.002, 
Figure 6.8A). While there was no interaction between genotype and age in the 
trigeminal ganglia (F(1,11) = 2.287, p = 0.159), there was also a main effect of 
genotype, regardless of age (F(1,11) = 5.495, p = 0.039). Similar to the NPG, VG and 
DRG, the number of neurons in the TG was not significantly different between TrkB-
overexpressing embryos and controls at E13.5 (p = 0.601), but by E18.5 this difference 
was significant (p = 0.011, Figure 6.8A). Conversely, the number of neurons in the 
SCG at E18.5 was not significantly different between genotypes (F(1,7) = 4.733,  
p = 0.066, Figure 6.8C). 
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Figure 6.8 Number of neurons in the dorsal root, trigeminal and 
superior cervical ganglia in TrkB-overexpressing embryos. Number of 
neurons in E13.5 and E18.5 A) dorsal root ganglia, and B) trigeminal 
ganglia. Number of neurons in the C) superior cervical ganglia at E18.5. 
Error bars – standard deviation. N = number of embryos from a minimum 
of two litters per age. NS – not significant, * - p <0.05, ** - p <0.01 (two-
way ANOVA with Bonferroni pairwise comparisons, other than the SCG 
where a one-way ANOVA was performed).  
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Figure 6.9 Number of neurons in the nodose-petrosal and vestibular 
ganglia of TrkB-litters. Number of neurons in the A) nodose-petrosal and 
B) vestibular ganglia at E13.5 and E18.5. Error bars – standard deviation. 
N = number of embryos analysed per group, from a minimum of two litters 
per age. NS – not significant, *** - p <0.001 (two-way ANOVA with 
Bonferroni pairwise comparisons).  
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6.6. Summary 
 
This chapter described the consequence of ubiquitous TrkB-overexpression 
throughout mouse development. Unlike with TrkA overexpression (Chapter 5), TrkB 
overexpression did not result in any clear, gross morphological phenotypes (Figure 
6.2). Indeed, embryos were normal in terms of body size (Figure 6.3A) and weight 
(Figure 6.3B), and CNS tissues such as the hippocampus, eye and nose appeared 
remarkably normal (Figure 6.4). Furthermore there was no effect of TrkB-
overexpression on pup survival (Figure 6.1); TrkB-overexpressing mice survived into 
adulthood (Figure 6.1), and were also fertile giving birth to viable litters when crossed 
together.  
Gangliogenesis of nodose-petrosal (NPG) and vestibular (VG) ganglia did not seem 
to be affected in TrkB-overexpressors, as there was no significant difference between 
genotypes VG or NPG neuronal counts at E13.5 (Figure 6.9). This time point is during 
the period of ganglia formation of the VG (E13 to E16 (Ernfors et al., 1995)) and the 
NPG (E13.5 to E18 (Forgie et al., 2000; Katz et al., 1990; Piñón et al., 1997)). By 
E18.5, there was a significant reduction in the volume of these ganglia in TrkB-
overexpressing mice compared to controls (Table 6.1). The reduction in ganglia 
volume appears to be due to the significant loss of 92% of NPG and 45% of VG 
neurons at E18.5 (Figure 6.9). In other sensory ganglia expressing all three Trk 
receptors such as the dorsal root and trigeminal ganglia, there was a significant 
reduction in the number of neurons at E18.5 in TrkB-overexpressing mice compared 
to controls. As in the NPG and VG, the volume (Table 6.1) and number of neurons 
(Figure 6.9), were not different between TrkB-overexpressing mice and the controls 
at E13.5, which is during the period of ganglia formation (E12 to E14.5 for DRG, 
E9.5-E13.5 for TG (Huang et al., 1999; White et al., 1998)). This data supports the 
notion that loss of neurons in TrkB-overexpressing mice follows the pattern of 
naturally occurring cell death. In the superior cervical ganglia (SCG) that do not 
endogenously express TrkB there was no significant reduction in the ganglia volume 
(Table 6.1) or in the number of neurons (Figure 6.8) across any age. In summary, 
ubiquitous TrkB-overexpression during mouse development resulted in significant 
reductions in the number of neurons in sensory ganglia. This decrease was particularly 
marked in the NPG, whilst the number of neurons in the SCG remained unchanged. 
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These results indicate that the overexpression of TrkA and TrkB using the same 
strategy leads to very different results not only with regard to the peripheral ganglia 
affected by this genetic manipulation but also in terms of the overall postnatal survival. 
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7. Discussion 
 
7.1. Summary of the main findings 
 
The main objective of this study was to explore the roles of the TrkA receptor from 
the earliest stages of development. Still very little is known about the functions of this 
receptor in the absence of activation by their ligands, beyond a single report that TrkA 
induces cell death in the absence of activation by NGF (Nikoletopoulou et al., 2010). 
A conditional expression strategy was chosen given the previous knowledge that TrkA 
expression may lead to the death of the embryos (Nikoletopoulou et al., 2010). TrkB 
was used as a control given that it is a closely related receptor, and has not been 
reported to cause cell death (Nikoletopoulou et al., 2010; Tauszig-Delamasure et al., 
2007). To undertake this study, a two-pronged approach was developed utilising an  
in vitro neuronal assay to further examine the mechanisms of TrkA dependence 
receptor activity, whilst concurrently generating, and analysing ubiquitous TrkA- and 
TrkB-overexpression in animal models. Unexpectedly, the in vitro models turned out 
not to be practicable within the context of this thesis (Chapter 3). However 
examination of the in vivo models demonstrated that the overexpression of TrkA and 
TrkB under the control of the Rosa26 promoter led to contrasting outcomes: while 
overexpression of TrkA led to early postnatal death, the overexpression of TrkB led 
to viable and fertile animals with no overt phenotypes. This chapter discusses the 
generation and technical aspects of the in vitro and in vivo models, and analyses 
possible reasons for the differences between TrkA- and TrkB- overexpressing mice.  
 
7.2. Overexpression of TrkA- and TrkB- in vitro  
 
Chapter 3 outlined the generation of targeting constructs and various mouse ESCs with 
the aim of generating a model of conditional TrkA and TrkB overexpression in 
neurons under the same Mapt promoter used in the previous study by Nikoletopoulou 
et al. (2010). The Trk sequences were preceded by a loxP-flanked STOP cassette 
which prevented constitutive expression of the receptors until the STOP cassette had 
been excised by Cre-recombinase. Utilising the CreERT2 system, where Cre remains 
inactive until the addition of Tamoxifen, R26-CreERT2;Mapt-LSL-TrkA and –TrkB 
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ESCs were successfully generated. In order to further elucidate the effects of TrkA 
and TrkB, these ESCs were differentiated following a well-established protocol to 
generate cortical-like, glutamatergic neurons (Bibel et al., 2004, 2007). However, 
while wild type mouse ESCs were able to differentiate into homogenous populations 
of neurons, R26-CreERT2;Mapt-LSL-TrkA and TrkB ESCs, even those not treated with 
tamoxifen, were unable to generate sufficiently pure neuronal populations, thus 
preventing meaningful further analyses. Possible reasons for these ESCs not to 
differentiate, and the various parameters tested, are discussed in the following 
sections. 
 
7.2.1. Differentiation protocol 
 
The inability of untreated R26-CreERT2;Mapt-LSL-TrkA and TrkB ESCs to 
differentiate did not appear to be a shortcoming of the differentiation procedure itself, 
as homogenous cultures of neurons could be derived from both wild type, and 
alternative genetically-modified ESC lines of both J1 and E14 genetic backgrounds. 
This also indicates that the issue was not due to manual handling of the ESCs, a notion 
supported by the observation that other lab members attempting the differentiation of 
R26-CreERT2;Mapt-LSL-TrkA and –TrkB ESCs encountered similar problems. The 
ability to generate wild type ESC-derived neurons also indicated that there was no 
issue of culture media components. These were thoroughly checked, by batch number, 
to ensure they were not faulty. Although other differentiation protocols to generate 
glutamatergic, cortical-like neurons from mouse ESCs do exist (Alsanie et al., 2017; 
Gaspard et al., 2009), these do not result in the same level of neuronal culture 
homogeneity as the Bibel et al. (2004) protocol and would not have been suitable as 
alternative differentiation protocols. 
 
7.2.2. ESC quality 
 
The quality of the initial ESC culture is known to affect the quality of neuronal 
differentiation (Kolodziejczyk et al., 2015). Indicators of quality include: the 
proliferation rate of ESCs, their morphology, and the number of spontaneously 
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differentiating cells (Bibel et al., 2007). However the inability to generate homogenous 
neuronal populations with R26-CreERT2;Mapt LSL-TrkA and -TrkB ESCs does not 
seem to be an issue of the ESC quality. Indeed, efforts to maximise the quality of ESC 
cultures, such as adapting the culture media, passaging frequency, split ratios, and 
substrate, did improve the appearance of the ESCs, but it did not result in any improved 
neuronal culture outcome with the R26-CreERT2;Mapt-LSL-TrkA and TrkB ESCs. 
Furthermore, the ESCs routinely tested negative for mycoplasma, and were selected 
on the basis of having the correct karyotype. However it is possible that events such 
as chromosome duplications, deletions or recombination may have occurred in the 
genetically-modified loci that affected the differentiation capacity of the ESCs. This 
seems unlikely as multiple clones of different genetic backgrounds had the same 
differentiation issues, although if these cells are to be used in the future, it may be 
important to test chromosome stability via fluorescence in situ hybridisation 
(Gaztelumendi and Nogués, 2014).  
 
7.2.3. Genetic modification 
 
Individually targeted R26-CreERT2 or Mapt-LSL-TrkA and -TrkB ESCs were able to 
differentiate into neurons. However Mapt-LSL-TrkA and –TrkB ESCs did show a 
reduction in the homogeneity of the resulting neuronal culture, suggesting that the 
effects could have been due to off-targeting effects. In the future this could be tested 
through southern blotting, and perhaps could be resolved by testing different sgRNAs 
when targeting the Mapt locus with CRISPR.  
The observation that neuronal differentiation was mostly affected in ESCs with both 
the R26-CreERT2 and Mapt-LSL-TrkA and -TrkB constructs raised the question as to 
whether the CreERT2 system was leaky, resulting in TrkA and TrkB expression that 
may affect differentiation. However it was demonstrated that expression of TrkA and 
TrkB only occurred when tamoxifen was applied, and expression of either receptor 
could not be detected in untreated cultures. Furthermore, as R26-CreERT2 ESCs were 
able to be differentiate into homogenous populations of neurons, it does not seem that 
there is an interaction of the inactive CreERT2 protein in this differentiation procedure.  
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It is important to note that Mapt or Rosa26 are widely targeted both in vitro and in 
vivo, and in the majority of cases has not been reported to impair neuronal 
development in vivo or in vitro (Friedrich and Soriano, 1991; Garcia et al., 2012; 
Harada et al., 1994; Nikoletopoulou et al., 2010; Tucker et al., 2001; Zambrowicz et 
al., 1997). Mapt encodes a major microtubule-associated protein (tau), and it has been 
shown that the nervous system of tau-deficient mice (Mapt-/-) is essentially normal 
(Harada et al., 1994). This is thought to be due to several other microtubule-associated 
proteins compensating for the absence of tau (Harada et al., 1994). However more 
recent studies have indicated that in the case of haploinsufficiency of tau (as observed 
in Mapt+/- mice) there is no compensatory increase in microtubules such as MAP-1A, 
and that compensation only occurs when tau is completely knocked out (Zheng et al., 
2017). This could potentially explain why the targeting of both Mapt alleles in the 
study by Nikoletopoulou et al. (2010) did not affect neuronal differentiation. 
Conceivably, targeting a single Mapt allele in this thesis may have interfered with the 
differentiation process. Whether the ESCs target one, or both Mapt allels could be 
analysed in the future by southern blotting, or by quantitative PCR for Mapt mRNA 
levels. Additionally, the function of Rosa26 has not yet been identified, but mice with 
a disrupted Rosa26 locus are viable, fertile and do not exhibit any noticeable 
abnormalities (Friedrich and Soriano, 1991; Zambrowicz et al., 1997). Yet, there have 
not been detailed studies specifically investigating the effect of disrupted Rosa26 
function on in vitro neuronal differentiation. It is therefore also possible that targeting 
of Rosa26 could have contributed to the inability for cells to differentiate into 
homogenous neuronal populations.  
 
7.2.4. Use of antimitotic agents 
 
Even if neurons could be generated using R26-CreERT2;Mapt-LSL-TrkA and TrkB 
ESCs, the presence of large numbers of non-neuronal cells affected the survival of 
neurons by DIV8. Non-neuronal cells proliferate, whilst post-mitotic neurons cannot, 
resulting in non-neuronal cells outcompeting neurons for space, and nutrients from the 
media (Burry, 1983). Whilst this is a common problem in primary cultures, where 
neurons are isolated from tissues that contain multiple cell types, the benefits of using 
this particular neuronal differentiation protocol is that it normally generates a very 
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high proportion, up to 95% of glutamatergic neurons, and another 4% are other 
neuronal types. A small (<1%) proportion of the resulting culture are non-neuronal 
cells, but after even three weeks in culture, they do not proliferate enough to overtake 
the dish (Bibel et al., 2004, 2007). Some ESC differentiation protocols allow for the 
use of antimitotic drugs to prevent over-proliferation of non-neuronal cells, and 
antimitotics have been found to improve the survival of neurons in cultures (Burry, 
1983; Oorschot, 1989). One of the most commonly used antimitotics is  
5-flourdeoxyuridine (5FdU). 5FdU is an inhibitor of thymidine synthase, and thereby 
prevents nucleotide synthesis in proliferating cells (Mori et al., 2017). However the 
use of this drug leads to cytotoxic effects that affect the conclusions drawn from cell 
culture experiments, especially when neuronal death may have been one of the 
possible outcomes of the proposed genetic manipulation (Oorschot, 1989). 
Furthermore, studies have reported that even at concentrations where 5FdU does not 
result in cell death, neurons do not appear as healthy (Burry, 1983; Oorschot, 1989), 
while lower concentrations are no longer effective at inhibiting non-neuronal 
proliferation. Whilst cytosine arabinoside (Ara-C), a deoxycytidine analogue which 
inhibits DNA polymerase, is reported to be the least harmful of the antimitotics to 
neuronal culture, it still affects neuronal health and survival (Burry, 1983). As one of 
the main aims of generating this in vitro model was to dissect the mechanisms of TrkA-
induced cell death, applying mitotic inhibitors that are cytotoxic would invalidate any 
results obtained from this in vitro model. It is of note that the first report on the death-
inducing activity of TrkA was based on the use of the same in vitro differentiation 
protocol using a similar HA-tagged TrkA construct inserted in the Mapt locus 
(Nikoletopoulou et al., 2010).  
 
7.2.5. Alternative routes to express Cre 
 
The generation of Mapt-LSL-TrkA and -TrkB ESCs that could differentiate into 
neurons, albeit of questionable purity compared with wild type ESCs, suggested a need 
to test alternative methods of excising the STOP cassette in neurons. However 
transfection of neural progenitors/neurons with a Cre plasmid, either by 
electroporation, viruses, biolistics or biochemical methods such as Lipofectamine 
2000, are not typically not very efficient (Karra and Dahm, 2010; Ohki et al., 2001). 
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An alternative to this could be a cell-permeable Cre; a purified Cre protein from E.coli. 
Here the Cre-recombinase enzyme is modified so that the protein also contains an N-
terminal histidine tag (H6), a translocation peptide from HIV-TAT (TAT), and a 
nuclear localisation sequence (NLS). This fusion protein is referred to as HTN-Cre (or 
HTNC), and due to the presence of TAT and NLS is able to enter the nucleus and 
excise the STOP cassette preceding the Trk receptor sequences. However, this 
approach also failed to reach the desired efficiency and in addition, it turned out to be 
incompatible with prolonged neuronal survival (Haupt et al., 2007; Nolden et al., 
2006; Peitz et al., 2002). As the ability to generate a healthy, homogenous population 
of TrkA-overexpressing neurons was a prerequisite to performing meaningful 
biochemical analyses on in vitro cultures, these methods were not explored further. 
7.2.6. Summary of in vitro experiments 
 
In summary, the expression of TrkA and TrkB in genetically-modified mouse ESCs 
could be temporally controlled by tamoxifen, but the ESCs could not be differentiated 
into neurons of sufficient purity, despite extensive optimisation as detailed above. 
Although this prevented testing of our hypotheses, these ESC lines may still be 
compatible with differentiation protocols that produce alternative neuronal 
populations. 
 
7.3. In vivo TrkA- and TrkB-overexpression models 
 
7.3.1. Generation of TrkA- and TrkB- mice 
 
As constitutive expression of TrkA under the control of the Mapt promoter has been 
previously reported to be lethal embryonically (Nikoletopoulou et al., 2010), the TrkA, 
as well as the TrkB sequences here were preceded by a loxP-STOP-loxP sequence. In 
this way, expression of the receptors could only occur after a Cre-mediated 
recombination event, thus allowing the establishment of a stable transgenic line. By 
crossing these mouse lines, designated R26-LSL-TrkA and R26-LSL-TrkB, with 
different Cre driver lines, the expression of TrkA or TrkB can be controlled in terms 
of the timing of expression, and the cell types or tissues that express TrkA or TrkB. 
To ensure ubiquitous and early expression of the Trk constructs in the embryos, a Cre 
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line was used where Cre was under the control of the human cytomegalovirus (CMV) 
promoter that had been randomly inserted into the X chromosome (Schwenk et al., 
1995).  
 
7.3.2. Excision of the STOP cassette 
 
As described in Chapter 4, complete excision of the STOP cassette was not evident in 
both male and female embryos that inherited both the CMV-Cre and R26-LSL-TrkA or 
-TrkB genes. To control for this only offspring with >95% deletion of the STOP 
cassette, as demonstrated by genotyping PCR, were included for analysis (hereby 
referred to as TrkA- or TrkB-overexpressing). Genotyping of tail (E11.5-E18.5 
embryos), ear notches (pups) and whole embryos (E6.5 embryos) indicated that the 
variability in excision efficiency was present regardless of the age of the offspring. 
While it could be argued that genotyping tail or ear tissue may not guarantee that 
recombination has occurred in a similar extent across all cells in the entire embryo, 
observation of IRES-EGFP at E6.5 (Chapter 4) is consistent with the notion that at 
E6.5 Cre is active across the embryo. Importantly, genotyping PCR also predicted the 
levels of overexpressed Trk protein as determined by western blot (Chapter 4). It is of 
note that a previous study utilised a very similar in vivo strategy to the one outlined in 
this thesis with a different RTK family member, namely Met, the receptor for 
hepatocyte growth factor (Fan et al., 2015). In their experiments, Met was 
conditionally expressed under the control of the Rosa26 promoter, with a STOP 
cassette preceding the Met construct, which was excised by crossing with the same 
CMV-Cre driver line used here. In line with the findings reported here, the authors 
reported that the efficiency of recombination varied among offspring, with the degree 
of STOP cassette excision observed by genotyping PCR being reflected by the extent 
of β-galactosidase staining across entire E10.5 embryos. The authors also observed 
that the degree of β-galactosidase staining seemed to be equivalent between tissues. 
As a result, the authors restricted their analysis to embryos where genotyping indicated 
almost complete excision of the stop cassette, the same approach as used in this thesis. 
In line with the observations outlined in chapter 4, Fan et al. (2015) also did not 
observe any effects of gender on the efficiency of recombination.  
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For this reason, while it may seem an obvious query that incomplete excision could be 
due to X inactivation affecting the expression of CMV-Cre, this does not seem to be 
the case. X inactivation occurs in females, and is a process of dosage compensation; 
ensuring comparable expression levels of genes that are found on the X chromosome 
between males (that only inherit one X chromosome, XY) and females (that inherit 
two, XX). While females inherit one from their mother (designated Xm) and one from 
their father (designated Xp), while males inherit their only X chromosome from their 
mother (Augui et al., 2011; Krietsch et al., 1982; Takagi and Sasaki, 1975). There are 
two types of X chromosome inactivation. In imprinted X chromosome inactivation Xp 
is preferentially inactivated during the preimplantation stages of embryogenesis, while 
Xm is constitutively active after fertilisation (Augui et al., 2011; Krietsch et al., 1982; 
Takagi and Sasaki, 1975). Random X inactivation however occurs around the time of 
blastocyst implantation, and silences either Xm or Xp in each cell of the female 
embryo, resulting in mosaic expression of X-linked genes that continue throughout 
life (Lyon, 1961). Therefore females that inherit CMV-Cre from their mother have a 
uniform, early expression of Cre prior to blastocyst implantation/X-inactivation, 
ultimately resulting in uniform expression of TrkA/TrkB across the embryo. However 
female pups that inherit CMV-Cre from their father will have Cre activated later, 
around the time of X-inactivation, and ultimately result in mosaic expression (Mak et 
al., 2004; Okamoto et al., 2004; Patrat et al., 2009; Tan et al., 1993) of TrkA/TrkB. 
The finding of incomplete excision in male offspring observed here (also previously 
reported by Fan et al., 2015), seems to exclude the possibility that X inactivation is the 
cause of the partial Cre recombination, as X inactivation occurs only in females. 
Furthermore, incomplete recombination was consistently observed in our breeding 
scheme where CMV-Cre was inherited from the mother, which in theory should bypass 
the issues associated with paternal X-inactivation.  
 
7.3.3. Functionality of the model 
 
Littermate controls were established as R26-LSL-TrkA or -TrkB mice (hereby referred 
to as “controls”) that did not inherit the CMV-Cre gene. Indeed, HA-tagged TrkA or 
TrkB could only be detected in TrkA- and TrkB-overexpressors, while HA could not 
be detected in controls. This is expected, as the HA epitope is not endogenously found 
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in mice (Wilson et al., 1984). Thus, lack of detection indicated that there was no leaky 
expression of TrkA or TrkB protein in the controls. Further confirmation that the 
model design worked came with the observation that excision of the loxP-flanked 
STOP cassette could be detected in offspring by genotyping PCR as early as E6.5 
(Chapter 4). Furthermore STOP cassette excision correlated with increased levels of 
green fluorescence due to the IRES-EGFP sequence in the TrkA- and TrkB-
overexpressing embryos. By contrast, very little fluorescence could be detected in the 
littermate controls, presumably a result of autofluorescence (Chapter 4). Additionally, 
Trk receptor levels, as assessed using pan-Trk antibodies in western blot analysis of 
limb extracts (that contain very low levels of endogenous Trk), as well as the use of a 
TrkA-specific antibody in iDISCO, were clearly increased in Trk overexpressing mice 
compared to controls. These results therefore suggested that TrkA and TrkB were 
widely expressed early during embryogenesis. 
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7.4. TrkA-overexpression 
  
7.4.1. Effects in early development 
 
TrkA-overexpressing mice did not reveal any obvious early developmental deficits in 
comparison to the sex-matched, littermate controls and up until E18.5, TrkA-
overexpressing embryos were still normal in terms of weight. However, a comparative 
analysis of late embryos did reveal a slight, but significant reduction in body size, for 
reasons that are unclear. This was followed by the early postnatal death of all TrkA-
overexpressing pups.  
 
7.4.2. Cell counts 
 
A detailed analysis of the embryos at E18.5 revealed differences in the size of specific 
sensory and sympathetic ganglia in TrkA-overexpressing embryos compared to the 
sex-matched, littermate controls. To quantify these observations, a well-established 
method of calculating unbiased ganglia volumes and neuronal counts, was used 
(Sterio, 1984). This technique combines the Cavalieri method which calculates total 
ganglia volume, and the physical dissector method to calculate neuronal number 
(Coggeshall, 1992) (see section 2.8.4) for details). To ensure that values reported here 
were accurate, control counts for both TrkA and TrkB controls for each ganglia were 
compared to those previously reported in the literature. These counts vary somewhat 
depending on the background strain, and counting method, so averages were taken 
where data was not available for C57BL/6J mice. Overall, counts appeared to be 
consistent with what has been reported in the literature (Table 7.1). 
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Table 7.1 Comparison of neuronal counts 
 
  Reported  
Neuronal Count 
(x103)  
Observed 
Neuronal 
Count (x103) 
G
a
n
g
li
a
 
Superior Cervical Ganglia  17 (1) 25 
C1 Dorsal Root Ganglia  5 (2) 6.7 
Nodose-Petrosal Ganglia  4.5 (3) 4.7 
Vestibular Ganglia  5.0 (4) 5.0 
Trigeminal ganglia  30 (5) 40 
 
(1) – Bamji et al. 1998; Kameda et al. 2012; Kameda et al. 2008; Patrik Ernfors et al. 1994; 
Farinas et al. 1994; Liu et al. 1995, (2) - Farinas et al. 1994, (3) - P Ernfors et al. 1994; Farinas 
et al. 1994; Fox et al. 2001; ElShamy & Ernfors 1997), (4) - Katayama et al., 2009; Liu et al., 
2000; Schimmang et al., 1997, (5) - Ernfors, Lee and Jaenisch, 1994; De Felipe et al., 1999; 
Liu et al., 1995; Smeyne et al., 1994.  
 
In contrast, the number of neurons recorded for TrkA-overexpressing mice at E18.5 
were significantly lower than their littermate controls in specific ganglia. Remarkably, 
neuronal loss seemed to only be observed in NGF-dependent ganglia known to express 
TrkA in large number of neurons such as the TG (Huang et al., 1999), DRG (Mu et 
al., 1993; Wetmore and Olson, 1995), and SCG (Wetmore and Olson, 1995). 
Meanwhile in the NPG where 13% of NPG neurons express TrkA (Wetmore and 
Olson, 1995), there was a modest, but significant reduction of neuronal numbers in 
TrkA-overexpressing embryos. In the VG, a group of placode-derived sensory neurons 
that do not endogenously express TrkA (Schecterson and Bothwell, 1994), there was 
no significant loss of neurons in the TrkA-overexpressing mice compared to controls. 
In sensory ganglia displaying reduced cell numbers, immunohistochemical staining 
for cleaved caspase-3 indicated that the neuronal losses were likely to be explained by 
increased cell death via apoptosis, as indicated by a three-fold increase in caspase-3 
activity. This result therefore supports the notion that TrkA overexpression induces 
cell death once NGF-dependent neurons have left the cell cycle. Indeed, there was no 
evidence for neurogenesis being affected as there were no significant differences 
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between genotypes at early developmental stages, such as E11.5 for the DRG and TG, 
and E15.5 for the SCG. This indicates that the overexpression of TrkA did not affect 
gangliogenesis, adding weight to the notion that TrkA may not act as a dependence 
receptor during early development. Furthermore, this observation, combined with the 
low-level of caspase-3 staining in control DRG and TG (Chapter 5), indicates that the 
timing of neuronal loss in TrkA-overexpressing mice seems to occur within the 
window of naturally occurring cell death; E12-E14.5 in DRG, and E11.5-P4 in the TG 
(White et al., 1998).  
 
7.4.3. Comparison with Ngf-/- models 
 
The phenotype of TrkA-overexpressing animals outlined in this thesis are reminiscent 
of what has been reported in Ngf-/-pups ( Table 7.2). This appears to include the 
early postnatal death of most TrkA-overexpressors, and them being slightly smaller in 
size than their sex-matched, littermate controls by E18.5. These similarities extend to 
the proportion of neurons lost in sensory ganglia ( Table 7.2). At first glance it 
appears that the SCG may not quite follow the expected pattern, as it almost entirely 
ablated in  
Ngf-/- mice by P10 (Chen et al., 1997; Crowley et al., 1994; Fagan et al., 1996; Smeyne 
et al., 1994). However, due to the early postnatal lethality in TrkA-overexpressing 
mice, the latest analysable time point here was P0, where the number of SCG neurons 
was reduced by ~40% in TrkA-overexpressors. As naturally occurring cell death in 
the SCG continues during the first postnatal weeks (Coughlin et al., 1977), it could be 
anticipated that loss of SCG neurons would be more severe at later time points.  In line 
with this notion, the one TrkA-overexpressing pup that survived until P14 
demonstrated marked ptosis; the drooping of eyelids which indicates a loss of SCG 
neuron functionality. 
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 Table 7.2 Proportion of neurons lost: comparison with Ngf-/- mice  
 
 
 
 
 
 
 
 
Values calculated from: (1) (Chen et al., 1997; Crowley et al., 1994; Smeyne et al., 1994), between 
E18.5-P5.  (2) TrkA-overexpressing reduction calculated at E18.5.  
 
7.4.4. Interpretation of results 
 
Superficially, the results of TrkA overexpression reported here resemble those 
obtained previously in a paradigm of TrkA-overexpression using the Mapt locus that 
led to an early lethal phenotype (Nikoletopoulou et al., 2010). However, the cell death 
phenotype observed here is much more specific than previously observed by 
Nikoletopoulou and colleagues, as only TrkA-expressing, NGF-dependent neurons 
were eliminated in the TrkA-overexpressing mice, whilst in the previous study, the 
entire nervous system had been eliminated by E13.5. It appears likely that the use of 
a different promoter, Rosa26 versus Mapt, may explain this apparent discrepancy. A 
possible explanation for the more selective phenotype described in the above is that 
increasing TrkA levels over and above the endogenous levels of TrkA may be 
sufficient to tilt the balance towards cell death. Moderate levels of TrkA-
overexpression driven by the Rosa26 promoter, as opposed to higher levels of TrkA 
generated by the use of the Mapt promoter, could readily explain the selectivity for 
neurons endogenously expressing TrkA in the current TrkA-overexpression model. 
Indeed, the Mapt promoter is strong enough to drive visible levels of GFP expression 
during neurogenesis (Tucker et al., 2001), whilst the Rosa26 locus is known to be 
expressed at low levels in post-mitotic neurons (Allen Institute for Brain Science, 
2004a, 2004b).  
 Reduction in Neuronal Number (%) 
Ganglia/Genotype Ngf-/-(1) TrkA-overexpressing (2) 
DRG 70-90 72 
TG 70-90 75 
SCG 95-100 37 
VG 0 7 
NPG 15 18 
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However there is another explanation for the findings reported here that appears more 
plausible as it would also explain the observations made with mice overexpressing 
TrkB (see below). NGF has long been known to be secreted in limited amounts during 
development by the target tissues innervated by neurons requiring NGF for their 
survival (Bibel and Barde, 2000). This widely accepted model accounts for the 
phenomenon of naturally occurring cell death by the failure of the dying neurons to 
access sufficient quantities of the survival factor NGF. It has been directly 
demonstrated that the provision of additional quantities of NGF during normal 
development almost completely suppresses cell death in dorsal root ganglia 
(Hamburger et al., 1981). Given this well-documented phenomena, it is conceivable 
that the ubiquitous expression of TrkA as achieved here acts to scavenge secreted NGF 
(Figure 7.1). In this way, the overexpression of TrkA may prevent sufficient access of 
TrkA-expressing nerve terminals to NGF secreted by peripheral sources, such as the 
developing whisker pad. Indeed, the results of the iDISCO experiment using TrkA 
antibodies (Chapter 5) demonstrated increased immunoreactivity in the whisker 
follicles where selective Ngf gene expression has been documented (Bandtlow et al., 
1987; Davies et al., 1987).  
  
 
Figure 7.1 Proposed mechanism of cell death in TrkA-overexpressors. A) Schematic of the well-established paradigm of naturally 
occurring cell death in wild types (controls). NGF, secreted by target tissues, diffuses and binds to TrkA receptors on innervating neurons. 
Where TrkA does not bind NGF, the neurons undergo apoptosis and die. B) In TrkA-overexpressing mice, NGF may be sequestered by 
the overexpressed TrkA receptors in the target tissue. In this way, less NGF is available to the axon terminals of innervating neurons, 
resulting in increased neuronal death compared to that of controls. 
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7.5. TrkB-overexpression 
 
7.5.1. General effects of TrkB-overexpression 
 
Using the same overexpression strategy as in the TrkA mice, very different results 
were obtained in TrkB-overexpressing mice. While TrkA pups died perinatally, TrkB 
pups survive postnatally, did not exhibit any clear phenotype in comparison to 
littermates, became sexually mature, and were even able to give birth to viable litters. 
Additionally, TrkB-overexpressing animals were normal in terms of weight and body 
size across age. Due to logistical constraints TrkB-overexpressors were not generated 
until June 2018, and as a result the phenotypes in adults could not yet be examined in 
aging adults. However at the time of writing, TrkB-overexpressing mice do not show 
any overt phenotypes by six months of age. 
 
7.5.2. Loss of sensory neurons 
 
Detailed histological analyses revealed a significant loss of neurons in specific sensory 
ganglia, most notably in ganglia endogenously expressing TrkB that are reported to 
depend on BDNF and NT4 for survival, such as the NPG (Ernfors et al., 1992; Ernfors, 
Lee and Jaenisch, 1994; Huang et al., 1999; Jones et al., 1994), VG (Ernfors et al., 
1992; Ernfors, Lee and Jaenisch, 1994; Jones et al., 1994; Schecterson and Bothwell, 
1994; Ylikoski et al., 1993), TG (Ernfors, Lee and Jaenisch, 1994; Huang et al., 1999; 
Jones et al., 1994; Liebl et al., 1997; Wetmore and Olson, 1995), and C1 DRG 
(Kashiba et al., 1995; Liebl et al., 1997, 2000; Wetmore and Olson, 1995). In contrast, 
in the SCG where there have been no reports of neurons expressing TrkB, nor of 
BDNF/NT4-dependency for survival (Ernfors, Lee and Jaenisch, 1994; Jones et al., 
1994; Wetmore and Olson, 1995), there was no significant loss of neurons in TrkB-
overexpressing mice. Whilst stainings for cleaved caspase-3 have not yet been 
completed for the ganglia of TrkB-overexpressing embryos to confirm that the loss of 
neurons in these ganglia is attributable to increased cell death (as discussed for the 
TrkA-overexpressing embryos, section 7.4.2), this appears to be the most likely 
explanation given the observation that gangliogenesis was not affected in the VG, 
NPG, DRG and TG of TrkB-overexpressing mice. This is supported by observations 
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that there were no significant differences between genotypes in the number of neurons 
in these ganglia at E13.5.  
 
7.5.3. Comparison with Bdnf-/- and Ntf4-/- models 
 
As with TrkA-overexpressors, TrkB-overexpressing mice were compared to knockout 
models of the respective ligands; Bdnf and Ntf4. While Bdnf-/- mice die within the first 
postnatal week, and demonstrate severe movement and breathing deficits (Conover et 
al., 1995; Erickson et al., 1996; Ernfors, Lee and Jaenisch, 1994; Hellard et al., 2004; 
Jones et al., 1994; Liu et al., 1995), Ntf4-/- mice are long-lived and have no obvious 
phenotype (Conover et al., 1995). TrkB-overexpressing pups therefore appear to 
phenocopy Ntf4-/- mice as TrkB-overexpressors survived postnatally and were fertile. 
However upon closer comparison of the neuronal losses in sensory and sympathetic 
ganglia, it became obvious that the losses in the VG, NPG and TG of TrkB-
overexpressing mice compared to Ntf4-/- were much larger (Table 7.3). ). In fact, TrkB-
overexpressing mice showed a pattern and proportion of loss more reminiscent of 
Bdnf-/-,Ntf4-/- double knockout pups (Table 7.3). However double knockouts die within 
48 hours of birth (Liu et al., 1995), which is in sharp contrast with the results obtained 
with TrkB-overexpressing pups. Furthermore, the proportion of neurons lost in TrkB-
overexpressing mice still appears to be slightly less in VG compared to Bdnf-/-,Ntf4-/- 
pups. The reduced losses in the VG may therefore explain the lack of severe balance 
deficits in TrkB-overexpressing animals that are characteristic of Bdnf knockouts.  
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Table 7.3 Proportion of neurons lost: comparison with Bdnf-/-;Ntf4-/- mice  
 
 Reduction in Neuronal Number (%) 
Ganglia/Genotype 
Bdnf-/-
(1) 
Ntf4-/- 
(2) 
Bdnf-/-;Ntf4-/-
(3) 
TrkB-overexpressing 
(4) 
DRG 30 15 None 47 
TG 30-40 None 10-30 29 
SCG None None None None 
VG 75-90 21 82 45 
NPG 40-60 40-60 80-90 82 
 
Values calculated from: (1) - Conover et al., 1995; Erickson et al., 1996; Ernfors, Lee and 
Jaenisch, 1994; Hellard et al., 2004; Jones et al., 1994; Liu et al., 1995 , (2) - Conover et al., 
1995; Erickson et al., 1996; Ernfors, Lee and Jaenisch, 1994; Liu et al., 1995, (3) - Conover et 
al., 1995; Liebl et al., 2000; Liu et al., 1995, between E18.5-P5. (4) - TrkB-overexpressing 
values reported for E18.5. 
 
7.5.4. Interpretation of results 
 
As discussed for TrkA (section 7.4.4), the results obtained with TrkB-overexpressing 
mice may be due to the receptor acting as a BDNF/NT4 scavenger. Whilst TrkB 
overexpression would then be expected to phenocopy mice carrying germ line 
deletions of Bdnf and Ntf4, this is clearly not the case (see above) as TrkB-
overexpressing pups survived postnatally and were fertile, whilst Bdnf-/-and Ntf4-/- die 
shortly after birth (Liu et al., 1995). One possible explanation for this apparent 
discrepancy could be that a proportion of the neurons comprising peripheral sensory 
ganglia express Bdnf, including the TG, NPG and DRG (Wetmore and Olson, 1995; 
Zhou et al., 1998). BDNF secretion by BDNF-responsive neurons has been proposed 
to be part of an autocrine signalling mechanism thought to play a role in axonal 
elongation after lesions (Acheson et al., 1995), and neuronal survival during 
development (Brady et al., 1999). These BDNF-secreting neurons would be expected 
not to depend on an exogeneous BDNF supply and thus to escape the scavenging effect 
of overexpressed TrkB.  In this setting, neurons secreting BDNF may even have a 
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survival advantage by activating additional TrkB in the overexpressing embryos. This 
notion fits well with the results obtained with the TrkA-overexpressing embryos as, 
by contrast with the situation with BDNF, NGF-dependent neurons have not been 
reported to express the Ngf gene (Wetmore and Olson, 1995).  
  
 
Figure 7.2 Proposed mechanism of cell death in TrkB-overexpressors. A) Schematic demonstrating the well-established paradigm of naturally 
occurring cell death in wild types (controls). BDNF, secreted both by target tissues and a proportion of the innervating neurons, binds to TrkB 
receptors on sensory neurons. Where TrkB does not bind BDNF, the neurons undergo apoptosis and die. B) In TrkB-overexpressing mice, BDNF 
may be sequestered by the overexpressed TrkB receptors in the target tissue, so less BDNF is available for innervating neurons. However as BDNF 
is synthesised by a proportion of the sensory neurons, these neurons survive TrkB-overexpression.  
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7.6. Conclusions and perspectives 
 
The results detailed in this thesis demonstrate remarkable differences in the phenotype 
of transgenic animals expressing two closely related tyrosine kinase receptors. While 
a similar, general conclusion was previously reported (Nikoletopoulou et al., 2010), 
the mechanisms best explaining the corresponding phenotypes are significantly 
different. Firstly, the experimental design by Nikoletopoulou and colleagues involved 
the constitutive expression of TrkA and TrkB under the Mapt promoter. Due to the 
use of this neuron-specific promoter, conclusions could only be drawn about Trk 
receptor function in neurons. Due to early lethality of TrkA-overexpressing embryos, 
it was not possible to establish a transgenic mouse line constitutively expressing TrkA. 
Embryos were therefore generated using a tetraploid complementation method. As this 
technique leads to significant late embryonic lethality (H. Lickert, personal 
communication), it was not possible to achieve analysis of postnatal embryos. Indeed, 
in the previous study, no embryos were observed past E16.5 irrespective of which Trk 
receptor was expressed. By contrast, this thesis detailed the generation of mouse lines 
conditionally expressing TrkA and TrkB under the control of the Rosa26 promoter. 
This opens the possibility to, in future studies, use selective Cre drivers to assess and 
compare the expression of these receptors in specific tissues of interest. 
As discussed, ubiquitous TrkA and TrkB overexpression led to a much more specific 
phenotype than anticipated from the work by Nikoletopoulou et al.. In particular, the 
overexpression of the Trk receptors did not appear to affect early embryogenesis or 
gangliogenesis. These mice instead exhibited a specific loss of neurons in sympathetic 
and sensory ganglia. Given the wealth of data accumulated in the neurotrophin field, 
this specificity may be plausibly explained by a scavenging function of the 
overexpressed receptors: the ubiquitous expression of TrkA and TrkB would deprive 
neurotrophin-dependent neurons from neurotrophins secreted by the corresponding 
target tissues as they would be retained at the sites of secretion.  This scavenging 
function in the future could be directly demonstrated by overexpressing Trk mutant 
receptors that lack the corresponding neurotrophin-binding domain, to separate the 
dependence-receptor role from sequestering.  
The most novel and unexpected finding was that TrkB-overexpressing mice, whilst 
losing significant numbers of BDNF- and NT4-dependent neurons, show prolonged 
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postnatal survival, unlike previous reports for mice lacking the corresponding ligands 
(Conover et al., 1995; Erickson et al., 1996; Ernfors, Lee and Jaenisch, 1994; Hellard 
et al., 2004; Jones et al., 1994; Liebl et al., 2000; Liu et al., 1995). The proposed 
mechanism of sensory neuron survival as a result of autocrine BDNF signalling could 
be further explored by examining the phenotype of surviving neurons in TrkB-
overexpressors. Detailed studies with Bdnf and Ntf4 knockouts led to the conclusion  
that BDNF is essential for the survival of a small population of chemoreceptor 
afferents critically involved in the control of respiration, and in line with the proposed 
autocrine hypothesis, these neurons also express the Bdnf  gene (Brady et al., 1999; 
Erickson et al., 1996; Wetmore and Olson, 1995). Interestingly, many neurons have 
been shown to co-express BDNF and tyrosine hydroxylase, the rate limiting enzyme 
in the biosynthesis of catecholamines (Nagatsu et al., 1964). Experiments are 
underway to determine the phenotypic identity, as well as the connectivity, of the 
surviving NPG neurons in TrkB overexpressing mice. Using X-clarity and whole-
mounts, the projections of the NPG including the carotid body and the baroreceptor 
fields will be investigated using antibodies to both neurofilaments and tyrosine 
hydroxylase. The results will be compared with those obtained using pups lacking 
Bdnf. In sum, these results suggest that autocrine signalling in vivo may represent a 
hitherto underappreciated aspect of the mechanism of BDNF action in the developing 
nervous system.  
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